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Abstract 
The following work documents three studies undertaken using solid phase 
synthesis techniques. 
Interaction of the zinc metallopeptidase, Endothelin Converting Enzyme-i 
(ECE-1), with its natural peptidic substrate, big endothelin-1 (big ET-1), has been 
investigated via an SAR study using solid phase peptide synthesis (SPPS). Truncated 
forms of the substrate had been previously reported to inhibit ECE- 1, this was 
confirmed however the big ET-1 analogues were shown to be alternative substrates 
for the enzyme. A short study of the substrate specificity of ECE- 1 was carried out. 
The synthesis of vast libraries of peptides using combinatorial synthesis has 
been used to accelerate the drug discovery process. Purification of these mixtures has 
not been previously attempted. 1 7-Tetrabenzo[a,c,g,i]fluorenylmethoxylcarbonyl 
(Tbfmoc), developed for use with single peptides and proteins, has been used to 
achieve facile purification of five peptide libraries synthesised using SPPS. The 
methodology was fully optimised for the efficient separation of the desired library 
members from all impurities by exploiting the affinity of Tbfmoc for carbon. 
A potential small molecule inhibitor of the zinc metalloenzyme, Farnesyl 
transferase (FTase), was designed. The efficient solution phase synthesis of this novel 
structure is reported. Its adaptation to solid phase synthesis is described, with the 
view to using multiple parallel synthesis techniques to synthesise a range of 
analogues. 
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COS combinatorial organic synthesis 
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DEAD diethyl azodicarboxylate 
DIC N, N'-diisopropylcarbodiimide 
DIEA N, N-diisopropylethylamine 
DMAP dimethylaminopyridine 
DME dimethoxyethane 
DMF N, N- dimethylformamide 
DMS dimethylsuiphide 
DMSO dimethylsuiphoxide 
DNA deoxyribonucleic acid 
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ECE Endothelin Converting Enzyme 
ECGC electron capture gas chromatography 
EDT ethane-1, 2-dithiol 
EDTA ethylenediaminetetraacetic acid 
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FAB fast atom bombardment 
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Fmoc 9-fluorenylmethyloxycarbonyl 
FPP farnesyl pyrophosphate 
FTase Farnesyl transferase 
FTIR Fourier Transform Infra Red 
GGTase geranylgeranyl transferase 
GDP/GTP guanosine diphosphate/ guanosine triphosphate 
GuHC1 guanidine hydrochloride 
h hours 
HOBt 1 -hydroxybenzotriazole 
HOCt 1 -hydroxy-4-ethoxycarbonyl- 1,2,3 -triazole 
HPLC High performance liquid chromatography 
HRMS high resolution mass spectroscopy 
Hz Hertz 
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JR infra red 
1050 concentration at which 50% inhibition occurs 
kcat turnover number 
Km Michaelis constant 
M molar 
m meta 
MALDJ-ToF Matrix assisted laser desorption ionisation-time of flight 
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PEG polyethylene glycol 
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PG protecting group 
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Ph phenyl 
pip piperidine 
Pmc 2,2,5 ,7,8-pentamethylchroman-6-sulfonyl 
iv 
PPA polyphosphoric acid 
ppm parts per million 
Pr propyl 
PS polystyrene 
q quartet (nmr) 
q quaternary 
RB round bottomed (flask) 
Rf retention factor 
RF radio frequency 
RNA ribonucleic acid 
RP reverse phase 
rt room temperature 
s singlet (nmr) 
SAR structure activity relationship 
so1ECE- 1 soluble recombinant endothelin converting enzyme-i 
SPOS solid phase organic synthesis 
SPPS solid phase peptide synthesis 
t triplet (nmr) 
t tertiary 
TBDMS t-butyldimethylsilane 
Tbfmoc 1 7-tetrabenzo[a,c,g,i]fluorenylmethoxycarbonyl 
'Bu t-butyl 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
TIS triisopropylsilane 
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Amino Acid Abbreviations 
SIDE CHAIN FUNCTION 
alanine -CH3 Ala A 
asparagine -CH2CONH2 Asn N 
cysteine -CH2 SH Cys C 
glutamine CH2CH2CONH2 Gin Q 
glycine -H Gly G 
isoleucine -CH(CH3)CH2CH3 lie I 
ieucine -CH2CH(CH3)2 Leu L 
methionine -CH2CH2 SCH3 Met M 




serine -CH20H Ser S 
threonine -CH(OH)CH3 Thr T 
tryptophan Trp W 
tyrosine 
HO CH2 Tyr Y 
valine -CH(CH3)2  Val V 
aspartic acid -CH2COOH Asp D 
glutamic acid -CH2CH2C00H Giu B 
arginine -CH2CH2CH2NHC(=NH)NH 2 Arg R 
histidine N His H 
lysine -CH2CH2CH2CH2NH2 Lys K 
a-aminoisobutyric acid* -C(CH3) 2 Aib - 
2-aminobutyric acid -CH2CH3 Abu - 
penicillamine -C(SH)(CH3 )2 Pen - 
*Complete structure of Pro is given. 
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Part I: Solid Phase Peptide Synthesis 
Chapter 1 
Introduction to Chemical Peptide Synthesis 
1.1 Overview 
Peptides and proteins are highly versatile biological components of 
enormously varying size, form and function. They are employed in vivo to execute an 
immense array of biological functions, from mediating biological response, as 
enzymes and hormones, to cellular construction. In addition, peptides are conversely 
responsible for a whole range of pathological diseases but can also be of great 
therapeutic value. Primary metabolites are important probes in the study of biological 
systems, enabling us to understand at a molecular level the highly complex and 
critical mechanisms fundamental to life. 
These biological species are constructed through the repetitive condensation 
of cc-amino acids to produce polymers of enormously varying length, containing a 
trans amide backbone. Peptides have a relatively low molecular weight compared 
with proteins; while the distinction between the two is not absolute, polymers of 50 
amino acids or less are generally considered peptides; between 50 and 80 are 
sometimes referred to polypeptides; while those of greater than 80, proteins. 
A more definite criterion for distinction is based on the overall biopolymer 
structure. Large polypeptides with definite three-dimensional structure, or tertiary 
structure, are normally classified as proteins. This structure, unique to each protein, is 
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essential for protein function. It is achieved through the interplay of two other 
structural properties of the protein: primary structure, the sequence of a-amino acids 
in the peptide chain, and secondary structure, local conformation within the chain in 
blocks of 4-20 residues. All peptides and proteins possess primary structure by 
definition, and may possess secondary structure; however, only proteins then fold 
into a distinct tertiary structure, often bringing residues close together that are far 
apart in the primary structure. The tertiary structure is thermodynamically favoured 
and is maintained via interatomic forces such as hydrogen bonding, hydrophobic and 
charge interactions. Some proteins also possess quaternary structure, existing when 
the final, active form of the 'protein' consists of more than one polypeptide chain 
interwoven into a larger complex, interacting through non-covalent forces. 
Figure 1.1: Three dimensional structure of Lvso:y ,ne. 
Nature has designed a highly sophisticated, fast and efficient method for 
protein synthesis. DNA is the permanent record of all biological peptide and protein 
sequences, contained within the cell nucleus; this information is transcribed into a 
nucleic acid template, messenger RNA, which moves to the nbosome protein in the 
cytoplasm, which translates information into the required protein species. The 
majority of biological peptides originate from much larger protein precursors, 
through enzyme mediated post-translational cleavage and modification of the 
polymer chain. 
Recent developments in recombinant DNA and peptide synthesis have 
provided powerful tools with which to study many biological processes; however, 
2 
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they have limitations: recombinant peptide synthesis is restricted to the 20 naturally 
occurring amino acids; there is minimum control over protein expression and 
isolation of the desired protein sequence from the fermentation broth can be 
difficult. Therefore an alternative method would be beneficial. 
1.2 Chemical Peptide Synthesis 
One alternative approach is chemical peptide synthesis. This technique is not 
restricted to the 20 naturally occurring amino acids, and is easily adaptable to 
primary structure variation via specific site alteration, with complete control over the 
peptide construction. This flexibility allows the incorporation of non-genetically 
encoded material into the polypeptide, such as artificial amino acids or NMR probe 
nuclei at a specific site. These modifications provide information on how individual 
residues contribute to the overall activity and conformation of the peptide or protein, 
and furnishes an insight into the complex mechanisms associated with these species. 
It also opens up the possibility of designing totally artificial structures for therapeutic 
use. 
The first reported chemical synthesis of an amide bond was made in 1901 by 
Emil Fischer. 3 He synthesised the dipeptide glycyiglycine from two glycine 
monomers, see jig. 1.2. 
R 
. 'co2- 
HT 	&IUH R, R' = H for glycyiglycine H 3 N I I 
Figure 1.2: Dipeptide with highlighted amide bond. 
The synthetic construction of the amide bond through the condensation of 
two a-amino acids is hampered by two fundamental factors. The zwitterion nature of 
the amino acids means they will not spontaneously react, but must be activated in 
some way, most obviously at the carboxyl terminus. In addition, all non-participating 
functional groups, including reactive side chains (see page vi), must be protected to 
prevent their participation in the reaction. 
3 
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Several solution phase strategies were developed in the early part of the 201h 
century to facilitate chemical peptide synthesis. 4 These methods were laborious and 
time consuming, with a large number of repetitive steps required for the synthesis of 
even very small peptides. Each synthetic step was required to go almost to 
completion in order to ensure the final product could be achieved. Using solution 
phase synthesis meant that each of the intermediates required purification, hence 
reducing the yield and making the synthesis of longer peptides impractical. These 
restrictions limited the application of solution phase methodology, hence progress in 
the area of synthetic peptide synthesis was slow. 
1.3 Solid Phase Peptide Synthesis. 
In 1963 Bruce Merrifield offered his solution. 6 His idea was to attach one 
starting material to a functionalised, otherwise inert, solid support; to add excess of a 
second starting material in solution; then wash away that excess, leaving the isolated 
product attached to the solid support. This technique has two important advantages 
over solution phase strategies: 
• The reaction could be forced to completion by the addition of a large excess of the 
reagent, which could later be easily removed without affecting the product. 
• Purification and characterisation of intermediates was not required, as they 
remained attached to the solid support, hence were isolated by simple filtration. 
These advantages made the synthesis faster and the yield higher. The concept is now 
employed in much oligonucleotide 6 and oligosaccharide 7 synthesis, with much 
traditional heterocyclic chemistry also being adapted to utilise the methodology. 8 
Merrifield's original protocol for solid phase peptide synthesis (SPPS) involved the 
stepwise elongation from the C-terminus, see fig. 1.3. 
4 





NH2 1. DCC HOCbz 	 N 	N H 2 
o 	R1 	2.HOAc/HBr 	02*) 	
R 1 0 
I 	o 	R2 H 	 I 
NaOH 	
HO(1fL N H 2 	 = polystyrene, 1% crosslinked 
R 	0 	
with divinylbenzene 
Figure 1.3: Merrfields' solid phase peptide synthesis. 
His synthesis heralded a new era in synthetic peptide chemistry, and forms the basis 
of all solid phase synthesis performed today. 
In biological systems, peptides are synthesised from the N- to the C-terminal, 
in SPPS, however, the peptides are grown nearly exclusively from the C- to the N-
terminus. The necessity for this was recognised early, when it was realised that 
synthesising from N to C could result in the loss of stereochemical integrity through 
oxazolone formation, see fig.  1.4. On activation of the carboxylic acid (see later), it is 
possible that the growing peptide chain could undergo intramolecular cyclisation, 





Peptide 	°, Peptide 
X = activating substituent 
Figure 1.4: Intramolecular oxazolone formation when SPPS isperformedfrom 
N- to C-terminal. 
The basic principle of solid phase peptide synthesis involves the attachment 
of the C-terminal amino acid to a solid support (resin) via the carboxyl function, 
which effectively acts as a Ca  protecting group; after removal of the Na_protecting 
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group, the coupling reaction is carried out as in solution phase strategies, however, 
the system allows the use of a large excess of the required pre-activated amino acid 
species. The excess reagent and soluble impurities are then washed away, leaving the 
dipeptide product attached to the resin. Any of the original resin-bound amino acid 
that failed to react is capped using acetic anhydride, to prevent further involvement. 
The process is then repeated with the third and subsequent amino acids, until the 
desired sequence is achieved, see fig 1.5. 
Cycle is repeated 
until desired 





Wash repeatedly I PG = Na protecting group x = activating substituent 
H 
+ 
R 1 	 R2 




R 1 0 
Cap any unreacted Na  sites 
I 	 with acetic anhydride 
Wash repeatedly 
L Q — O — NPG 
R 1 0 
Acidolytic cleavage and deprotection 
0 	R 0 	I 
Ho( N (N(NH 2 I 
R1 	H RN 
TARGET SEQUENCE 
Figure 1.5: General protocol for stepwise solid phase peptide synthesis. 
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The highly repetitive nature of stepwise synthetic peptide synthesis makes it 
amenable to automation. Merrifield was quick to realise this, and published details of 
his automated peptide synthesiser in 1965. He synthesised the nonapeptide 
bradykinin, in greater yield and less time than was possible by manual synthesis.' ° 
Proteins of over 100 residues, impractical by manual techniques, are now routinely 
synthesised by automated synthesisers. 
An alternative strategy to stepwise SPPS, which is gaining popularity as 
methodology advances, is fragment coupling or convergent peptide synthesis. The 
protein is constructed as a number of smaller fragments, using conventional stepwise 
methodology, which are then linked together to produce the final target sequence. 
This technique has been used to great effect for a number of proteins, achieving the 
synthesis of much longer sequences than is possible via its stepwise counterpart.' 
 has been described, solid phase peptide synthesis developed rapidly from 
Merrifields' original pioneering work, and is now well established as a highly 
efficient, versatile method for peptide and protein synthesis. New methodology 
continues to advance the technology. Several comprehensive reviews have been 
published, 12  and so this discussion will be limited to three key considerations. 
1.3.1. Amide Bond Formation 
As described previously, peptide bond formation is achieved by the activation 
of the carboxyl group, making it susceptible to nucleophilic attack by the a-amine 
function of the growing peptide chain. The activated species must be capable of 
achieving rapid, quantitative amide formation, under mild conditions, without 
compromising the stereochemical integrity of the growing peptide chain. Although 
the activating substituent is required to be a good leaving group, if it is too labile it 
may promote racemisation at the chiral centre. 
The most commonly used method of carboxylate activation in other areas of 
organic chemistry is as the acid chloride, as used by Fischer in his early work. 4 
Unfortunately, it is of limited use in peptide chemistry due to its lability and tendency 
to cause racemisation. Use of the acyl azide, pioneered by Curtius, also dates back to 
7 
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the beginning of the century.' 3 This method is also highly activating, but with 
negligible racemisation; however, it is disadvantaged due to a tendency to rearrange 







H 	 on exposure to water H HOH 
PG(N-NN 	
PGN(N=C=O + N2 	 10 PG I 
Decomposes 
PGN(NH2+ H20 + CO2 
Figure 1.6: Curtius rearrangement of the acid azide. 
Carboxylate activation via the anhydride has achieved greater success in 
peptide synthesis. The symmetric anhydride has be constructed using both 
dicyclohexylcarbodiimide (DCC) 14 and diisopropylcarbodiimide (DIC),' 5 and offers 
rapid acylation of amines. DIC is the preferred reagent for SPPS, since the N-N'-
diisopropylurea by-product is fully soluble. The highly reactive o-acyl-isourea 
intermediate can unfortunately cause racemisation in some amino acids, namely His. 
Also, where the amino acid possesses an amide side chain function, nitrile formation 
is possible. ' 6 Two equivalents of amino acid are required for formation of the 
symmetric anhydride; although the method is effective, a major drawback is that it is 
highly wasteful, using only half of the expensive protected amino acid species in the 
peptide. 
PGN)O 	 PGNYLOH PGNHCH(R)
IN 	 0 
R 	 I 	 R 	HN—< 	 PGNHCH(R)— 
/\ 0 
Figure 1.7: Amino acid activation as the symmetrical anhydride using DIC. 
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Alternatively, a mixed anhydride species may be used. These also offer rapid 
acylation of amines, and have the advantage of requiring only one equivalent of the 
amino acid. As there are two possible sites for nucleophilic attack in such a system, 
the amine must be encouraged to attack at the correct site by either decreasing the 
reactivity of the activating portion, or by increasing its steric bulk. Several strategies 
have been developed to achieve this,' 7 but unfortunately such methods tend to be 
more suited to solution phase peptide synthesis, as they generally require low 
temperature to prevent disproportionation to the symmetric anhydride. 
The most popular method of activation used in SPPS is via the active ester. 
DCC or DIC is used to form the highly reactive O-acyl substituted urea, which is 
then reacted with some form of hydroxyl function to form an active ester. This 
activated species is capable of rapid acylation of amines, but is more stable than the 
anhydride, hence racemisation is suppressed. The first active esters employed were 
ortho- and para-nitrophenyl esters, subsequently a range of alcohols have been 
developed. 18  One species which has shown exceptional properties is N-
hydroxybenzotriazole, see jig. 1.8.19  Originally designed to suppress racemisation, its 
potential as an effective coupling agent was soon recognised. A number of alternative 
N-hydroxyl compounds have been designed based on this structure, including ethyl 1-
hydroxy-1,2,3-triazole-4 carboxylate, developed by Ramage et al . 20 This compound 
offers increased coupling efficiency and hence reduced by-product formation, whilst 
retaining negligible racemisation. 
N N-OH 




- 	Ethyl 1-hydroxy-1 ,2,3-triazole-4-carboxylate 
C2H 50 	 (HOCt) 
0 
Figure 1.8: N-Hydroxyl compounds used in the formation of active esters. 
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A number of different methods are employed for the effective chemical 
synthesis of peptides and proteins, and ongoing research continues to develop 
alternative improved strategies for amide bond formation, comprehensive reviews of 
which are available.' 2 
1. 3.2 Orthogonal Protection. 
In order to achieve a single unique product from the condensation of two a-
amino acids, all non-participating functional groups must be protected. This includes 
all non-participating cc-amino and cc-carboxyl groups, plus all reactive side chains. In 
SPPS, the a-carboxyl group is tethered to the solid support which effectively acts as 
a protecting group. 
If a peptide of more than two amino acids is desired, it is necessary to 
implement a strategy whereby the Na amino protection can be cleaved selectively, 
leaving the other protecting groups intact for the entire synthesis; this is termed 
orthogonal protection. Merrifield incorporated orthogonality into his 1963 
tetrapeptide synthesis by using an acid labile Na protecting group with a base labile 
resin, see fig. 1.3. 
A prerequisite for all protecting strategies is that the protecting group be 
stable to the reaction conditions to which it is exposed during the assembly phase, but 
capable of quantitative deprotection when required, under specific, mild conditions. 
Failure to completely remove the Nx  protecting group could lead to the build up of 
deletion peptides, i.e. sequences with one or more of the amino acid residues missing. 
The sequences retaining Na protection are unable to couple with the next amino acid, 
however, subsequent deprotection steps may liberate the Na amine allowing the 
depleted sequence to participate in succeeding chain elongation. Deletions are a 
particular problem in peptide synthesis, as they result in both a reduced yield and 
difficult purification. 
10 
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o R 
R N (N 
R \H 	 R H 
	-H : 	 -__H 
	
HN)O -HA 	 _______ 
R OX 	 R0 	H R° 	-H 	R° 
N" protecting group 	
H 
0 R 
RA N (N 
0 
Figure 1.9: Amino acid racemisation with use OfNa  acyl protection. 
The most obvious choice of Na protection was via an acyl group; however, 
this form of protection has a tendency to form the intramolecular oxazolone during 
carboxylate activation, see fig.  1.9. Hence the main class of Na protecting groups 
employed in peptide synthesis are the urethanes. These do not have this tendency, 
and offer stable protection under the required conditions. On cleavage of the urethane 
group, the resulting carbamic acid spontaneously decarboxylates to give the free a-
amino terminus, see fig.  1.10. 
0 	 0 




peptide - N OH 	
IN- 
H 
Figure 1.10: Removal of the urethane protecting group. 
The first Na urethane protecting group was developed in 1932.21  The 
benzyloxycarbonyl (Z or Cbz) group, used by Merrifield, was cleaved either via 
strong acid, for example HBr in HOAc, or by hydrogenation. 
JON-peptide 	 OAN_ peptid e 
H 	 4 H 
Benzyloxycarbonyl group (Z or Cbz) 	tButyloxycarbonyl group (Boc) 
Figure 1.11: Acid labile N' protecting groups. 
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The demand for milder deprotection conditions, which did not damage the 
polypeptide product, led to the development of the t-butyloxycarbonyl (Boc) group 
which could be cleaved under milder acidic conditions. 22  Subsequent developments 
gave rise to other more acid labile protecting groups. 23  Consideration of the various 
deprotection requirements of these groups enabled the peptide chemist to design 
suitable orthogonal protection schemes, based on alternative acid labilities. The most 
commonly used strategy was that of NaBoc  with side chain Z group protection. 
The development of the 9-fluorenylmethoxycarbonyl (Fmoc) protecting group 
offered the first truly orthogonal protecting strategy. 24  It was developed due to 
concern that the repeated TFA acidolysis used in Boc chemistry, and the strong acid 
conditions (HF) required for cleavage from the resin, could have a deleterious effect 
on the growing peptide. By contrast, Fmoc cleavage was performed under mild basic 
conditions, using the secondary amine piperidine. 
/\ 	0 A 
H 	 O-1J 
N - pepti de— -Q 
III 
0 + H2N - pepti d e -4 
V— 
UV absorbance at 302nm 
Figure 1.12: Cleavage of the Fmoc protecting group. 
The fulvene-piperidine adduct produced during Fmoc cleavage is UV active 
(isosbestic point at 302nm), offering a method for monitoring the coupling efficiency 
of each step by measuring the absorbance of the deprotection effluent (see Chapter 
2). Under this strategy, the side chains are typically protected with highly acid labile 
groups, which remain completely intact during repeated base cleavage of the JyU 
12 
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protection. Taking this in conjunction with more acid labile resins (see later), the 
requirement for strong acid treatment was eliminated. 
Choice of side chain protection will depend on the choice of the transient a-
amino protecting group. A multitude of side chain protecting groups have been 
developed to be compatible with the Fmoc strategy; these have been 
comprehensively reviewed elsewhere.' 2 Researchers continue to develop new, 
innovative protecting groups to replace those with less than ideal properties. Table 
1.1 gives a summary of the most common groups currently employed for use with the 
Na Fmoc protection strategy; the majority of functionalities are efficiently protected 
using trimethyl phenyl (Trt), t-butyl ethers or t-butyl esters, however, the side chains 
of Arg, Cys and His require special consideration. 
Amino Acid 	I Side Chain PG 
Arg Pmc25/Pbf26 
AsnlGln Trt 




Ser/Thr/Tyr 'Bu ethers 
Trp Boc 
Table 1.1: Summary of the most common side chain protecting groups used with 
Na Fmoc protection. 
1. 3.3 Nature of the Solid Support and Linker Group. 
The basic criteria for a solid support (resin) are that it be insoluble; contain a 
functionality to which the first reactant can be attached; be completely inert to all 
reagents/solvents to which it will be exposed during the synthesis; and finally, on 
completion of the synthesis, give quantitative release of the product under mild 
conditions which will not degrade the product. 
Merrifield performed his synthesis on a co-polymer of styrene and 
divinylbenzene (DVB), functionalised with chloromethyl groups. Cross-linking gave 
an extended rigid structure, whilst chloromethylation afforded reactive sites through 
13 
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which the C-terminal amino acid could be attached via an ester linkage. Cleavage 
occurred through an alkyl-oxygen fission, see fig.  1.13. 
peptide—NH2 	HF 	 HOOC—peptide—NH2 0 )::) 
OH 
Figure 1.13: Cleavage of Peptide from Merrifield resin. 
The resin is produced in the form of small spherical beads of typical diameter 
-75-200jim. Over 99% of the functional sites are located within the spherical 
structure, it is therefore vital that the resin swells to allow maximum penetration of 
the reagents into the structure to reach the active sites. Merrifields' polystyrene based 
resin offered favourable swelling properties in aprotic, non-polar solvents suitable for 
much organic and peptide synthesis. 
An alternative polymeric support, a polyamide resin, was developed by 
Sheppard , 3 ' by copolymerisation of dimethylacrylamide with ethylene bisacrylamide, 
and functionalisation with acryloyl sarco sine methyl ester. The more polar support 
was designed to be more compatible with the polarity of the growing peptide chain, 
aiding solvation of the peptide and preventing the fall in yield with increased peptide 
length witnessed with the polystyrene based resins. These solid supports are now 
available as co-polymers with polyethylene glycol (PEGA resins). They have 
demonstrated improved swelling properties in aqueous solvents, however, the 
polyamide based resins have not superseded their polystyrene based counterparts, 
which remain the most popular choice of polymeric support. 
The equivalent polystyrene/polyethylene glycol (PEG) co-polymer 
(TentagelTM)32  was also developed on this same principle, to counteract the 
hydrophobic nature of the polystyrene. These resins also offered the advantage of 
separating the growing peptide from the bulky polymeric support, thus reducing 
steric hindrance. The long flexible linker group provided greater mobility, creating a 
14 
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more 'solution-like' environment. This has proved favourable for many solid phase 
organic reactions (SPOS). However, Tentagel TM has a comparatively low level of 
functionalisation, which has limited its application. 
The development of side chain protecting groups susceptible to cleavage 
using TFA (see earlier), encouraged the development of resins cleavable under 
similarly mild conditions. This was the stimulus for the development of the 'linker' 
system, in which a linker or spacer group was introduced between the polymeric 
support and the growing peptide, making it possible to control the lability of the 
peptide-resin link. The vast majority of resins used today are based on Merrifields 
DVB cross-linked polystyrene (PS) matrix, but with the chloromethylene group 
derivatised with alternative linker groups. 
At an early stage, Merrifield modified his original resin to counteract the 
depletion of the growing peptide chain from the solid support observed on repeated 
treatment with strong acid (TFA). This gave rise to PAM resin, see fig.  1.14, still a 
popular resin for use with Boc chemistry today. 33 
I
Jj(01  peptide 
":rH Ester bond formed with peptide 
is cleaved in strong acid (HF) 
Figure 1.14: PAM resin, for use with Boc chemistry. 
The first real breakthrough in resin technology was made by Wang. 34  He 
designed a linker system attached to the original PS matrix, for use with the Fmoc 
orthogonal protecting strategy. It has remained one of the most popular and widely 
used resins to date. 
0 
I 	0 	peptide rEter bond is cleaved in mild acid (TEA), 
however is stable to mild base (i.e. piperidine). 
Figure 1.15: p-Benzyloxybenzyl alcohol (Wang) resin. 
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Although it was synthesised from the Merrifield resin by substitution of the 
chloromethylene group, it did not require the use of strong acid conditions to afford 
the final peptide cleavage. This could be achieved using TFA, by virtue of the p-
oxygen which allowed resonance stabilisation of the carbocation intermediate. 
Figure 1.16: Resonance stabilisation of the Wang resin carbocation. 
Resin technology is a major area of research for solid phase synthesis, and an 
enormous array of linkers attached to the PS polymeric support are now 
commercially available. 35 Virtually all early work with solid phase technology 
concentrated on peptide synthesis, hence the majority of resins were designed to 
immobilize carboxylic acids, Table 1.2 gives five of the resins used for this purpose. 
2-Chiorotrityl resin; 36 
cleaved with 10% AcOH, enabling the 
preparation of side chain protected peptides 
NHFmoc 	Sieber Amide resin;  37 
I 	
cleaved with 1%TFA/DCM giving the peptide 
J::~O amide product. 0 
X 	 Rink acid (X=OH); 38 
cleaved with AcOHIDCM to give the acid, or 
Rink amide (X=NHFmoc); 
cleaved with AcOHIDCM to give the amide. 
00H 3  
0 	 4-Hydroxymethylbenzoic acid 
(HMBA) resin ;39 
- 	 OH 
extremely versatile resin capable of producing 
numerous C-terminal derivatised peptides (see 
later). 
Table 1.2: Five resins designed for immobilizing carboxylic acids. 
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In addition to being extremely acid labile, the 2-chlorotrityl resin prevents 
racemisation of the C-terminal amino acid, which can be a problem with other resins. 
This is especially beneficial for the synthesis of peptides with C-terminal His or Cys. 
The shear bulk of the resin also suppresses diketopiperazine formation by C-terminal 
Pro, which occurs readily with the use of benzyl ester linkages more susceptible to 
nucleophilic attack. 
H 
o 	 OH 







Figure 1.17: Diketopiperazine formation by Pro. 
Many biologically active peptides have non-acid C-terminal functionalities. 
Such modifications are therefore of potential interest in drug applications, in 
peptidomimetics, and also offer a site for further chemical modification. Many resins 
have therefore been purposely designed to liberate derivatised carboxyl terminal 
peptides. 
A frequently encountered C-terminal modification in biological proteins is the 
C-terminal amide, consequently many resins have been developed to achieve this. 
Sieber and Rink amide resins (shown in table 1.2), are early examples of resins 
enabling this modification. They incorporate nitrogen into the linker, allowing 
attachment of the C-terminal acid group through an amide linkage. Subsequent 
cleavage of the completed product liberates an amide functionality, as opposed to the 
free carboxylic acid. 
The hydroxymethylbenzoic acid or HMBA resin is one of the most versatile 
peptide resins. The completed peptide can be cleaved under a wide variety of 
conditions, and changing the nucleophile alters the product (see Table 1.3). Hence 
this enables a diverse range of C-terminal modifications to be achieved using the 
same resin. 
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Peptide methyl ester 
Peptide alcohol 
Table 1.3: Effect of changing the nucleophile when cleaving the HMBA resin. 
The increased interest in the application of solid phase technology to organic 
small molecule synthesis has seen the development of linkers capable of 
immobilizing functional groups other than carboxylic acids, many of these are now 
commercially available. 35 ' Attachment of the starting material to the resin is 
usually achieved through some polar functionality, which is recovered as the same or 
a slightly modified group. Strong polar groups are often undesirable in drug 
candidates, hence the development of 'traceless' linkers which enable compounds to 
be synthesised with no obvious linker attachment point. 40  Other popular resins 
include the safety-catch 4 ' and photolabile types. 
42  Alternatively, another approach 
sees the product synthesised in solution, with the reagents introduced immobilized on 
resin. 
There are an immense array of resins now commercially available, and 
researchers continue to develop new linker systems capable of achieving ever more 
sophisticated chemical manipulations on solid phase. Thus, the chemist may select 
the one most suited to their specific requirements. 
Since Merrifields' pioneering work, solid phase synthesis has developed into 
an important, diverse area of organic chemistry, including both synthetic peptide and 
small molecule synthesis. The basic principle has been applied to achieve all manner 
of on-resin chemical manipulations. In the following two chapters, SPPS is used to 
synthesise a variety of peptides and peptide libraries (see later) in a stepwise manner. 
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Chapter 2 
Investigation of the Endothelin Converting Enzyme 
through its Natural Substrate. 
2.1 Introduction 
2.1.1 Discovery of the Endothelins 
The critical role of the endothelium layer in the control of vascular tone, 
through release of vasoactive substances, was first demonstrated through its secretion 
of a vasodilatory agent termed Endothelin Derived Relaxing Factor, 2 later identified 
as nitric oxide. 3 The observation that the endothelium could also cause 
vasoconstriction was made in 1981. Hickey et a!5 demonstrated the presence of an 
endothelium-derived vasoconstrictor, subsequently identified to be of peptidic 
nature. 6 It was Yanagisawa et al,7 in 1988, who first isolated and characterised this 
vasoconstrictor from cultured porcine aortic endothelial cells, which they named 
endothelin (ET). It was shown to act on the vascular smooth muscle cells causing a 
powerful and long lasting vasopressor effect. It has been recognised as the most 
potent vasoconstrictor known to date, with an activity ten times more potent than 
angiotensin 18 
Its structure was determined to be a twenty one amino acid peptide, 
containing two intramolecular disulphide bonds across the cysteines in positions 1-15 
and 3-11. The N-terminal domain was shown to determine its affinity for the 
receptor, while the C-terminal domain contains the receptor binding site. The parent 
cDNA was identified and cloned. 9 Three distinct genes were identified, encoding 
three closely related peptides. The original endothelin, re-named endothelin- 1 (ET-1), 
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was determined to be one of a family of closely related peptides, with endothelin-2 
(ET-2) and endothelin-3 (ET-3) differing from ET-1 by only two and six residues, 
respectively. The endothelins also show considerable sequence homology with that of 
the sarafotoxins, a family of vasoactive peptides found in the venom of the snake 
Atractaspis engaddenis.' ° Both families of peptides activate the same receptors in the 
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Figure 2.1: Structural similarities between the endothelin family members. 
ET-1 was first isolated from the endothelium, subsequent studies have 
isolated it in non-vascular tissues such as lung, pancreas, kidney, spleen and brain. 12 
ET-2 and ET-3 have been detected in other tissues such as the intestine and adrenal 
gland. ET-3 is relatively abundant in neuronal tissues and is thought to be the neural 
form of the endothelins.' 3 
In addition to being potent vasoconstrictors, the endothelin peptides have 
been shown to possess mitogenic activity and may participate in vascular modelling 
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a wide variety of both vascular and non-vascular tissues, each invoking slightly 
different biological responses. Increased levels of endothelin have also been detected 
in a number of cardiovascular disease states. 15  It is this that has led to the widespread 
interest in the role of the endothelins and the potential benefits that inhibiting the 
action of these peptides may have in the treatment of cardiovascular diseases. 
ET-1 was the first of the endothelins to be isolated and identified. It is not 
only the most abundant, but is also the most potent vasoconstrictor of the three. 
Hence the majority of research into the endothelins has focused on the ET-1 peptide 
and unless otherwise stated, the overview of research reported here refers to ET-1 
2.1.2 Biosynthesis 
Endothelial cells do not contain dense secretory granules in which to store the 
ET for later release. Instead, under normal conditions, ET is secreted continuously 
from endothelial cells through the constitutive secretory pathway and is regulated at 
the level of peptide synthesis. The parent gene can be switched on by a variety of 
physiological stimuli including: adrenaline; thrombin; vasopressin, angiotensin II; 
insulin; cytokines; growth factors and physical stimuli. 19 ET production can also be 
reduced by the presence of various chemical factors including nitric oxide and 
prostacyclin.' 6" 7  The most important physiological factor regulating the production 
and release of ET may be blood flow. 18 
As mentioned previously, the endothelins are derived from three distinct 
genes which encode for three precursor proteins, known as preproendothelins 
(prepro-ET). All are of highly conserved sequences of approximately 200 amino 
acids. Contained within this initial species, sandwiched between pairs of basic 
residues which serve as recognition sites for an endopeptidase, is a sequence of 38 or 
39 amino acids (species dependant) named big endothelin (big ET). This species is 
almost devoid of vasoconstriction activity, less than 1% of that of the corresponding 
ET. 19  To achieve the fully active mature ET species, a further unique processing 
event takes place, catalysed by a previously unknown enzyme termed Endothelin 
Converting Enzyme (ECE) . This species specifically cleaves the Trp 21 -Va1 22 bond 
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in big ET-1 and big ET-2, and the corresponding Trp 21 -Ile 22 bond in big ET-3, to give 
the mature ET and the C-terminal fragment (CTF). Fig. 2.2 illustrates the 
biosynthetic pathway established for endothelin. 
Preproendothelin-1 
I 	 ICOOH 





Trp Val j 









Figure 2.2: Biosynthetic pathway of ET-1. 
ECE is a zinc metal lopeptidase characteristically inhibited by 
phosphoramidon, see later. 20 Two ECE isoenzymes have been identified, 
distinguishable by their localization, optimal pH and their sensitivity to 
phosphoramidon. They are located both on the surface of vascular smooth muscle 
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cells and the endothelial cells, where the majority of conversion is suspected to take 
place as a post secretory event. 
After ET is released from the endothelium it is secreted into the basolateral 
compartment where it acts in a paracrine manner as a local hormone on the surface of 
the endothelial cells and the vascular smooth muscle. 21  It is not released into the 
plasma as a circulating hormone, in fact, under normal physiological conditions the 
plasma concentration is insufficient to achieve vasoconstriction. 22  ET has a very 
short half life in blood because it bonds quickly with the tissue where an Endothelin 
Degradent Enzyme (EDE) is present, which metabolizes it rapidly. 23 
2.1.3 Endothelin Converting Enzyme (ECE) 
Identification, isolation and cloning of the physiologically relevant ECE took 
six years from the first isolation of ET- 1. The first suggestion that the final step in the 
biosynthesis of the endothelins was achieved via a unique catalytic event was made 
in 1988 by Yanagisawa. 7 It was not until 1993,24  that the species responsible was 
finally established, despite considerable , wide ranging research. 
The search for the relevant ECE embraced all classes of proteases including a 
chymotrypsin type, aspartyl, serine and thiol proteases. 25 However, all were 
superseded by the discovery that the conversion was sensitive to phosphoramidon, a 
potent inhibitor of many zinc metal lopeptidases, see fig. 2.320 This halted other lines 
of investigation, and subsequent work focused on ECE as a phosphoramidon 
sensitive, zinc metalloprotease. Since phosphoramidon did not readily enter the cell, 
it was proposed that ECE was an ectoenzyme and that the final stage in the ET 
processing occurred as a post-secretory event on the surface of the cell. 26 








Figure 2.3: Structure ofphosphoramidon. 
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The zinc metalloprotease, neutral endopeptidase-24. 11 (E-24.11 or NEP) has 
been shown to exhibit similar properties to ECE and has consequently been used as a 
model for ECE (see later). The two enzymes show a 37% sequence homology, with 
10 of the 14 Cys residues conserved between the two and evidence suggesting similar 
tertiary structures. Both proteases are inhibited by phosphoramidon, however, unlike 
NEP, ECE is not sensitive to other common metalloprotease inhibitors such as 
thiorpan or the ACE inhibitor, captopril. 27 NEP cleaves peptide bonds on the amino 
side of hydrophobic residues, hence it cleaves the Trp-Val bond of big ET. However, 
it will also degrade ET at other hydrophobic residues, unlike ECE it is not specific to 
that one site .26 
Isolation of ECE was hampered firstly because no rich tissue source of ECE 
was found for use as starting material, and secondly, since ECE was thought to be so 
specific to the natural big ET substrate, attempts to develop a rapid, sensitive assay to 
test for the enzyme have been unsuccessful. In 1993 the isolation of ECE from rat 
lung and porcine aortic endothelium was simultaneously reported by Takahashi et a! 
and Olmaka et al,24 who purified the enzyme to homogeneity. The corresponding 
gene was identified and cloned in 1994.28 
The enzyme was identified as a membrane bound, zinc metalloprotease with 
an optimal activity at neutral pH. It was shown to possess a preference for big ET-1 
over other isoforms of bigET. ECE mRNA has been located in a wide variety of 
tissues including lung, pancreas, placenta, adrenal gland, ovary and testis. With the 
enzyme itself localised in the extracellular face of the endothelial cell membrane in a 
variety of tissues including the aorta, lung, kidney, liver, heart and some secretory 
cells. It was not however detected in the thyroid gland or brain. 29 Evidence supports 
the existence of another non-selective form of ECE located on the surface of smooth 
muscle cells, enabling big ET released from the endothelial cells to be converted to 
the mature ET directly on the smooth muscle surface. 30 
In 1995, a second form of ECE was cloned '31  this was named ECE-2 (with 
the ECE originally isolated re-named ECE-1). It was found to posses an overall 59% 
amino acid sequence homology with ECE- 1, but was shown to have an acidic pH 
optimum of 5.5, in contrast with the neutral pH optimum for ECE-1, and presents a 
27 
Investigation of ECE 
200-fold greater sensitivity to phosphoramidon. Like ECE-1, it is selective for big 
ET-1 over both big ET-2 and big ET-3. This second ECE is located within the 
endothelial cells, acting as an intracellular enzyme, cleaving endogenously 
synthesised bigET- 1 to ET- 1, probably at the trans-Golgi network where the vesicular 
fluid is acidified. The significance of the contributions from both intra and 
extracellular sources to the final ET concentration is unclear, as is the relevant ECE 
involved in the major biosynthetic route. 
Two isoforms of ECE- 1 with distinct N-terminal tails have been found to 
exist, categorised as ECE-la and ECE-113. 32 Both are encoded by the same gene by 
way of alternative splicing of the mRNA transcripts. No significant differences in 
location, specific activities or substrate specificities have yet been observed between 
the two isoforms. 
Both ECE-1 and ECE-2 are type TI integral membrane proteins with a short 
N-terminal cytoplasmic tail, a transmembrane hydrophobic domain and a large 
extracellular domain containing the catalytic site and a typical zinc-binding motif 
HEXXH (His-Glu-X-X-His, where X is a hydrophobic amino acid). Both isoforms 
show significant sequence homology, particularly in the C-terminal region, to NEP 
and the human Kell blood group protein. It is also evident from molecular 
estimations that both enzymes are highly glycosylated, with a predicted ten N-
glycosylation sites. 28(a), 33 
It was first suggested in 1995 that ECE-1 existed as a disulphide linked dimer 
when it was observed that ECE appeared as a 130kDa protein under reducing 
conditions, but as -'300kDa under non-reducing conditions. 21(b),34 Site directed 
mutagenesis established that ECE-1 forms a dimer through its C 412 residue . 35 This 
dimeric structure is preferential for effective conversion of bigET to ET. The C 412 
residue is conserved in ECE-2, strongly suggesting that it also exists as a disulphide 
linked dimer. 
Both ECE-1 (ECE-la and ECE-113) and ECE-2 have been shown to cleave 
bigET-1 more efficiently than either bigET-2 or bigET-3, hence it is predicted that 
there may well be additional members of the ECE family to be discovered which 
would preferentially convert bigET-2 and/or bigET-3, especially in the brain. 
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Site directed mutagenesis studies are building up information on the 
important structural features and residues essential for ECE activity. 1,36  However, 
results from different sources are in some cases contradictory and the conclusions 
presented are based on limited facts. Detailed cell biology of the processing of the 
endothelin precursors, especially the site of action of ECE in the final stage, remains 
controversial. 
Evidence continues to support the hypothesis that the final processing of 
bigET-1 to ET-1 occurs as post-secretory processing event, predominantly at the 
endothelin surface on the extracellular face of the plasma membrane. Not all data 
support this location. When ECE- 1 cDNA is expressed at high levels, intracellular 
accumulation of ET-1 is observed, particularly in the Golgi complex. 29  Some groups 
suggest that the intercellular conversion of bigET- 1 to ET-1 (probably by ECE-2) is 
the major route. Further analysis of the endothelin processing is required to resolve 
these discrepancies, amongst others, and to evaluate the relevant roles and locations 
of the different ECE isoforms. 
2.1.4 Endothelin Receptors 
After release from the endothelial cells, the mature ET peptide rapidly 
achieves its physiological action through attachment to specific endothelin receptors. 
Endothelin receptors exist both on the surface of vascular smooth muscle and the 
endothelium. In 1990, two receptors were isolated and cloned, termed ETA and 
ETB . 37 Characterisation showed both to consist of seven transmembrane segments of 
20-27 amino acids. Their structures possess a sequential and topographic similarity to 
the G protein-coupled superfamily. 
The ETA receptor exists on the surface of vascular smooth muscle. It shows a 
differential affinity for the three isoforms of endothelin in the order ET-1>ET-
2>>ET-3, the ETB receptor however shows no selectivity. 38  In 1993, the existence of 
two ETB receptor subtypes was confirmed, named ETBI and ETB2. 39 ETBI receptors 
are located on the surface of the endothelium and ETB2 on the vascular smooth 
muscle surface. 
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The endothelins control vascular tone by both causing vasoconstriction and 
dilation. This is achieved by stimulation of the different receptors. Stimulation of the 
ETA and ETB2 receptors on the vascular smooth muscle causes vasoconstriction, 
while stimulation of ETBI on the endothelium causes vasodilation via release of 
relaxing factors . 40 In 1994, a third type of ET receptor was cloned, termed ETC, it has 
been shown to display greater affinity for ET-3 over ET-l. 4 ' Located on the 
endothelium surface, stimulation results in vasodilation by release of NO. Fig. 2.3 
gives a summary of the ET interactions. 
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Figure 2.4: Endothelin, other endothelin-derived vasoactive factors 
and their interactions. 
Research employing ET- 1, the most potent and widespread of the endothelins, 
revealed that under physiologically normal conditions, the level of endothelin 
produced in the endothelium is very low. At this concentration the hormone acts 
locally on the receptors in the endothelium itself, ET8 1 and ETC. These cause the 
release of other endothelium derived vasoactive factors, nitric oxide synthase and 
cycloxygenase 1, which can pass both into the adjacent smooth muscle causing 
vasodilation and into the lumen inhibiting platelet aggregation. It is now generally 
accepted that ET-1, under normal physiological conditions, is a vasodilator acting on 
the endothelium ETBI receptors. 1,42 
Under certain physiological stimuli, ET levels increase and the peptide 
becomes capable of passing through the endothelial cells into the smooth muscle, so 
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acting directly on it via stimulation of the ET A and ETB2 receptors, causing 
vasoconstriction through a heightened level of intracellular Ca 2 .43 Furthermore, 
under pathophysiological conditions ET levels can become so high that it can pass 
into the lumen and act as a circulatory hormone. Increased plasma levels of ET have 
been reported in a variety of disease states. 
In addition to its effect on vascular tone, stimulation of the different 
endothelin receptors in different tissues causes a variety of responses.' 4 The 
documented mitogenic activity of ET-1 promotes proliferation of vascular 
endothelial cells, vascular smooth muscle and fibroblasts, mediating cardiac growth 
and hypertrophy. Recently it has been shown, through targeted gene disruption of 
mice, that the endothelin peptides may also have a morphogenic role in a variety of 
developmental events. Disruption of the ET genes caused severe craniofacial 
abnormalities. 44 Undoubtedly, further biological processes in which the endothelins 
play an essential role will be revealed. 
2.1.5 Pathophysiology 
Increased ET levels have been indicated in a wide variety of disease states. 45 
Cardiovascular diseases: 
myocardial ischemia 











acute/chronic renal failure 
Vascular disorders: 
atherosclerosis 
other vascular disorders, 
e.g. Buergers disease, Takayasu's arteries 
Raynauld' s phenomenon 
complications in diabetes 
Cancer, esp. pulmonary carcinoma 
Gastric mucosal damage 
gastrointestinal disorders 
Other: 
Endocrine: 	 endtoxic shock, septicemia 
pre-eclampsia 
Table 2.1: Disease states in which the endothelins have been implicated. 
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Their role in a number of cardiovascular, renal and central nervous system diseases is 
well documented, including hypertension and heart failure, 46 myocardial infarction, 47 
acute renal failure, 48  neointimal thickening, asthma, global and focal cerebral 
ischemia and vasospasm, including subarachnoid haemorrhage 49  and Raynauld's 
disease. 50  In addition to causing sustained vasoconstriction, ET stimulates the 
generation of a cocktail of neurotransmitters and hormones including: renin; 
angiotensin II; aldosterone and adrenaline.' 
The majority of ET synthesised in the endothelium is released towards the 
underlying smooth muscle hence does not necessarily result in increased plasma 
levels, however elevated circulatory ET-1 levels have been reported in a variety of 
pathogenic conditions. In pulmonary hypertension and hypertension developed 
during pregnancy, heightened plasma levels have been recorded due to ET-1 over 
production. Increased levels are seen during acute myocardial infarction and unstable 
angina, where ET receptor antagonists have been reported to reduce myocardial 
infarction size. ET-1 levels are also significantly increased in the cerebrospinal fluid 
of patients after subaracimoid haemorrhage causing cerebral vasoconstriction. Other 
disease states in which endothelin may play a role continue to be identified. 
The increasing experimental and clinical evidence that overproduction of the 
endothelins (especially ET-1) may play a significant pathogenic role in such a wide 
variety of disease states, has attracted significant attention to the possibility that 
inhibition of the endothelin activity could be ,a useful therapeutic tool for use in 
cardiovascular medicine, particularly in conditions in which these peptides are clearly 
implicated. Research has focused on inhibiting the normal endothelin processing 
pathway at two points, either at the ET receptor using an antagonist, or by inhibition 
of ECE-1, see fig.  2.5. 
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Figure 2.5: Strategies used to inhibit the biological effects of ET-]. 
Due to the relatively early identification and cloning of the endothelin 
receptors, the development of potential endothelin antagonists has been widely 
pursued. Researchers have embraced all manner of chemical candidates, this work 
has been comprehensively reviewed elsewhere.  23,51  One of the most promising to 
have emerged (currently in clinical trials) is R047-0203, known as bosentan, see fig 





—X' 0 ,,~OH 
l~~ 
Figure 2.6: Bosentan. 
Studies have shown that systemic administration of bosentan to patients with severe 
chronic heart failure produced systemic, pulmonary and peripheral venous 
vasodilation and improved cardiac performance. Several potential antagonist 
candidates have now reached clinical trials, with early results suggesting a beneficial 
therapeutic use combined with ACE inhibitors in the treatment of chronic heart 
failure. 
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ECE-1 proved more elusive and was not isolated until 1993. This restricted 
the development of ECE-1 inhibitors, hence research in this area lags behind that of 
the endothelin antagonists. ECE-1 offers an ideal candidate for blocking the 
endothelin pathway since it appears highly specific to its natural substrate big ET, 
cleavage of which is essential for full ET activity. 53  Despite problems obtaining the 
pure enzyme, much research has been carried out with the view to developing viable 
ECE-1 inhibitors, again this has been comprehensively reviewed elsewhere. 54 
2.2 Structure Activity Relationship Study of Big ET-1. 
2.2.1 Background 
Although much progress in our appreciation of ECE- 1 has been made since 
its isolation, there is still a great deficit in our fundamental knowledge of the enzyme. 
Significant understanding of the enzyme active site and critical residue interactions 
can be gained by Structure Activity Relationship (SAR) studies of the natural 
substrate. Such studies are widely used to probe the conformational and biochemical 
requirements of Iigandlreceptor interaction. The major substrate of ECE-1 is big ET -
1 (BET-1), a 38 amino acid peptide containing the major structural features: two 
disulphide bridges between residues 1-15 and 3-11; a-helix: residues 8-12; n-sheet: 
55 residues 27-30 and 32-35; 13-turns: residues 4-7 and 22-26. 
NH 
Lys 	 21 22 
 ECE 
Glu Cy Val Tyr Phe His 	
HOOCgProSerGIyLeuGIyTr0 




Figure 2.7: Big endothelin-] (bigET-1). 
34 
Investigation of ECE 
As discussed earlier, BET-i is cleaved by ECE-1 exclusively at the Trp 21 -Val22 bond 
to give the mature ET-1 peptide and CTF. 56 
Several groups have performed limited investigations into the effect of 
truncating the BET-1 substrate on enzyme recognition. In 1991, it was reported that 
BET-1 [17-26] was not recognised by ECE- 1, suggesting that residues within the 
substrate, distant from the site of cleavage, may be essential for enzyme 
recognition. 57  Okada et al. established, through specific site mutations, that residues 
27-34 within the C-terminal region were important for enzyme recognition, though in 
what capacity was not understood .58  They later proposed BET-1[19-34] as the 
minimum sequence to be recognised by ECE-1. The N-terminal disulphide loop 
appeared to hinder conversion to the mature species, as BET[16-37] showed a 2 fold 
faster rate of hydrolysis than the natural substrate, while BET[ 18-34, Phe 22] showed a 
12 fold increase. 59 
A limited study by Fabbrini et al. demonstrated that substitution of residues 
bordering the scissile bond was tolerated, with the mutants being hydrolysed by ECE-
1, indicating that the conformation rather than sequence of the substrate was 
important for enzyme recognition. 60 Tentative suggestions were made that, while the 
P1 residue (Trp) was critical, the P1' residue could tolerate substitution, but only by a 
hydrophobic amino acid. 6 ' 
The fact that ECE-1 recognised a relatively long carboxyl-terminal sequence 
in addition to the processing site made the enzyme unique. Heightened interest in the 
big ET substrate was triggered when Morita et al. reported that the enzyme did not 
cleave truncated analogues with D-amino acids at positions 20, 21, 22 & 23, and that 
one of the analogues, BET[16-38, D-Val 22], showed potent competitive inhibitory 
activity, comparable to that of phosphoramidon (Ki 2.5x10 5M). 62 These studies 
were very limited, to determine definitively the requirements for enzyme recognition, 
further research exploring sequence changes and truncation of the substrate would be 
necessary. 
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2.2.2 Preliminary SAR Investigation of ECE-1. 
A systematic SAR investigation of big ET-1 analogues was undertaken to 
elucidate the minimum peptide sequence required for enzyme recognition and the 
residues critical to binding. The inhibitory nature of these species provided a handle 
with which to compare and evaluate each analogue. It also offered the possibility of 
designing a potential ECE inhibitor drug candidate. 
A suitable peptidic ECE inhibitor candidate would posses a minimal IC 50 
value, offset against the shortest chain length for enzyme recognition. Longer 
peptides are more prone to in vivo enzymatic cleavage, the shorter the sequence the 
more easily it can be protected against hydrolysis, making it potentially orally active 
and more favourable pharmacokinetic properties. In addition, shorter sequences offer 
better templates on which to base small molecules, which are preferred drug 
candidates. An inhibitor must be able to attach to the active site of the enzyme, 
preventing the natural substrate from binding, but must not be cleaved by the enzyme 
in any way. 
The project was initially taken up by Jiang, 63  whose investigation overlapped 
with the subsequent findings made here. A preliminary discussion of this study 
should therefore be made. 
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PEPTIDE 	 % INHIBITION IC 50QtM) 
1 	 Big ET- 1(16-38) 92.1@1.tIvI 	0.038 
2 Big ET- 1(19-38) 	 39@200.tM 12.5 
3 	 Big ET- 1(19-34) 2.5 
4 Big ET-1(19-34, Leu34) 7.0 
5 Big ET-1(19-34, Leu32'34) 70.1@200tM 
6 Big ET-1(27-34, Leu34) 0@200tM 
7 Big ET-1(19-38, Pen(Acm) 22) 12.1200pM 
8 Big ET-1(19-38, Pen 22) 1.0 
9 Big ET-1(19-34, Cys(Acm) 22) 46.3@100tM 
10 Big ET-1(19-34, Cys 22) 17.3 
11 Big ET-1(19-34, Pen(ACM) 22) 43.4@1001.iM 
12 Big ET-1(19-34, Pen 22) 60.5@100tM 
13 Big ET-1(16-34, Cys(Acm) 22) 0.33 
14 Big ET-1(16-34, Cys 22) 0.040 
15 Big ET-1(16-34, Pen(ACM) 22) 5.5 
16 Big ET-1(16-34, Pen 22) 10.2 
17 	Big ET- 1 (Cys(Acm)" 3" 5 ,Trpp(CI-I2NH)Val) 	 13.5 
18 Big ET- 1(Cys" 3"5 , Trp(p(CH2NH)Val) 5.3@10,.iM 	32.2 
19 Big ET- 1(12-3 8,Cys(Acm)' , Trp(p(CH2NH) Va!) 	 13.2 
20 	Big ET-1(19-38 ,Trpp(CH2NH)Val) 	0@100M 
Table 2.2: SAR Results from study by Jiang. 
From the % inhibition and IC 50 results it could be confirmed that truncation 
from both the N and C termini was possible whilst retaining enzyme recognition. The 
BET-1(16-38) truncate demonstrated a highly favourable IC 50, suggesting it was 
efficiently recognised by ECE-l. Both BET-1(19-38) and BET-1(19-34) were 
recognised by the enzyme, in concordance with the previously reported results, 
however the truncation was accompanied by a large increase in the IC 50 . Truncation 
of the C-terminal from 38 to 34 did not have such a dramatic effect on the IC 50 as 
cutting the N-terminal from 16 to 19, suggesting that residues 16 to 18 may be more 
important for enzyme recognition. 
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Peptides 4 and 5, with Leu substituted for Gly at residues 32 and 34, showed 
a greater IC 5 0 value than BET-1(19-38) suggesting that residues 35 to 38 were not 
essential for enzyme recognition. BET-1(27-34, Leu 34) showed no inhibitory activity, 
whether it was in fact recognised by the enzyme was not established. 
Previous studies had shown that some substitutions of residues 21 and 22, 
flanking the natural cleavage site of BETA, were tolerated. Sulphur containing 
amino acids are frequently found to give interesting results in enzyme inhibitory 
studies, hence a number of analogues containing both protected and unprotected Cys 
and Pen at residue 22 were synthesised. All SH protected species showed decreased 
inhibitory activity compared with the unprotected analogues, indicating that the free 
SH was important. Comparison of the free Pen with the corresponding free Cys 
analogues, showed that both the size of the residue and the free SH group were 
significant. The BET-1(16-34, Cys 22) analogue showed the greatest inhibitory 
activity, and presented the most likely potential ECE- 1 inhibitor candidate. 
Jiang also made a series of reduced isostere truncates to alter the 
conformation of the peptide at the scissile bond, with the natural amide bond 
mimicked by the reduced peptide bond p(CH 2NH). The large increase in IC 50 
suggested the peptides were no longer efficiently recognised by the enzyme. 
The main points of interest from this study were that BETA could be 
truncated to BET-1(19-34) whilst retaining enzyme recognition, in concordance with 
the results from Okada et al, however residues 16 to 18 appear to play an important 
role. BET- 1(16-38) displayed a favourable IC 50 value. Substitution of residues 32 and 
34 were tolerated, hence further C-terminal truncation maybe possible without 
jeopardising recognition. Substitution of residue 22 with sulphur containing amino 
acids revealed a potential ECE- 1 inhibitor candidate, BET- 1(16-34, Cys 22). 
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2.2.3 SPPS of Truncated Big ET-] Analogues. 
All peptides in this chapter were made singly using automated SPPS on an 
Applied Biosystems 430A peptide synthesiser, employing the NaFmoc  orthogonal 
protecting strategy (see chapter 1). Where necessary, the amino acid side-chains were 
protected using standard acid labile protecting groups. 
All peptides, except BET-1(16-27) and BET-1(16-27, Cys 22), employed 
Wang resin as the polymeric support. The C-terminal amino acid was manually 
coupled to the functional sites of the resin via the symmetrical anhydride. The level 
of loading was quantitatively checked by deprotection of the NaFmoc,  using 
piperidine and the UV absorbance of the deprotection solution measured at 302nm 
(corresponding to the chromophoric piperidine-fulvene adduct). The two remaining 
peptides were synthesised on 2-chlorotrityl chloride resin as they possessed C-
terminal His which is prone to racemisation on the Wang resin. 
The degree of amino acid loading onto both resins was determined by the 
reaction time. Low levels of loading are often desirable when synthesising large 
peptides as steric interactions between growing peptide chains can be detrimental to 
the synthesis; however, all the peptides contained here were relatively short, hence 
amino acid loadings of 65-80% of the total functionalised sites on the resin 
(achieved through 2.5-3 hours sonication) were used. 
Each synthesis was performed on a 0.25mmol scale, via a stepwise strategy 
from the C to N terminal, using the standard protocol detailed in chapter 5. 
Activation of the protected amino acid was achieved using DIC and HOCt, a novel 
coupling agent designed and synthesised by Ramage et al. (see chapter 1), to form 
the actived ester. This was then introduced to the deprotected N-terminus of the resin 
bound peptide and coupling allowed to proceed. It is essential that near quantitative 
coupling be achieved for each residue in order to ensure the synthesis goes to 
completion. Previously, using conventional DIC and DIC/HOBT coupling methods, 
this was achieved by coupling each amino acid twice, known as double coupling. 
However, the use of HOCt made this unnecessary, as a single coupling step for each 
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residue was normally sufficient to achieve the required > 90% coupling efficiency. 
This has made the peptide synthesis both faster and more economical. 
The NaFmoc  was cleaved from the resin-bound peptide between residues, in 
preparation for the next amino acid, using 20% piperidine in 1:1 DMF/dioxane. The 
chromophoric nature of the piperidine-fulvene adduct provides a non-invasive means 
of monitoring the coupling efficiency of each residue, hence estimate the potential 
yield of the completed peptide. An aliquot of the deprotection solution is 
automatically transferred from the synthesiser to an on line UV detector, set at 
302nm, connected to an integrator. This allows the size of the deprotection peak to be 
compared with that of the previous amino acid, enabling the relative coupling 
efficiency of each step to be monitored. A deprotection profile can be constructed for 
the peptide synthesis, fig 2.10 gives the profile for the BET-l(16-38, Leu 22) peptide, 
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Figure 2.10: Deprotection profile for big ET-1(16-38, Leu 22) 
After completion of the synthesis, the NaFmoc  of the final N-terminal amino acid 
was left intact allowing the quantitative calculation of that amino acid, hence the 
completed peptide, attached to the resin. 
The Fmoc group was cleaved manually using piperidine, prior to acidolytic 
cleavage of the peptide from the resin using 95% TFA with a cocktail of scavengers. 
This treatment cleaved both the peptide from the resin and removed all side-chain 
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protecting groups, giving the fully functionalised, free peptide. The scavengers are 
carbocation sequesting agents, their presence in the cleavage mixture prevents 
electrophilic attack of the amino acid side chains by the protecting groups liberated as 
carbocations, a consequence of the acidolytic cleavage. The scavengers selected for 
the cleavage depend on the amino acids (and protecting groups) in the sequence, a 
general guide is given in Table 2.3. 
Choice of Scavenger 	 I Amino Acid 
Water 	 All residues 
Ethanedithiol (EDT) 	 All 'Butyl and Trityl protected amino acids, 
esp. Trp, Met and Cys(Trt) 
Thioanisole 	 Met, Arg(Pmc) 
Triisopropylsilane (TIS) 	 Substitute for EDT, particularly for Arg(Pmc) 
and Trp(Boc) 
Phenol 	 Tyr, Trp 
Table 2.3: Use of Scavengers in Acidolytic Cleavage. 
The optimum cleavage time was established for each peptide as 2-2.5 hours by trial 
cleavages with small quantities of resin. The crude product was isolated from the 
TFA and scavengers by trituration with diethyl ether, then re-dissolved in a suitable 
solvent system to a concentration of —5mg/ml. The majority of peptides completely 
dissolved in 1:2 acetonitrile/water. 
Purification was achieved via preparative RP HPLC. The analytical RP HPLC 
profile of the crude material provided guidelines by which to set the preparative 
conditions. The exact gradient profile was individually tailored to each peptide to 
afford maximum separation, the general gradient profile is detailed in chapter 5. 
Analytical RP HPLC confirmed the purified material to be single peak, and 
its composition was analysed via MALDI ToF mass spectroscopy and amino acid 
analysis (see Appendices I and II). Each peptide was then sent to Parke Davis 
Pharmaceuticals, Aim Arbor, Michigan, where its IC 50 value was measured against 
cloned soluble ECE-1 (solECE-1). This value offered a simple method for 
comparison and evaluation of each analogue. 
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2.2.4 SAR Study of Truncated BigET-] Analogues. 
PEPTIDE 	 %INHIBITION 	IC5o(iM) 
1 	Big ET-1(16-38, D-Va1 22) 	 2 
2 	Big ET- l(16-34) 	 0.085 
3 Big ET-1(17-34) 0.57(±0.057) 
4 	Big ET- 1(18-34) 	37%@50.M 
5 	Big ET- l(16-32) 	 0.14 
6 Big ET-1(16-27) 0.37 
7 Big ET-1(16-38, Cys 22) 0.059 
8 Big ET-1(16-32, Cys22) 0.15 
9 Big ET-1(16-32, Cys 21 ) >1 
10 Big ET-1(16-32, Cys 21 '22) >1 
11 Big ET-1(16-27, Cys22) 1.07 
Table 2.4: Inhibition results for the SAR study of Big ET-1 analogues. 
Initially BET-1(16-38, D-Va1 22) was synthesised for comparison with that 
same peptide made by Morita et al. The 10 5 0 was determined to be 2iM, this was in 
concordance with that previously reported. 
In continuation of the study made by Jiang, the effect of further truncation of 
the BET- 1(16-38) analogue was more closely studied. Truncation of the N-terminal 
to residue 34 caused a two fold increase in the IC 50; however this figure is 
comparable with that of BET-1(16-38) when the associated error is taken into 
consideration. Subsequent reduction from the C-terminal to residues 32 and 27 
caused a greater increase in the IC 5 0, suggesting enzyme recognition may have been 
more significantly weakened by the removal of C-terminal amino acids after residue 
34. 
Truncation of the N-terminal, peptides 3 and 4, saw a more dramatic increase 
in the IC 5 0 suggesting that residue 16, His, was important for ECE-1 recognition. A 
potential ECE- I inhibitor based on the BET-i substrate should therefore contain this 
residue to enable efficient enzyme recognition, whilst truncation of the C-terminal to 
residue 27 may be tolerated. 
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Jiang's investigation of the effect of sulphur containing amino acids was 
expanded by substitution of the favoured unprotected Cys, see earlier, for the 
residues flanking the natural cleavage site in a number of truncated analogues. 
Substitution of Cys into position 22 (P1') of BET-1(16-32) and BET-1(16-38) had 
virtually no effect on the IC 50, while substitution into the (16-27) analogue caused a 
significant increase. This was in contrast with the previous investigation of BET-
1(16-34, Cys 22), which had been shown to posses two fold greater activity 
(IC50 =0.040) than the corresponding BET-1(16-34). Substitution of Trp for Cys at 
position 21 (P1) was not tolerated (peptides 9 and 10). 
From this investigation it can be said that although BET-1 can be truncated 
from the N-terminal to residue 19 and still retain some enzyme recognition, residue 
16 is essential for strong binding of the peptide to ECE-1. Truncation of the C-
terminal to residue 27 is also tolerated. The dramatic fall off in activity associated 
with the N-terminal truncation was not as obvious; however, as the residues 38 to 27 
were systematically removed, the 10 50  was seen to increase in an exponential-like 
manner, allowing for the conclusion that residues 28 to 34 are also significant to 
enzyme recognition. From this study it could be extrapolated that BET-1(19-27) 
would be recognised by the enzyme, however, the Km value for BET-1(16-27) was 
determined (Parke Davis, Michigan) to be significantly greater than that of BET-
1(16-38) (see later), indicating that it bound more weakly to ECE- 1. 
A potential peptidic enzyme inhibitor candidate should posses the 
optimal balance between 10 50  value, strength of binding and minimum chain length. 
Of the analogues investigated, the three most promising candidates were: 
IC 50 (1..tM) 
Big ET- 1(16-38) 	 0.038 
Big ET-1(16-34) 0.085 
Big ET-1(16-34, Cys22) 	0.04 
All showed strong enzyme binding characteristics and worthy of further 
investigation. 
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2.2.5 Substrate Testing of Potential ECE-1 Inhibitor Leads. 
The truncated analogues BET-1[16-34] and BET-1[16-38] were shown to 
bind to ECE- 1, with IC 50 values comparable with ECE- 1 inhibitors reported by other 
groups. 54  Both were considered worthy of more extensive subsite investigation, by 
systematically substituting key residues with alternative amino acids to optimise 
inhibitory activity, using the powerful technique of combinatorial chemistry (see 
chapter 3). 
Combinatorial chemistry is the term given to the principle whereby, instead of 
synthesising single compounds, multiple (in some cases many millions of) 
compounds are generated simultaneously. This technique has gained popularity, 
particularly in the pharmaceutical industry where recent advances in high throughput 
biological screening has placed a great demand on the supply of novel compounds for 
testing. 
The BET-1[16-34], being four residues shorter, was the preferred candidate 
for combinatorial exploration, and it had already been demonstrated that substitution 
of Va122 by Cys halved the IC 5 0 value. However, prior to launching further 
investigations, it was necessary to establish whether or not these potential lead 
candidates acted as substrates for ECE. 
The theoretical post cleavage C-terminal peptide fragments of the BET-i [16-
34] and BET-1[16-34, Cys 22] analogues (BET-1[22-34] & BET-1[22-34, Cys 22]) 
were synthesised and sent to Parke Davis, where they were used as references when 
analysing the products from the peptide interaction with ECE-1 by HPLC. 
Both analogues showed cleavage by ECE-1. BET-1[16-34] was rapidly 
hydrolysed exclusively at the Trp 21 -Va1 22 bond. Substitution of the Va1 22 by Cys 
slowed the rate of cleavage of the 21-22 bond, and mass spectrometric analysis 
revealed the formation of several products. In addition to the predicted [16-21] and 
[22-34] products, fragments [20-34], [21-34], [20-28] and [21-28] were detected due 
to the cleavage of the Ile"-Ile 20,  1le20-Trp2 ' and Va128-Va129 bonds. The fragments 
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went on to form di-sulphide bridged species; [22-34] formed a di-sulphide linkage 
with the free substrate, while either [20-34] bridged to [21-28] or [21-28] bridged to 
[20-34] (both possessing the same mass). 
It appeared that, contrary to what had been previously thought in earlier 
research of ECE, the enzyme was capable of cleaving several bonds in the BET-i 
peptide, however only at a much slower rate than that of the Trp 21 -Va1 22 . In the BET-
1[16-34] analogue, the Trp 21 -Va122  hydrolysis occurred rapidly, allowing insufficient 
time for the relatively slow cleavages at the other sites to occur at a detectable rate. 
Once the substrate was cleaved at the Trp 21 -Va1 22, ECE-1 was incapable of cleaving 
the resulting smaller peptides. However, because the rate of hydrolysis of the Trp 21 -
Cys22  bond was much slower, this allowed cleavage at the alternative sites to occur at 
a comparable rate before the substrate was hydrolysed into shorter peptides which 
behave as poor ECE-1 substrates. 
2.2.6 Conclusions 
The truncated BET-i analogues, being alternative substrates for the enzyme, 
were unfortunately unsuitable as potential ECE- 1 inhibitors, bringing this line of 
investigation to a close. The SAR study did however furnish us with considerable 
information into the enzyme/substrate interaction; residue 16 (His) was critical for 
enzyme recognition, the minimum sequence which demonstrated strong binding was 
BET-1[16-34], limited substitution at P1' position was also tolerated. Hence these 
findings concur with previous reports that the 27-34 sequence C-terminal sequence is 
important for ECE- 1 recognition. 
The revelation that the truncated big ET-1 analogues were cleaved both at the 
21-22 bond and alternative sites along their length, is in contrast to the previously 
held belief that ECE- 1 hydrolyses the Trp 21 -Va1 22 bond in its natural BET-1 substrate 
exclusively. This observation opened up an alternative line of investigation. 
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2.3 Subsite Specificity Study of ECE-1. 
2.3.1 Introduction to Kinetic Study of Substituted B1gET-] (16-38) Analogues. 
A recent substrate specificity study by Parke Davis, Ann Arbor, revealed that 
ECE-1 was capable of metabolising a number of biologically active peptides 
differing in both size and structure, including: neurotensin; substance P; angiotensin I 
and oxidised insulin B chain, as efficiently as its known in vivo substrate big ET-1. 64 
This study was further to that made by Turner et al. ,65  who observed that ECE- 1 was 
capable of hydrolysing bradykinin. This was in contrast to previous assertions that 
ECE- 1 cleaved the big ET peptides exclusively. 
The study revealed ECE-1 to have a substrate specificity similar to that of 
neprilysin (NEP or neutral endopeptidase 24.11), a mammalian cell-surface zinc 
metallopeptidase of the same enzyme family as ECE- 1, preferring to cleave the 
substrate at the amino side of hydrophobic residues. NEP had been used previously 
as a model for ECE-1 due to their chemical and physical similarities, both are 
phosphoramidon-sensitive zinc metal loproteases with significant amino acid 
sequence and structural homology. However a number of differences in their 
substrate specificity and sensitivity to inhibitors had been observed; NEP was known 
to metabolise a broad range of substrates, while ECE- 1 was thought to be specific to 
the endothelin precursors. 
The results of the study by Parke Davis opened up the possibility that ECE-1 
is potentially involved in the metabolism of a broad range of biologically active 
peptides distinct from the endothelins, both at the cell surface and in the secretory 
pathway. The revelation that all the truncated big ET-1 analogues from section 2.2.4 
were also alternative substrates for ECE- 1, presented a new area for investigation of 
these species. As discussed previously, the analogues were cleaved by ECE-1 at 
varying rates (i.e. with different kca t values). It was also observed that if the cleavage 
at the 21-22 site was hindered, as in big ET-1(16-34, Cys 22), ECE-1 was able to 
cleave the peptide at a number of other sites along the backbone at a compatible rate. 
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When the 21-22 bond was rapidly hydrolysed, further cleavage of the 
resulting peptide fragments was not seen, presumably the shorter peptide fragments 
were poor substrates for ECE- 1. The substrate specificity study by Parke Davis had 
observed that ECE-1 had been incapable of metabolizing substrates smaller than 
hexapeptides, also that the enzyme preferred to cleave amide bonds with a 
hydrophobic P1' residue but that a variety of residues were tolerated at the P1 
position. 
A kinetic study of the P1 and P1'positions, flanking the cleavage site of the 
big ET-1(16-38) truncate, with systematic sub-site variation was undertaken to 
elucidate the sub-site specificity of BCE-i. Such information is useful in the design 
of both enzyme substrates and inhibitors. 
2.3.2 Michaelis-Menten Enzyme Kinetics. 
The relationship between the rate of catalysis and substrate concentration 











Substrate Concentration [5] 
Figure 2.11: Relationship between rate of enzyme catalysis 
versus substrate concentration. 
At low substrate concentrations, for a fixed concentration of enzyme (E), the rate is 
first order (linearly proportional), but at high substrate (5) concentrations the rate 
becomes independent of that concentration and is therefore zero order. 
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In 1913 Leonor Michaelis and Maud Menten proposed a simple model to 
account for these characteristics, based on the assumption that the enzyme forms a 
specific intermediate complex with the substrate prior to product formation. This 
model is illustrated by the scheme: 
k 1  
E + S - 	ES FAST STEP 	(1) 
ES 	
k2 	
Products + E SLOW STEP 	(2) 
where E = enzyme 
S = substrate 
ES = enzyme-substrate complex 
At high concentrations of substrate all the enzyme active sites are occupied, the 
enzyme will exist solely as the enzyme-substrate complex and the reaction velocity 
will reach maximum. Then, the rate of decomposition of the complex to the 
product(s) will determine the overall speed of the process, i.e. is the rate determining 
step. 
Hence, 
Rate forward (Vf) = k2 [ES] 	 (3) 




MICHAELIS-MENTEN Equation I 
Krn+[S] I 
Vm ax = Maximum velocity, achieved when enzyme is 
fully saturated with 
[5] = Concentration of substrate 
Km = Michaelis Constant 
where Km = k 1 /k 1 , based on an equilibrium approach 	 (4) 
or, Km = (k 1  + k2)/k 1 , based on a steady-state approach (5) 
The steady state approach is often considered the more realistic as the equilibrium 
method assumes a true equilibrium to be achieved in the first step. 
The Km value is routinely determined when characterising an enzyme as it is 
a reproducible constant, unique to that enzyme. It is dependant on both the specific 
substrate and environmental conditions such as pH, temperature and ionic strength. 
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The Km value has two meanings; firstly it is equal to the substrate concentration at 
which the reaction rate is half its maximum value, that is, the substrate concentration 
when half the enzyme active sites are filled, see fig.  2.11. 
Km = [S] at 0.5V m 	 (6) 
Hence the lower the Km value, the more compatible the substrate is with the enzyme 
active site, and the lower the concentration required to saturate the enzyme. 
Secondly, the Km value is related to the rate constants of the individual steps 
of the catalytic scheme, in fact it is equal to the dissociation constant of the ES 
complex, see equations 4 and 5. This relationship is only true for the equilibrium 
approach if k.1 is much greater than k 2 (k 1 >>k2), that is, when the dissociation of the 
ES complex to E and S is much more rapid than the formation of E + products, see 
steps 1 and 2. When this is true Km is a measure of the strength of the ES complex 
(how tightly the substrate binds); a high Km indicates weak binding, while a low Km 
indicates strong binding of the substrate to the enzyme active site. 
The turnover number, k cat , of an enzyme is the number of substrate molecules 
converted into product by an enzyme molecule in a unit time, when the enzyme is 
fully saturated with substrate, i.e. at V ma, when [S]>>Km. 
Then, kcat = k2 	 (7) 
Hence, Vmax  
= kcat[Etotai], -(8) 
since [ES] = [Etotail 
It is a reflection of how fast the enzyme will work when saturated with substrate, and 
is dependant on the amount of enzyme present. The turnover numbers for most 
enzymes with their physiological substrates are in the range 1 to 104  per second. 
Under normal physiological conditions however, most enzymes are not 
saturated with substrate. When [S]<<Km and most of the enzyme active sites are 
unoccupied, the enzymatic rate is much less than V m . Under these conditions the 
enzyme velocity, that is, the rate of forward reaction, Vf, depends on the value of 
kcat/Km and on [S]. The kcat/Km value (specificity constant) is independent of the 
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amount of enzyme present and is comparable against other enzymes, making it a very 
useful parameter. The higher the k cat/Km ratio, the better the substrate. 
The ultimate limit on the value of kcat/Km is set by the rate of diffusion 
controlled encounter between the enzyme and its substrate, hence the maximum 
1(cat/Km is between 108  and109m's'. If the kcat/Km ratio of an enzyme lies within this 
range, it is said to have obtained kinetic perfection and its catalytic velocity is 
restricted only by the rate at which it encounters substrate in solution. The k cat/Km 
ratio holds for enzymes with more complex reaction pathways than the simple two 
step scenario given here; therefore it is a commonly used parameter for comparison 
in enzyme kinetic studies. 
Although the Michaelis-Menten model does not hold for all enzymes, the big 
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Figure 2.12: Plot of reaction velocity verses [Big ET-1 (16-38)]. 
In the subsequent subsite specificity study of big ET-1(16-38) analogues, the initial 
velocity data for each substrate was plotted as a function of concentration to fit the 
Michaelis-Menten equation, using KaleidaGraph Software (Synergy Software, 
Reading, PA) to obtain Km and V m a., values. Turnover numbers, kc at, were calculated 
from the expression kca t = Vmax/[E], using a subunit molecular mass of 1.2xl0 51)a for 
so1ECE-1 (recombinant soluble ECE-1). 
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2.3.3 Subsite Specificity Study of ECE-]. 
In order to evaluate the specific effects of changes at the P1 and P1' positions, 
it was necessary to use a series of peptides identical in structure apart from the side 
chains at the P1 and P1'. The Km values of a number of previously submitted big 
ET-1 truncates were measured, see Table 2.5, to determine the most suitable 
candidate for the subsite specificity study. 
TRUNCATE Km(p.M) 	kcat(sec') 	kcat/Km(M' s) 
Big ET- 1(16-38) 13.8 3.3 2.4x10 5 
Big ET-1(16-34) 42.1 	 6.7 	 1.5X10' 
Big ET-1(16-32) >400 - 	 - 
BiET-1(16-27) >400 	 - 	 - 
Table 2.5: Km and k 1 data for previously submitted Big ET-] analogues. 
Measurement of the Km value of big ET-1(16-32) and big ET-1(16-27) was 
hampered by poor solubility making these peptides unsuitable for use in the kinetic 
study. The big ET- 1(16-38) analogue was selected as the most suitable substrate 
since it possessed the most appropriate (lowest) Km value for convenient 
measurement in the HPLC assay, it bound strongly to the enzyme, was efficiently 
cleaved and was shown to be the most soluble of the truncates. 
A series of 12 big ET-1(16-38) analogues were individually synthesised by 
SPPS, using the protocols described previously in section 2.2.3, with the 6 amino 
acids Leu, Phe, Pro, Arg, Glu and Ala substituted at residues P1 and P1' flanking the 
natural cleavage site 21-22. Each peptide, purified to single peak by RP HPLC, was 
sent to Parke Davis, Michigan, where it was assayed against so1ECE- 1. 
The hydrolysis of each was characterised by the determination of the kinetic 
constants Km and keat. The initial velocity (Vo) data for the rate of cleavage at the 
labile bond, 21-22, was determined for each analogue by the appearance of the C-
terminal (22-38) product by HPLC analysis. This was plotted as a function of 
substrate concentration to fit the Michaelis-Menten equation. The data were analysed 
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by KaleidaGraph (Synergy Software, Reading, PA) to determine the kinetic 
parameters displayed in Table 2.6. 
PEPTIDE Km(.tM) kcat(S ' ) k,.at/Km(M- ' s- 'L- 
Big ET-1 2 0.052 2.5x104 
Big ET- 1(16-38) 13.8 3.3 2.4x105 
Big ET-1(16-38, Phe2t ) 7.1 1.83 2.6x105 
Big ET-1(16-38, Leu21 ) 70 6.1 8.7x104 
Big ET-1(16-38, Ala 21 ) 4.2 0.63 1.5x105 
Big ET-1(16-38, Pr021 ) 57 5.2 9.1x104 
Big ET-1(16-38, G1u21 ) 190 6.9 3.6x104 
Big ET- 1(16-38,Arg21 ) 360 15.4 4.3x104 
Big ET-1(16-38, Phe22) 	 18.2 15.4 	 8.5x105 
Big ET-1(16-38, Leu22) 	 29.6 15.36 5.2x105 
Big ET- 1(16-38, Ala 22) 	 131 26.3 	 2.0x105 
Big ET-1(16-38, Pr0 22) 	 - - 	 - 
Big ET-1(16-38, G1u22) 	 134 7.9 5.7x104 
Big ET-1(16-38, Arg22) 	 - - 	 - 
Table 2.6: Kinetic data from systematic subsite specificity study of ECE-1. 
All the 16-38 analogues were substrates for ECE-1, except big ET-1(16-38, 
Pro 22) and big ET-1(16-38, Arg 22) which were not hydrolysed at a detectable rate. 
None of the peptides in this study, including big ET-1(16-38), were found to bind to 
ECE-1 as effectively as big ET-1, indicated by the high Km values, making them 
comparatively poor substrates. However, higher k cat/Km values were seen for the 
majority of analogues, indicating a higher rate of hydrolysis of the labile bond. This 
observation is consistent with previous reports suggesting the C-terminal loop of big 
ET- 1 may hinder conversion to the mature ET- 1 species in some way. 
It was predicted that ECE-1 would preferentially cleave the peptide chain 
directly prior to a hydrophobic residue, while a number of different residues were 
thought to be tolerated at position 21 (P1). Hence analogues with a hydrophobic 
residue at position 22 (P 1') should be more readily cleaved. 
It was found that all analogues with a variable 21 residue were primarily 
cleaved at the X21 -Va1 22 bond, except for the Arg 2 ' which was also cleaved at the 
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Asp' 8-Il& 9 site. Small amounts of (19-38) product were detected after prolonged 
incubation with ECE-1 for the other peptides. All obeyed Michaelis Menten kinetics, 
except big ET-1 (16-38, Ala 21 ), although big ET-1 (16-38, Arg 2 ') required prolonged 
incubation. From these results it is apparent that varying the P1 residue does not have 
a dramatic effect on the rate of hydrolysis by ECE- 1 as the k cat/Km values were all 
comparable with big ET-1(16-38). However, the charged side chains of hydrophilic 
Glu and Arg made relatively poor substrates, with significantly higher Km values for 
those peptides. The corresponding rate of hydrolysis was slow allowing, in the case 
of big ET-1(16-38, Arg21 ), cleavage at the alternative 18-19 site. 
Big ET-1(16-38, Ala21 ) showed strong binding to ECE-1, with a Km value 
only two fold greater than big ET- 1 itself; however, its rate of hydrolysis was ten fold 
greater due to its larger turnover number. It obeyed Michael is-Menten kinetics up to 
3OtM, but was shown to inhibit ECE-i at higher concentration (10 50>35p.M). 
It was predicted that the P1' position would be more specific. Although the 
majority of analogues were still recognised as substrates, substitution of the P1' site 
with the hydrophilic residues Pro and Arg, led to compounds neither cleaved by 
BCE-i nor that were inhibitors of the enzyme. Since no detectable hydrolysis at the 
labile bond was observed, the kinetic study was not performed for either. Big ET-
1(16-38, G1u22) was found to be an ECE-1 substrate, although the big ET-1(16-38, 
Pro 22) analogue, containing the less hydrophilic Pro residue, was not. This 
phenomenon has been seen for other peptidases on substituting Pro at the P1' site of 
the substrate. It is thought that it must cause a distinct conformational change at the 
cleavage site. 66  Phe and Leu are more hydrophobic than the natural Trp, although 
they did not bind as strongly as big ET-1(16-38), they were the most rapidly 
hydrolysed of all the analogues. 
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2.3.4 Summary and Conclusions 
As predicted, substitution at the P1 position was tolerated with k cat/Km values 
remaining fairly consistent, although the large Km values indicated weak binding. All 
obeyed Michaelis-Menten kinetics, except big ET-1 (16-38, Ala 21 ), although big ET-
1 (16-38, Arg 2 5 required prolonged incubation. This is concordant with the predicted 
results, that the P1 site was not specific. Big ET-1 (16-38, Ala 21 )obeyed Michaelis-
Menten kinetics up to 30M concentration, above this it acted as an ECE inhibitor, 
although no explanation has been offered. 
Substitution at the P1' position also appeared to be tolerated, except for 
substitution with Arg and Pro. This was unexpected, one explanation is that other 
residues in the peptide sequence are recognised by the enzyme, enabling binding of 
the substrate despite substitution of the P1' residue. 
These findings support assertions that ECE-1 is not wholly specific to the 
cleavage of big ET to give the mature ET, but is capable of cleaving a variety of 
substrates. 
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Chapter 3 
A Novel Purification Protocol for Soluble 
Combinatorial Peptide Libraries 
3.1 Introduction to Combinatorial Chemistry 
It has been estimated that a new drug requires the preparation and evaluation 
of approximately 10,000 compounds over a period of twelve years at a cost of -224 
million.' These figures, together with ever increasing competitiveness, have forced 
the pharmaceutical industry to adopt new technologies which promise more efficient 
and economic approaches to drug discovery. 
Advances made in the 1980's, such as the development of robotics and the 
miniaturisation of in vitro testing methods, have enabled biologists to screen 
thousands of compounds against a large number of biological targets in a matter of 
days. This high-throughput screening technology revolutionised the pharmaceutical 
industry's ability to evaluate novel compounds for desirable biological activity, 
which had previously been a bottle neck in the drug discovery process. The rate 
limiting step was then defined by the ability of the chemist to provide a continuous 
supply of novel molecules for testing, the philosophy being that the greater the 
number of compounds screened, the greater the probability of identifying one with 
desirable activity. 
Traditional sources of molecules include the internal chemical portfolio of the 
company, together with commercial and university collections; or alternatively from 
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natural sources such as fermentation broths, plant and marine animal extracts. 
However, these sources are exhaustive and represent only a small fraction of the 
potential diversity possible. Over the past decade a new thinking has emerged to 
revolutionise traditional chemical synthesis, bringing it in line with the high-
throughput screening technologies. 
The term combinatorial chemistry refers to the simultaneous synthesis of 
multiple (in some cases many millions of) compounds, all chemically and structurally 
distinct. Whereas traditionally each compound is synthesised and purified one at a 
time before submission for biological testing; combinatorial chemistry aims to 
rapidly produce a diverse range of permutations of a given molecule, without 
necessarily maintaining total control of the absolute chemical nature of each species 
within the mixture. This, in theory, should accelerate the drug discovery process at 
the 'lead generation' and 'lead optimization' stages. These vast mixtures, or libraries, 
are created within a similar time frame to that traditionally taken by the chemist to 
create single compounds, and opens the door to a degree of chemical diversity 
previously inaccessible. 
The *extent of diversity achievable through combinatorial chemistry is 
dependant on the number of locations within the molecule selected to introduce 
diversity at, and the number of different functionalities or building blocks introduced 
at those positions. When considering a library of peptides, the number of members of 
that library is determined by the number of residues into which diversity is 
introduced and the number of amino acids introduced at that residue according to the 
relationship N = b", where N = number of compounds in library, b = number of 
building blocks and x = number of synthetic steps. Hence a library of hexapeptides, 
varied at each residue with each of the 20 naturally occurring amino acids, would 
contain 205 =3.2 million members. This is further illustrated in Table 3.]. 
Purification of Peptide Libraries 
Number of Steps at which Number of building blocks Theoretical size 
diversity is applied at each step of library 
1 20 20 
2 20 400 
3 20 8000 
4 20 160000 
5 20 3200000 
2 5 25 
6 5 15625 
12 5 244140625 
5 50 313500000 
Table 3.1: Size of library achieved depends upon both the number of building 
blocks used and the number of steps at which diversity is introduced. 
The sudden explosion of interest in combinatorial synthesis was accompanied 
by the development of numerous technologies for the simple, efficient synthesis and 
deconvolution of ever increasing numbers of libraries containing the maximum 
possible diversity. 
Combinatorial chemistry is synonymous with solid phase synthesis. Only 
using this methodology can such vast numbers of compounds be practically created. 
This is due to the well documented advantages of the technique: purification of 
intermediates is unnecessary, isolation of the resin-bound intermediates is achieved 
through simple filtration; reactions may be driven to completion using excess 
reagents and catalysts, which are easily removed from the mixture after the reaction; 
solid phase techniques are amenable to automation. 
Perhaps due to this, the combinatorial principle was initially used to create 
vast libraries of peptides using the well established SPPS methodology, although 
recent years has seen a revival of interest in Solid Phase Organic Synthesis (SPOS) as 
the potential benefit of small molecule libraries has been realised. Advances in 
immunology, the human genome project and the molecular cloning of numerous 
bioactive receptors, enzymes, hormones etc. placed a huge demand on the supply of 
synthetic peptides for SAR exploration studies, which also threw combinatorial 
peptide synthesis into the limelight. 
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3. 1.1 Combinatorial Peptide Libraries. 
It was in 1984 that Mario Geysen first developed a technique to synthesize 
multiple peptides simultaneously, known as the 'mimotope strategy' 
2  He synthesised 
96 different peptides concurrently on a resin support covalently linked to the 
spherical pinhead surface of polyacrylic acid-grafted polyethylene pins arrayed in a 
96 microtitre plate format. By exposing each pin to a different activated amino acid, 
it was possible to synthesize only one peptide per pin and to know the structure of the 
individual peptides on each pin head. Using multiple plates it was possible to 
synthesize several thousand peptides simultaneously with specific spatial location. 
The biological activity of these peptides was tested, with the peptides still 
attached to the pins, using an ELISA binding assay against a biological target of 
pharmaceutical interest. Those pins carrying peptides which successfully interacted 
with the biological target could be visually identified, thus allowing manual 
separation and sequencing to reveal their identity. 
The methodology was initially met with much scepticism, but pressure on the 
pharmaceutical industry to produce more compounds forced the synthetic chemistry 
community to acknowledge the potential benefit of Geysen's concept. Modification 
of the original Multipin technology has improved and broadened its application; in 
particular the use of linker groups attached to the resin support, allowing cleavage of 
the peptides into solution, enabling competitive binding experiments to be run. This 
powerful methodology has been applied to the synthesis of a broad array of libraries. 3 
Houghten, another early pioneer of combinatorial chemistry, devised an 
ingenious method to rapidly produce large numbers of peptides simultaneously, using 
already established SPPS methodology, by physically dividing the resin into a 
number of individual porous polypropylene bags, known as the 'tea-bag' method. 4 
Each bag was separately exposed to different individual activated amino acids, then 
the bags combined for all common steps such as washing and deprotection; in this 
way specific, individual peptides were synthesised in each. Labelling each bag with 
its synthetic history enabled the incredibly simple identification of any peptides 
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displaying desirable biological activity. The size of the library was limited only by 
the number of bags used. 
The most obvious way to synthesise multiple peptides simultaneously might 
be to couple mixtures of amino acids to a single resin support, so that each bead in 
theory supports all the library members. This method has been used with marked 
success; however, there is little control over the final composition of the library as 
certain sequences would be favoured over others due to competing coupling 
reactions, hence equimolar representation is not achieved. This is essential to obtain 
meaningful biological results. The problem is circumvented by dividing the resin into 
a number of equal aliquots, according to the number of different amino acids to be 
coupled, then pooling the resin for all common steps. This technique was devised by 
Furka et al. and is illustrated in fig.  3. 
15  Each of the sublibraries could either be 
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Figure 3.1: Fur/ca's Split-Pool Synthesis. 
Libraries of up to approximately 106  members are obtainable using these 
techniques; however libraries of --10 3-104 members have been reported to be of 
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optimal size. Both the Multipin and Tea-bag methods have been used commercially 
for this purpose. 
One of the most sophisticated technologies which has emerged for the solid 
phase synthesis of peptide libraries is that of spatially discrete arrays, created on a flat 
surface or plate, employing photolithigraphic methods. 6 The technique uses a 
photolabile N'-amino protecting group which can be photochemically removed from 
specifically defined portions of the plate surface. Therefore only those sequences 
which were previously deprotected will react with the activated amino acid to which 
the entire surface is subsequently exposed. The pattern of illumination (or masking 
against illumination) and the sequence of reactants define the products and their 
location 
The number of compounds possible is limited only by the number of synthetic 
sites that can be addressed with the available masking strategy. It is possible to 
prepare up to 400 different peptides on a 10mm x 10mm surface (with a spatial 
resolution of 0.5mm x 0.5mm), and, from a practical point of view, this technology 
could be used to prepare much larger libraries (-10 5) than the multiple peptide 
synthesis strategies discussed previously. 
Of vital importance in combinatorial chemistry is the ability to identify 
unambiguously the library components showing desirable biological activity, that is 
the ability to deconvolute the library. On-resin analysis of peptides or 
oligonucleotides is relatively simple, if a one-bead-one-product protocol has been 
employed, using reversible, colourmetric biological analysis to isolate the bead, 
followed by an appropriate microsequencing technique to identify the species. On-
resin colourmetric assays are also applicable to spatially addressable libraries 
including the Multipin, Tea-Bag and Photolithographic techniques, where the 
location and identity of each product is recorded throughout the synthesis. 
However, this strategy is not suitable if there are multiple peptides on any 
given bead, or the library has been cleaved from the solid support to be tested in 
solution. If the library is deemed to possess favourable activity, the component or 
components cannot be immediately isolated and identified; the active members are 
determined by an iterative process of sub-library synthesis and re-analysis. This 
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method, originally devised by Houghton et al., though time consuming, laborious 
and wasteful, is often unavoidable. 
Direct microsequencing analysis is limited to oligomeric libraries, since such 
sensitive methods of absolute identification are not possible when the library consists 
of small organic molecules. An alternative strategy, to avoid iterative testing and re-
synthesis, is to attach a unique identifier tag or code to the individual resin beads 
directly after each building block, using a split/pool technique. Each product can be 
deduced by the corresponding unique sequence of tags which give the complete 
chemical history of that bead. 
The tags must: have mutually compatible chemistries with the desired 
libraries; be stable to all reagents used in the synthesis; be readily cleaved under 
specific, mild conditions, independently of the product; be capable of very high 
sensitivity detection, providing unambiguous identification. A variety of tags have 
been employed to date including nucleotides for encoding peptides, 8 peptides for 
encoding non-peptides or non-sequencable products and photolabile aromatics (see 
fig. 3.2) again for encoding both peptides and small organic molecules. 9 
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Figure 3.2: Photolabile aromatics used to 'tag 'peptide libraries. 
Non-chemical methods of library tagging have also been reported, the most 
successful of which uses radio frequency (RF). The resin is divided into an 
appropriate number of porous micro-reactors each containing an RF encodable chip. 
A Split/Mix synthetic strategy is employed, as described previously, but prior to re- 
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combining each sub-section is subjected to a unique RF pulse, hence each RF chip 
has a record of the complete synthetic history of that reactor. This principle has been 
exploited in one of the most commercially successful combinatorial technologies, 
developed primarily for small molecule library synthesis, known as IRORITM. 
The high sensitivity of many of the encoding strategies makes unambiguous 
identification of minute quantities of material possible, enabling libraries of up to 
108 109  members to be rapidly deconvoluted. The technology is also amenable to 
small molecule synthesis and has facilitated the screening of combinatorial small 
molecule libraries. 
3.1.2 Combinatorial Organic Synthesis 
Synthetic peptide chemistry has the advantage over recombinant techniques in 
that it is not restricted to the 20 natural amino acids genetically encoded for, but can 
incorporate any form of unnatural amino acid or amino acid mimic that it is possible 
to create, thus greatly expanding the potential diversity achievable. Peptides are of 
central importance in nature, where they are used to control, catalyse and modulate 
all biological responses. Random screening and SAR investigation of peptides and 
proteins provides essential information into highly complex biological processes and 
often furnishes the researcher with a template on which to design novel 
pharmacophores. 
Unfortunately, peptides are frequently unsuitable as drug candidates due to 
their poor bioavailability and unfavourable pharmacokinetic and pharmacodynamic 
properties, being rapidly broken down by peptidase enzymes in vivo. The vast 
majority of pharmaceutical drugs available are small organic molecules. To truly 
explore the enormous potential of combinatorial chemistry, the unlimited reaction 
types as well as building blocks must be exploited. 
The development of Combinatorial Organic Synthesis (COS) was initially 
hampered by the limited solid phase methodology for organic transformations. It was 
Leznoff, in the 1970's, who first realised the advantages of performing organic 
reactions on a solid support. In its most simple sense, the polymeric resin could be 
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considered an insoluble protecting group and Leznoff reported its use as such in the 
synthesis of several small organic molecules, in particular for use with symmetrical 
bifunctional compounds.' 
 phase organic synthesis (SPOS) fell into disrepute due to the limitations 
of the methodology compared with solution phase synthesis: the range of compatible 
solvents was limited to those which enabled resin swelling; reaction temperatures 
were relatively low to avoid resin breakdown; reaction times were longer and 
analysis of resin-bound compound was problematic. Recently, however, SPOS has 
witnessed a major revival with the enormous potential of combinatorial chemistry. 
Current literature continuously reports the adaptation of known organic 
transformations to solid phase, making this one of the most rapidly expanding areas 
of organic chemistry. 12 
To date, small molecule libraries have been based on organic molecule 
templates of known biological interest. The libraries have been built up around the 
multifunctional basic skeleton of these proven pharmocophores by attachment of a 
range of building blocks with complimentary functionalities. Early heterocyclic 
combinatorial libraries included benzodiazapines,' 3 13-mercapto ketones 
14  and 
quino lone antibiotics. 15 
Many of the technologies developed for peptide library synthesis have been 
adapted for COS, in particular the encoding strategies which facilitate deconvolution 
of the libraries. In addition, COS has seen the development of a multitude of new 
technologies specifically designed for that purpose. 
3.1.3 Concluding Remarks 
Combinatorial chemistry has rapidly established itself as an important area of 
synthetic organic chemistry with a vast amount of literature published, scientific 
meetings and even companies dedicated to the advancement of the methodology. A 
comprehensive survey of the different methodologies available was outwith the scope 
of this report, however there have been several reviews published. 
16 
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It is perhaps too early to expect to see a new drug on the market which 
originated from a combinatorial library; however there have been sufficient 
discoveries made showing drug candidate potential, to persuade the pharmaceutical 
industry to adapt their drug discovery programs to include this enticing 
methodology. 17 
Combinatorial chemistry has revolutionized the drug discovery process 
through the vast chemical diversity achievable using this technology. The scale of 
research being performed and the technological advancements being made, mean that 
this area of synthetic organic synthesis is set to expand much further. 
3.2 Purification of Soluble Peptide Libraries. 
3.2.1 Aim of the Project. 
The importance of studying the interaction of peptides with biological targets 
of interest has already been established. Peptides have proven useful both as models 
on which to base small molecule leads and as potential drug candidates in their own 
right. The production of vast peptide libraries is therefore an important application of 
combinatorial chemistry. 
Deconvolution and evaluation of these complicated mixtures to establish 
which, if any, of the species posses desirable activity is not a trivial exercise; 
observed biological activity might be the cumulative effect of a number of the 
predicted library members or even due to some unpredicted impurity(ies) present. 
Iterative deconvolution techniques and sub-library resynthesis may fail to identify 
these 'false hits'. If the library is tested on-resin using a one-product-one-bead 
strategy, the active peptides can be visually observed, via an appropriate assay, and 
the relevant beads manually removed for microsequencing. The problem of false hits 
is particularly significant when the library is cleaved from the solid support and 
tested in solution. 
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Screening in solution can be advantageous as the peptides are likely to behave 
differently tethered to a resin compared with when completely free. Solution 
screening may therefore represent a more accurate evaluation of the libraries' 
biological activity. In addition, resin-bound libraries are limited to screening against 
soluble receptors, such as antibodies or enzymes. 
As with all chemical synthesis, peptide synthesis results in the accumulation 
of impurities and by-products. In peptide synthesis much of this takes the form of 
chemically similar truncated peptides (truncates); shorter lengths of the desired 
peptide sequence which, after Na deprotection, failed to couple with the next 
activated amino acid, hence to prevent their further participation in the synthesis 
were 'capped' with acetic anhydride. Due to their similar chemical nature they can be 
very difficult to eliminate from the desired sequence(s). When producing peptide 
libraries the problem of accumulating truncated peptides is obviously amplified. 
Limited efforts have been made to eliminate these species from the libraries, 
although due to their similar nature they are likely to interfere during library 
screening, either by masking the activity of genuine library members or they 
themselves resulting in 'false hits'. The highly sensitive screening techniques 
required as a result of the relatively low concentration of each library member 
present, makes it important to eliminate any additional complicating factors so that 
meaningful results might be obtained from the library. 
The acetylated N-terminal of the truncates, in principle, offers a handle with 
which to separate these species from the desired peptides with free N-termini. 
Ramage et al designed a pendant moiety, tetrabenzo[a,c,g,i]fluorenylmethoxycarbonyl 
(Tbfmoc), to exploit this distinction. 18  The aim of this project was to optimize the 
Tbfmoc purification protocol of chemically synthesised peptides and adapt it to the 
facile purification of soluble peptide libraries. 
70 
Purification of Peptide Libraries 
3.3 Tetrabenzo[a,c,g,i]fluorenyl methoxycarbonyl. 
0 
O A 
 N peptide I—OH 
Figure 3.3: Tetrabenzo[a, c, g, iJfluorenyl methoxycarbonyl (Tbfmoc) moiety attached 
to the peptide through its Na amino acid. 
Tbfmoc was based on the Fmoc protecting group, see section 1.3.2. It is 
attached to the Na-amino terminus of the completed peptide sequence, via the 
chloroformate, after removal of the Na  protecting group but prior to side chain 
deprotection and acidolytic cleavage from the solid support. The truncated peptides, 
having acetylated N-termini, will not attach the Tbfmoc thereby introducing a 
definite distinction between the peptide and truncates. The moiety imparts a number 
of useful properties onto the peptide to which it is attached, these have been 
exploited to facilitate the separation of the desired sequence from the truncates and 
other impurities accumulated during SPPS, see table 3.2. 
Property 	 Purification Advantage 
UV absorbance maximum at 364nm. 	Can easily differentiate between Tbfmoc 
and non-Tbfmoc material. 
Imparts different solubility characteristics 	Tbfmoc peptides can elute later on RP 
on peptide. 	 HPLC than non-Tbfmoc impurities. 
Extremely high affinity for carbon 	Tbfmoc-peptides adsorb, truncates can be 
washed away. 
Table 3.2: Properties imparted on the peptide by the Tbfmoc. 
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The extended conjugation system of the Tbfmoc species furnishes it with a 
characteristic absorbance at 364nm, enabling any peptides possessing this moiety to 
be easily identified by UV or RP HPLC. Tbfmoc also imparts different solubility 
characteristics on the peptide, increasing the hydrophobicity of the species. This can 
result in the peptide having a longer retention time on RP HPLC, so separating it 
from material which would normally co-elute. Tbfmoc, being an essentially planar, 
aromatic molecule, has been shown to possess a high affinity for carbon. This has 
enabled the desired peptide sequence to be pulled out of the crude synthesis material 
via an affinity chromatography technique; whereby all desired sequences are 
adsorbed onto the insoluble carbon, via the Tbfmoc, leaving all truncates and other 
impurities in solution. The carbon can then be washed, removing all remaining 
impurities, before cleaving the desired peptides back into solution. 19 
Tbfmoc has been used previously to purify single peptides and proteins, the 
following work describes its application to the purification of five randomly selected 
soluble peptide libraries. 
3.2.3 Synthesis of Combinatorial Peptide Libraries 
Five randomly selected libraries were synthesised via automated SPPS using 
the Fmoc orthogonal protecting strategy on Wang resin, see fig 3.4. 
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Figure 3.4: Five randomly selected peptide libraries. 
The first two libraries each consisted of a mixture of three truncated 
analogues of the 21 amino acid peptide hormone Endothelin- 1 (see chapter 2) in co-
operation with a separate investigation on going at that time. 20 The third and forth 
libraries were both based on a truncated segment of the leumorphin protein, 
21 
selected due to its ease of synthesis. Three amino acid diversity was introduced at 
three sites in library 3, resulting in 27 unique peptides (33,  section 3.]). Purification 
of this library to its predicted 27 members only, demonstrated the ability of Tbfmoc 
to pull out the relevant sequences from larger mixtures. The final library consisted of 
nine analogues (including the natural species) of the 40 amino acid f3-Amyloid 
protein, involved in the pathology of Alzheimer's disease. 22  The successful isolation 
of this library demonstrated the adaptability of Tbfmoc to the purification of small 
protein libraries. 
Each of the libraries was synthesised on an Applied biosystems 430A peptide 
synthesiser on a 0.25mmol scale using the general protocol outlined in Chapter 5, 
together with the most simple method of multiple peptide synthesis to achieve the 
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diversity. This entailed the cartridges corresponding to the sites of diversity being 
loaded with equimolar quantities (1/3 mmol each) of the three amino acids to be 
introduced at that position, such that the total amino acid content of the cartridge 
remained at immol. This enabled the libraries to be synthesised completely on the 
automated synthesiser without adapting the existing apparatus in anyway. 
Although this method could result in a non-equimolar concentration of each 
library member, it was selected due to its rapid, facile nature and yielded libraries of 
sufficient quality to which the Tbfmoc purification protocol could be applied. Amino 
acid analysis results of the libraries did however indicate a relatively good equimolar 
presence of each product, see Appendices III- VII. 
If the library was to be submitted for biological testing then equimolar 
quantities of each library member is essential to ensure equal representation in the 
assay. Since this is not guaranteed using the above method, a split/pool strategy was 
adopted in the synthesis of library 4. This was accomplished by dividing the resin 
into three equal portions at the positions of diversity and manually coupling each 
separately with the appropriate activated amino acid in the sonic bath, using similar 
conditions to those employed by the synthesiser. The portions were then re-combined 
for filtration and washing, before the resin was returned to the automated synthesiser 
which performed all common steps either to the next position of diversity, where the 
process was repeated, or to the end of the synthesis. 
Non-optimum conditions were applied to each synthesis using DIC/HOBT 
with single coupling throughout, except for library 5 (see section 3.7) in order to 
demonstrate the effectiveness of the Tbfmoc application in achieving pure peptide 
libraries. On completion of the synthesis the IVaFmoc  was cleaved from the resin-
bound library of peptides and Tbfmoc loaded via the chioroformate, see fig. 3.5. The 
crude libraries were all cleaved from the solid support and the functionalized side 
chains deprotected using a standard acidolytic cleavage protocol. 
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Figure 3.5: Loading of Tbfmoc onto the peptide libraries via the chloroformate. 
3.2.4 Initial Study Using the Original Tbfmoc Purification Protocol. 
Library 1 was solubilized in 1:1 6M guanidine hydrochloride/isopropanol (1:1 
6M GuHC1/iPrOH). RP HPLC of the crude material showed the Tbfmoc group to 
have caused increased retention of the three desired peptides, such that they were 
sufficiently separated from the other material to allow the use of simple preparative 
RP HPLC to achieve purification. All material with a corresponding 364 nm 
absorption was collected and analysed by analytical RP HPLC, MALDI ToF mass 
spectroscopy and amino acid analysis, which confirmed the presence and identity of 
the three peptides (see Appendix III). 
The RP HPLC trace of the crude second library was more complicated than 
that of the first, with the 364nm material overlapping with unidentified foreign 
material, such that simple preparative HPLC was unsuitable. Instead, for this and all 
subsequent libraries, Tbfmoc's affinity for carbon was exploited. Libraries two and 
three used porous graphitised carbon (PGC) to affect purification. 
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The crude material, isolated from resin cleavage, was adsorbed onto PGC 
from the 1:1 6M GuHC1/iPrOH solution by vortexing, leaving all non-Tbfmoc 
material, including truncates, in solution. A polar solvent system was required to 
achieve effective adsorption of the Tbfmoc-peptides from solution and a 1:1 6M 
GuHCl/iPrOH system was chosen due to the poor solubility of the Tbfmoc-peptide 
libraries. Complete adsorption of 364nm material was confirmed by HPLC, the 
suspension centrifuged and the supernatant discarded. The PGC was washed 
repeatedly with the solvent system, using the vortex/centrifuge technique, until a flat 
baseline was attained on RP HPLC, indicating that all the truncates and impurities 
had been washed away. The libraries were then cleaved from the Tbfmoc moiety 
using 10% piperidine in the solvent system, leaving the Tbfmoc group still adsorbed 
on the carbon. The piperidine supernatant, containing the library, was neutralised 
with glacial acetic acid and desalted using RP HPLC. 
Lyophilisation resulted in high quality, white peptide which was analysed by 
MALDI ToF mass spectroscopy and amino acid analysis, thus confirming the 
presence of each of the library members only. Fig. 3.6 shows the MALDI ToF mass 
spectrum of library 3 after carbon purification, this clearly illustrates the diversity 
within the library. Of the 27 members, 10 were of degenerate mass giving 17 mass 
variants (given in the table). 






1285 A11287.9 1361 E/1360.9 
1299 1363 F/1364.3 
1303 B/1303 1375 
1313 1379 6/1379.6 
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Figure 3.6: MALDI ToE mass spectroscopy results for Library 3. 
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3.2.5 Optimisation of the Tbfmoc Purification Protocol 
It was considered that improvements could be made to the Tbfmoc 
purification protocol. Having cleaved the library from the Tbfmoc, leaving the 
moiety adsorbed onto the carbon, the PGC is effectively spent. PGC being a very 
expensive form of carbon, meant that it was desirable to find a cheaper alternative to 
use in the purification protocol. This was found in ordinary acid washed, 
decolourizing, chromatographic charcoal. In addition, the guanidine hydrochloride 
solvent system was not ideal, being a charged species it tended to stick to the 
peptides making it difficult to eliminate. The purification protocol was thus 
optimised with the exclusion of this medium. 
The Tbfmoc strategy was revised by subjecting each of the nine members of 
Library 4, synthesised individually, to a number of modified procedures. Under the 
conditions described previously, in section 3.2.4, only 50% of the peptides were 
recovered as clean, white material, the rest being obtained as viscous gums after 
purification. This was possibly due to poor de-salting of the peptide as a result of the 
guanidine. A trial cleavage of the peptides without Tbfmoc showed the crude 
material to be highly soluble in 1:1 acetonitrile/water. The protocol was therefore 
modified; the Tbfmoc library was adsorbed onto charcoal from 1:1 6M 
GuHC1/iPrOH, then, after washing twice with that system, the charcoal was washed 
with 1:1 acetonitrile/water and the peptide cleaved off the Tbfmoc using 10% 
piperidine in 1:1 acetonitrile/water. De-salting was achieved using preparative RP 
HPLC, holding the gradient at 2 % acetonitrile until all the salt had been eluted. 
Unfortunately these modifications proved insufficient, the 6M guanidine 
hydrochloride was very persistent, therefore it was desirable to avoid the use of this 
solvent altogether. The 1:1 6M GuHC1/iPrOH system had been selected due to the 
strongly hydrophobic nature of the peptides when attached to the Tbfmoc. In order to 
eliminate the use of this system entirely, the peptides were adsorbed onto the 
charcoal directly from the TFA cleavage mixture without prior isolation of the crude 
product, making the Tbfmoc purification step an extension of the acidolytic cleavage. 
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The chromatographic charcoal was found to cause a persistent brown 
discolouration of the peptides. Although the carbon was pre-washed with each 
system to which it would be exposed, this was insufficient to prevent the charcoal 
from imparting these coloured impurities to the peptides. They were introduced 
during the 10% piperidine cleavage step, resulting in discolouration of the piperidine 
supernatant and a large number of fines. It was found, however, that after repeated 
washing with fresh 10% piperidine in 1:1 acetonitrile/water, the supernatant 
eventually remained colourless. The charcoal could then be rinsed with the neutral 
solvent system and finally with the TFA/scavenger cocktail, then used immediately to 
adsorb the Tbfmoc-peptides. It was found that the washed charcoal could not be dried 
or stored for later use. 
Having revised the purification strategy, the vortex/centrifuge method was 
directly compared with a dry flash approach. In both, equimolar quantities of a single 
resin-bound member of library 4 (DPNGYSGELFDA) with NaTbfmoc  was used, 
with approximately the same weight of carbon (0.5 g). The peptide was loaded 
straight from the TFA cleavage solution onto the carbon in both cases. 
The vortex/centrifuge method was performed as described previously. In the 
dry-flash method, the charcoal was loaded into a small column with a sintered glass 
frit at the bottom (a layer of cotton wool and Celite was necessary to prevent the 
charcoal fines from passing through the sinter). The column was fitted to a water 
pump vacuum filter apparatus, and the TFA cleavage solution of the peptide poured 
through the column three times until all the material with a corresponding 364 nm 
absorbance had been adsorbed from the solution. The carbon was washed with 1:1 
acetonitrile/water, before cleaving the peptide using 10% piperidine. The charcoal 
was allowed to remain in contact with the piperidine by removing the vacuum for 
several minutes, and by re-pouring the solution repeatedly through the column. 
Finally the carbon was rinsed with 1:1 acetonitrile/water. 
In both cases, the resulting piperidine solution was acidified with glacial 
acetic acid, the acetonitrile removed in vacuo and the solution subjected to 
preparative RP HPLC. The single peak, eluted at 33% acetonitrile, was collected 
and freeze dried. Although both methods resulted in clean, white product, the 
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vortex/centrifuge method resulted in a yield of 83.8% pure peptide, while the dry 
flash method 62.5%. Hence it was concluded that the vortex/centrifuge method was 
the better strategy for Tbfmoc purification. 
The efficiency of charcoal versus PGC was also assessed, again using the 
Tbfmoc-DPNGYSGELFDA peptide, using the vortex/centrifuge method with equal 
amounts of each form of carbon. The PGC was found to give a 53.7% yield 
compared with the 83.8% yield for charcoal, making charcoal the preferred form of 
carbon for the Tbfmoc purification strategy. 
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Purification of Peptide Libraries 
Library 4 was synthesised using a split/pool strategy, see section 3.1.1, giving 
a final coupling efficiency of 46%, hence the library contained a significant amount 
of impurities. When it was subjected to the optimised purification strategy (method 
2a, see chapter 5) an 82% yield of clean, white material was obtained. The power of 
the Tbfmoc/carbon purification strategy is illustrated in fig.  3.8, which compares the 
analytical RP HPLC of the crude Library 4, with that of the library after it had been 
subjected to the optimised purification strategy. 
Crude Library 4 with Tbfmoc 	 Purified Library 4 
(cross-hatched area shows the peptidic 
material containing Tbfinoc) 
Figure 3.8: RP HPLC traces of Library 4 before and after Tbfmoc 
carbon purification. 
With dual wavelength monitoring at 214nm and 364nm 
The purified library trace gave a pattern of seven separate peaks, all were eluted 
between 31% and 38% acetonitrile so were easily separable from any salts present. 
The composition of the library was confirmed by MALDI ToF mass spectrometry 
and amino acid analysis, see Appendix VI. 
3.2.6 Synthesis and Purification of Library 5. 
The final library of 3-amyloid analogues, Library 5, was constructed in order 
to demonstrate the ability of Tbfmoc to effectively purify libraries of small proteins. 
The library was synthesised, as described previously, with the amino acid cartridges 
at the two positions of diversity being loaded with multiple amino acids. The 
positions of diversity were randomly selected. The residues incorporated were chosen 
in order to achieve the maximum mass variation. 
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Initially diversity was introduced at residues 13 and 29, see fig. 3.5, with the 
incorporation of His, Arg & Ser and Gly, Lys & Tyr respectively. Being a longer 
peptide, the improved coupling agent, HOCt, was employed as opposed to HOBt. 
Unfortunately the synthesis failed, even when it was repeated with double coupling. 
The positions of diversity were revised and instead of replacing Gly(29) with 
much larger amino acids, Lys(28), a bulky amino acid, was chosen as the site of 
diversity and the less bulky Ala and Arg residues incorporated at this position. It was 
hoped that this would prevent the large drop in coupling efficiency observed at this 
residue during the previous two attempts at the library synthesis. HOCt double 
coupling was employed throughout, with extended double coupling times at the sites 
of diversity. The synthesis was performed on a 0.2 mmol scale, as opposed to 0.25, 
meaning five equivalents of amino acid were available for each coupling instead of 
four. The final quantitative Fmoc loading test indicated only a final 23% coupling 
efficiency. 
The library was cleaved as described previously, using standard acidolytic 
techniques. A trial cleavage of the library without Tbfmoc revealed that the crude 
material dissolved in 3:2 acetonitrile/water, hence this was selected as the solvent 
system for purification. The 'dry flash' column method (method 2b, chapter 5) was 
adopted for the purification, as opposed to the vortex/centrifuge technique; although 
the yield was not as good using this method, it was suspected that exposing the 
charcoal to less disruptive conditions might reduce the release of the unidentified, 
coloured impurities. 
Preparative HPLC of the piperidine cleavage solution showed a distinct series 
of sharp peaks, which were collected together and lyophilised giving clean, white 
peptide material (60% yield). Electrospray mass spectroscopy and amino acid 
analysis results gave good correlation with the predicted results, see Appendix VII. 
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3.3 Summary and Conclusions 
Tbfmoc has been successfully used to facilitate the separation and purification 
of five soluble peptide libraries from truncated peptide fragments and other 
impurities which accumulate during SPPS. The affinity of Tbfmoc for carbon, both 
PGC and charcoal, has been exploited in the purification of four of the five libraries 
with potentially better recovery from the charcoal than PGC. 
Adsorption of the peptide directly from the TFA cleavage solution eliminated 
the problem of insolubility of the Tbfmoc-peptides and hence the necessity of using 
non-ideal solvent systems. For each library the exact purification conditions were 
optimised, with an appropriate solvent system selected by establishing the solubility 
of the crude library without Tbfmoc. 
The instability of the charcoal under basic conditions can be overcome by 
thoroughly pre-washing the charcoal, however, the charcoal must be used 
immediately and cannot be stored dry. Comparison between the vortex/centrifuge and 
'dry-flash' column methods of charcoal purification suggest that, although the yield 
from the latter is slightly lower, disturbing the charcoal less during the purification 
protocol results in less brown discolourisation and hence a higher quality of resulting 
product. 
The versatility of the Tbfmoc purification strategy has been demonstrated 
with its effective purification of both Library 5, and much larger peptides and 
proteins at Edinburgh, which accumulate increased numbers of impurities during 
their synthesis. The Tbfmoc principle could therefore be adapted to achieve facile 
purification of small protein libraries. 
The methodology affords rapid, facile separation of peptide libraries from 
their chemically similar impurities, which could potentially interfere with the library 
screening. The method is adaptable and simple, resulting in high quality peptide 
libraries containing the predicted members only, whilst retaining the essence of the 
combinatorial approach. 
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Part II: Heterocyclic Synthesis 
Chapter 4 
Synthesis of a Potential 
Farnesyl Transferase Inhibitor 
4.1 Introduction 
4.1.1 Discovery of Protein Prenylation 
The prenylation of proteins in vivo is an important post-translational 
modification, whereby either a 15 carbon (farnesyl) or a 20 carbon (geranylgeranyl) 
isoprenoid group is covalently attached to the carboxy-terminal of a protein, via a 
thioether linkage to a cysteine residue. 
The first prenylated protein, discovered in 1978, was a mating factor from the 
fungus Rhodospiridium Toruloids. 2  The undecapeptide, named Rhodotorucine A, was 
shown to possess a carboxy-terminal S-farnesyl-L-cysteine methyl ester. Other 
species of fungus were subsequently observed to produce similarly farnesylated 
proteins. 3 
In 1980, a study into the effect of compactin (an inhibitor of the isoprenoid 
biosynthesis) on mammalian cell growth and morphology revealed the presence of 
prenylated proteins in mammalian cells. 4  It was shown that high concentrations of 
compactin inhibited the cell development of cultured fibroblasts. This effect was 
reversed by addition of mevalonic acid, suggesting that this, or some isoprenoid 
metabolite derived from it, was required for cell proliferation, see fig. 4.1. Insertion 
of radiolabelled mevalonic acid into compactin treated cells resulted in incorporation 
85 
Novel Ras FTase Inhibitor 
of the label into cellular proteins. 5  The first mammalian protein shown to undergo 
prenylation was the nuclear membrane-associated protein Lamin B in 1988.6 
Acetoacetyl CoA + Acetyl = C0A + H 20 
Jr 
0 CH3 O 
OH 
- 	 Compactin 
0 CH3 O 




11 	 11 	 a- 
H3CO— PO—-0 
I 	 I 





H 3CO—P-0— P-0 















Figure 4.1: Biosynthetic pathway of mevalonic acid and its metabolites. 
1(a) 
There are two types of prenylation which can occur in mammalian cells. 
Famesylation refers 	to 	the attachment of the 15-carbon famesyl group and 
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geranylgeranylatiOfl refers to the 20-carbon geranylgeranyl group. 7  The latter 
modification is responsible for the prenylation of 80-90% of all known prenylated 
proteins. 8 
All known farnesylated and geranylgeranylated proteins are characterised by 
the carboxyl-terminal sequence CAAX, where C is cysteine, A is any aliphatic amino 
acid and X is variable. The identity of X is a major factor in determining whether the 
protein is famesylated or geranylgeranylated; when X is methionine, serine, 
glutamine or alanine the protein is farnesylated, but when X is leucine or 
phenylalanine, geranylgeranylation occurs. 9  The CAAX motif is therefore critical to 
protein prenylation. This criterion opened up the investigation of other proteins 
containing the C-terminal CAAX motif, and has revealed a wide variety of protein 
families which undergo prenylation. A list of known prenylated proteins has been 
recently published. 10 
Of particular interest was the discovery that the Ras family of proteins, key 
cellular signalling molecules, were farnesylated." The Ras proteins are plasma 
membrane bound GTP-binding proteins, involved in the regulation of cell replication 
and transformation. 12 Oncogenic versions of the Ras proteins have been shown to 
undergo similar post-translational modification with subsequent membrane 
localisation. These species can lead to uncontrolled cell growth and have been 
implicated in a wide variety of proliferative diseases, -25% of all human cancers are 
associated with oncogenic mutants of Ras in tumour cells. 
13 
Farnesylation of these oncogenic variants of Ras and subsequent membrane 
localisation is imperative to the transformation of the cell to a tumorigenic state. This 
revelation has triggered widespread research into possible methods to disarm these 
mutated Ras proteins. 
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4.1.2 Ras Proteins 
Three functional Ras genes have been identified, cloned and sequenced in 
humans, H-Ras-1, K-Ras-2 and N-Ras. ' 4  They encode for three highly related 
proteins known as p21. Two other genes, H-Ras-2 and K-Ras- 1, have also recently 
been identified in rats and humans. 15  All are members of the Ras superfamily of 
GTPases which also includes Rho/Rac, Rab, Ran and ARF (ADP-ribosyl factor).' 
The Ras p21 proteins are either of 188 or 189 amino acids; the first 85 residues are 
completely conserved, the subsequent 80 posses 85% homology and the remaining 
are variable, except for the terminal CAAX motif present in all. 
After construction in the cystol, the p21 Ras proteins undergo a series of post 
translational modifications. These are common to the majority of known prenylated 
proteins, enabling their localisation into the inner plasma cell membrane, where they 
trigger a cellular signalling cascade. 
16 Fig. 4.2 illustrates these post translational 
modifications for the Ras proteins. 
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The initial step is the prenylation of the cysteine residue in the CAAX motif 
with farnesyl pyrophosphate (FPP) via a dedicated farnesyltransferase enzyme, see 
later, to give a thioether linkage. Subsequent modification involves the proteolytic 
cleavage of the three C-terminal amino acids via a specific membrane-bound 
endoprotease.' 7  This is followed by methylation of the S-prenyl-cysteine by a 
membrane-bound methyl transferase (using S-adenosyl-L-methionine as the methyl 
donor), to give the C-terminal methyl ester characteristic of the majority of 
prenylated proteins.' 8 
The farnesylation step has been shown to be obligatory to membrane 
localisation and hence Ras p21 activity; however the subsequent two steps, although 
shown to be important for the proper targeting of Ras to the plasma membrane and 
for full Ras function, have been shown to be less critical.  19 
K-Ras possesses a stretch of basic residues in its sequence, which are thought 
to increase the binding affinity of the protein. H-Ras and N-Ras lack in this sequence, 
but are acylated with palmitic acid (palmitoylation) at Cys residues upstream of the 
farnesylated Cys' 86 (Cys 18 ' for N-Ras, Cys' 8 ' and Cys' 84 for H-Ras) prior to 
membrane localisation. 20 This additional modification has been shown to greatly 
potentiate H-Ras function.  2 ' 
~nll NN Met Set HNLHN 
Pal CoA 
I~nl ~l NH 
Figure 4.3: Palmitoylation of the Ras proteins. 
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The prenyl group serves as a hydrophobic anchor to bind the protein to the 
cell membrane. One study has suggested that the farnesyl group inserts into the 
hydrophobic interior of the membrane, rather than binding to a well-defined pocket 
on a protein receptor. 
22 Once localised in the membrane, the Ras p21 proteins are 
capable of binding GDP/GTP and possess intrinsic GTPase activity. 
23 
The protein normally exists in the inactive GDP bound state, however 
interaction with a growth signal protein of the tyrosine kinase family, causes the 
protein to bind GTP, altering its conformation.' This change in conformation 
allows the active form to interact with cystolic serine/threonine kinases, the best 
characterised being Raf-1. 24  Raf-1 is recruited to the plasma membrane where 
activation occurs through an unknown mechanism, triggering an intracellular 
signalling cascade through the phosphorylation of MAP kinase kinase (MEK), which 
in turn phosphorylates the MAP (mitogen-activated protein) kinases. These species 
are then translocated to the nucleus, where they phosphorylate and consequently 
activate multiple transcription factors, including c-jun and c-fos, leading to cell 
proliferation and differentiation. This simplified explanation of the signalling 






Figure 4.4: Intracellular signalling cascade. 
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Other effector molecules have been shown to be involved in alternative Ras 
signalling pathways, investigation of which is continuing. 25 
The Ras protein acts as a switch, which is turned on or off depending on the 
guanine nucleotide attached to the protein. It regulates the on/off state of the 
signalling pathway by cycling between the GTP-bound active form and the GDP -
bound inactive form, depending on stimulus by the growth signal protein. In normal 
Ras, the active form is rapidly deactivated by the GAP NF 1 enzyme, which 
dephosphorylates the bound GTP, returning the Ras to its original inactive 
conformation and hence shutting down the signalling pathway. 26 
As mentioned previously, mutated forms of Ras proteins are found in a wide 
variety of human tumour types, see Table 5.1. The most commonly found mutations 
occur at positions 12, 13, 61 and 63, particularly at 12.27 
Tumour Type 	 Predominant 
Mutant Ras Gene 
Occurrence of 














H- and K-Ras 
K- and N-Ras 
H-, K- and N-Ras 
H-, K- and N-Ras 










Table 4.1: Occurrence of Ras proteins in human tumours. 1 
K-Ras is the most prevalent of the proteins found in oncogenic form in human 
tumours. Mutations disrupt the GTPase activity of the Ras by locking the protein in 
its active GTP-bound conformation, causing the signalling pathway to be 
permanently "on". This leads to the continuous production of growth promoting 
transcription factors and hence oncogenicity. 
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It is therefore desirable to disarm these Ras oncogens and so halt the 
signalling pathway. The most favourable point for interference in the pathway is 
thought to be the farnesylation step, possibly by inhibition of the dedicated farnesyl 
transferase enzyme. The farnesyl group is essential for the location of Ras to the 
inner membrane, such localisation is obligatory both for normal Ras function and 
also to the activity of oncogenic forms of the protein. 
4.1.3 Protein Farnesyltransferase 
There are three known prenyl transferase enzymes, all ap heterodimers 
consisting of two subunits: famesyltransferase (FTase), 28  geranylgeranyltransferase 
type I (GGTase 1)29 and geranylgeranyltransferase type II (GGTase 11)•30 The former 
is responsible for the farnesylation of biological proteins, while the latter two are 
responsible for their geranylgeranylation. Both FTase and GGTase I possess identical 
a-subunits (48 kDa), 3 ' while the p-subunits are distinct (46 kDa and 43 kDa 
respectively). GGTase II, involved with the prenylation of proteins characterised by 
the C-C or C-X-C motif, has distinct a and 3 subunits. All have been identified, 
cloned and characterised. Since this study is interested specifically in the 
farnesylation of Ras proteins, the discussion is limited to the FTase enzyme. 
FTase is a zinc metalloenzyme, containing a single bound zinc ion. 
32  It is 
responsible for the transfer of a farnesyl group from FPP to the cysteine SH of the 
CAAX motif of the relevant protein; the exact mechanism for which has not yet been 
precisely determined. One group has proposed an electrophilic mechanism for yeast 
FTase. 33  A nucleophilic mechanism has been proposed for the mammalian enzyme, 
in which the zinc ion activates the cysteine thiol of the peptide substrate as a thiolate 
anion for nucleophilic attack on the isoprenoid substrate. 34 
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Figure 4.5: Proposed mechanism for protein farnesylation. 
Several studies support the catalytic role of the zinc, 
32 and onehas shown the metal 
ion to be co-ordinated by the thiol of the CAAX Cys. 34  The rate limiting step for the 
process has been shown to be the dissociation of the farnesylated protein product 
from the enzyme. 35 
The crystal structure of this enzyme was published in 1997; 
36  within a highly 
helical, tightly bound structure, two potential binding sites were shown to exist. The 
13-subunit forms an a-a barrel structure, or deep pocket, containing a hydrophobic 
core. Modelling studies have shown that a farnesyl pyrophosphate (FPP) molecule 
fits exactly into this cavity. Placing the terminal carbon of the isoprenoid at the 
bottom of the cleft allows the diphosphate moiety to directly interact with the 
catalytic zinc at the enzyme active site. 
37 This is concordant with previous studies, 
which suggested that the FPP bound exclusively to the 13-subunit. 35 ' 38 
The exact depth of the cavity explains the enzyme discrimination between the 
FPP and GGPP substrates. Although the GGPP could also bind in this cavity, the five 
additional carbons places the diphosphate group out of range of the active site and 
hence FTase is unable to transfer this substrate to the Ras protein. 
The second binding site is near the subunit interface, and intersects the 
putative isoprenoid binding pocket at the enzyme active site (marked by the bound 
zinc ion between the two subunits). This site takes the form of a hydrophilic cleft 
running nearly orthogonally to the isoprenoid binding pocket. Evidence suggests that 
the protein substrate binds in this cleft through the final nine residues at the C- 
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terminus. 37 This would bring the Cys of the CAAX moiety exactly into register with 
both the zinc ion and the FPP a-phosphate. Site-directed mutagenesis studies have 
begun to identify residues critical to substrate binding, specificity and the catalytic 
activity of the FTase. 39 
4.1.4 Protein FTase Inhibitors 
As previously described, inhibition of FTase would prevent the membrane 
localisation of oncogenic versions of Ras, and hence may offer a valuable method for 
the treatment of a number of forms of cancer, many of which are resistant to current 
treatments. This possibility has been the focus of much research across the 
pharmaceutical industry over the past decade. The enormous variety of potential 
inhibitors that have emerged from these studies has been extensively reviewed. 40 
The Ras proteins were among the first shown to be farnesylated, the FTase 
enzyme appearing therefore to be exclusive to Ras. This presented an ideal candidate 
for inhibition. Some 20 other proteins have subsequently been shown to be 
farnesylated via the same enzyme, however so far this not been shown to be a 
problem, with some reports suggesting that the inhibition may even be specific to 
malignant cells. 4 ' 
Many of the potential inhibitors to emerge have shown great promise as novel 
anticancer agents, showing in some cases almost complete tumour regression 
apparently without any toxic side effects 
.42 Remarkably, some FTase inhibitors have 
been shown to be active against cancer cells which do not contain mutated Ras 
proteins. This suggests that other FTase substrates may play a role in the 
pathogenesis of proliferative diseases. 
42,43 
Early in the investigation of the Ras proteins, the CAAX motif of the natural 
H-Ras p21 substrate (CVIL) was found to be a Ras-competitive inhibitor of FTase, 44 
hence the design of many of the early inhibitors was based on this. Having explored 
peptidic analogues, non-peptide CAAX mimics emerged with a view to improving 
the pharmacokinetic properties of these species. Another key modification was the 
replacement of the thiol group with a more suitable candidate, due to concern about 
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the possible long term adverse effects of these functionalities.ta  These investigations 
have produced some of the most potent compounds to date, and provided much of 
the information on the biological consequences of FTase inhibition. 
FTase inhibitors have also been designed based on the farnesyl moiety, 
offering competitive inhibition with the FPP substrate as opposed to the Ras 
substrate. This class of inhibitors is less popular, since FPP is the substrate for 
several enzymes other than FTase, hence leading to side effects. However, Parke 
Davis have developed an FPP competitive inhibitor which has not shown such 
toxicological problems . 45 On the whole, however, this class of FTase inhibitors has 
generally been less potent, and has not demonstrated any in vivo activity. 
An alternative approach to specific design in the drug discovery process is 
through the high throughput screening of chemical libraries. This technique has been 
responsible for a number of novel, potent FTase inhibitors, several of which are now 
in clinical trials. 46 The mode of enzyme inhibition, for all these candidates, is via 
competitive inhibition with the Ras protein substrate. Preliminary clinical results 









(a) Janssen: R115577 
J
NlNH2 
(b) Schering-Plough: SCH66336 
Figure 4.6: FTase inhibitor leads from (a) Janssen and (b) Schering-Plough. 
The structures of the two most clinically advanced compounds are shown in 
Jig. 4.6. The Janssen compound ((+) isomer) is currently in Phase II trials; it is 
administered orally, with acceptable toxicity allowing further dose increases, and a 
mean terminal half-life in vivo of 13-14 hours. The Schering-Plough compound is 
also administered orally, and is currently between Phase I and Phase II trials. Merck 
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has a potential FTase inhibitor in Phase I trials but its structure has not yet been 
disclosed, nor has the structure of a reported Bristol-Myers-Squibb lead. 
Numerous other lead compounds have been reported, showing the continued 
level of interest in FTase inhibitors. Indeed, preliminary data from these first 
compounds to enter clinical trials have shown remarkable promise, with suggestion 
that they operate in a more complicated manner than simply preventing Ras 
famesylation alone. 47  Why these compounds should be so non-toxic has also created 
an on-going debate. 
The results suggest that a range of human cancers might respond to FTase 
inhibitor therapy. In addition, synergy between FTase inhibitors and other anti-cancer 
treatments currently available may further extend their therapeutic potential. 48 
The alternative forms of Ras (H-, N- and K-Ras) are differently distributed 
throughout the various forms of cancer, K-Ras oncogenes being the most 
predominant. Other distinctions between the proteins are emerging; 49  this raises the 
question as to whether the FTase inhibitors should be specific to each form. In 
addition, recent discoveries have shown that when the farnesylation of K-Ras is 
prevented by specific FTase inhibitors, the protein can be geranygeranylated allowing 
it to function. 50 This 'back-up' system may account for the lack of toxicity observed 
for these inhibitors, however it also raises the question of whether FTase specific 
inhibitors are sufficient or whether comprehensive FTase/GGTase inhibitors are 
required. 
Although the exact mechanism for tumour regression under FTase inhibition 
is not understood, it is hoped that the recent x-ray structure of the enzyme will aid 
understanding of this, and also elucidate fundamental aspects of protein prenylation 
and the consequences of suppressing this process. Ultimately, it should aid the design 
of improved FTase inhibitors. 
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4.2 Design and Synthesis of a Potential FTase Inhibitor. 
The aim of the project was to design and synthesise a novel heterocyclic 
structure which may offer potential FTase inhibitor activity, by modelling the target 
around other known inhibitors. The investigation would be complimentary to the 
ongoing work at Parke Davis Pharmaceuticals, Michigan. 
4.2.1 Design of a Novel Structure 
The ongoing Ras program at Parke Davis was based around a structure 
isolated from compound library screening, see Jig. 4. 7. 
0 
2((7 	 _N 
N / 
4 	5 
PD 405123, IC50 2.0tM 
Figure 4.7: FTase inhibitor isolated from mass screening at Parke Davis. 
An extensive SAR study based on this molecule was being carried out within Parke 
Davis, with the view to improving its in vitro and cellular potency against the 
enzyme. Work had concentrated solely on substitution at positions 2 and 6; early 
indications favoured the retention of the imidazole species at position 6, but with 
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IC50 0.11, 0.068.iM 	 IC50 2nM 
Figure 4.8: (a) Favoured structure from early Parke Davis study, (b) Janssen 
Pharmaceuticals patented lead structure. 
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A novel structure was designed based on the Parke Davis findings, with 
incorporation of key features from the Janssen study which had culminated in the 
highly promising drug candidate Ri 15777. Both these compounds act by competing 
with Ras protein substrate binding. The tetralone skeleton was replaced with a 
quinolinone structure. Since the 2-quinolinone structure was comprehensively 
protected by Janssen Patents, 51  the 4-quinolinone skeleton was substituted, retaining 
the N-methyl group. In addition, aromatic bulk at the imidazole was mimicked by the 
incorporation of ap-benzoic acid group, see jig. 4.9. 
0 
CS 	 N / 
N 	 (Z) 
CH 3  




Figure 4.9: Proposed target structure. 
The benzoic acid modification would also serve as a site for solid support 
attachment, with view to the solid phase synthesis of the target. 
The structure opened up a new line of investigation, complimentary to that at 
Parke Davis. It also offered the possibility of using combinatorial chemistry to 
perform an SAR study around the molecule, with a number of potential sites for 
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4.2.2 Initial Route to the Target. 
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Figure 4.10: Initially proposed synthetic strategy. 
The initial synthetic route was designed around Hay's synthesis of 
Ciprofloxacin, 52 which contained the 4-quinolinone skeleton. The advantage of this 
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was that the strategy had been fully optimised for both solution phase and solid phase 
synthesis, therefore the conditions could be directly applied to the synthesis of the 
target at the common steps (steps 1, 4, 5 & 6). Retrosynthesis of the target through 
this route reduced the structure to two precursors, marked A and B, see jig. 4.10. 
Neither of these were commercially available; however, precursor A was a 
known compound, prepared by Grey et alto its unprotected form via a three step 
synthesis from the relatively cheap starting material 3-fluorophenol. 53 
'a 	Br/CHC Br( 	CuCN NC.- 	NaOH HOOCI F 	OH2 NaOH F OH 	F - OH 	 F )aOH 
Figure 4.11: Synthesis of 3-fluoro-4-hydroxybenzoic acid by Grey et al. 
As this method was time consuming, a one step para-carboxylation of the 3-
fluorophenol using a Kolbe-Schmitt type procedure was preferable. 54  The conditions 
required for para-carboxylation, as opposed to ortho, could not be met (50 atm. CO, 
2400C); fortunately, alternative conditions to achieve this had been reported by 
Sasson and Radinsky, 55 based on previous work by Reimer and Tiemann. 56 They 
reported the selective para-carboxylation of phenol using carbon tetrachloride (Cd 4) 
in strong base, with a copper powder catalyst. 3-Fluorophenol was subjected to these 
conditions, giving the 2-fluoro-4-hydroxybenzoic acid product exclusively, in 24% 
yield. The copper was replenished twice during the reaction, as it was deactivated 
with time. 
Sasson and Radinsky proposed a mechanism for the process; they suggested 
the formation of the trichloromethyl cation on the surface of the copper catalyst. 
Preference for para-carboxylation over ortho was determined by the concentration of 
aqueous sodium hydroxide, with an initial 50% w/w NaOH solution in 50% molar 
excess giving the highest selectivity. They suggested that the concentrated basic 
solution induced a degree of geometrical organisation at the copper-aqueous 
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interface, forcing the phenolate anion to approach the trichioromethyl cation on the 
catalyst surface preferentially through the para position. 
Prior to formation of the 13-keto ester, via the acid chloride (fg. 4. 10, step 1), 
the phenolic function of the 3-fluoro-4-hydroxybenzoic acid required protection. 
Initially, the silicon based protecting group t-butyldimethylsilyl (TBDMS) 57 was 
investigated for the purpose. Unfortunately, the TBDMS ester was formed together 
with the ether on reaction with the TBDMSC1. 
Literature precedence existed for the direct conversion of the TBDMS ester to 
the acid chloride, using oxalyl chloride in the presence of a catalytic amount of 
DMF. 58 Unfortunately, repeated attempts using the cited conditions failed to achieve 
the desired manipulation. 
F 	 TBDMSO-F 
DMF 
CoCI + Co2 
TBDMSO 	
+ CO + C_i_Bu 
9 	I 	CICOCOCI 
Figure 4.12: Direct conversion of the TBDMS ester to the acid chloride. 
Benzyl protection was then attempted, by reaction with benzyl bromide. 59 
Again, the benzyl ester formed in addition to the ether, however the ester could be 
selectively removed via mild base hydrolysis to give the precursor A in an overall 
-15% yield for the three steps, as illustrated infig. 4.13. 
BnOOC 	 HOOC 
FI" 	
ccI4H00( 	B n B r 	 2M KOH, 
O NaOH, Cu F 	OH 	F-OBn 	F 	OBn 
	
10 	 11 
Figure 4.13: Formation of intermediate A. 
The benzoic acid was then converted to the acid chloride using thionyl 
chloride, and the product used directly in the formation of the 13-keto ester precursor 
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with potassium ethyl malonate, see fig. 4.14, as in the synthesis reported by 
Wemple. 6° 
00 0 	0 	1. MgCl, Et3N, CH 3CN, rt, 2.5hrs 
Et0 	0K 	0 	 Et0 	
0Bn 2. CIr(i 	rt, l6hrs 
F0Bn 
12 
Figure 4.14: Formation of the /3-keto ester via the acid chloride. 
This methodology had originally been developed as a route into the 13-(fluoraryl)-13-
oxo-ester precursors for the synthesis of quinoline antibacterial agents. Optimum 
conditions were established using potassium ethyl malonate with mild base, 
anhydrous magnesium chloride and triethyl amine to give a stable enolate 
intermediate. 
Selective cleavage of the benzyl ether via hydrogenation at atmospheric 
pressure gave 3 (47% yield for the combined steps); however the subsequent 
Mitsunobu reaction (see fig.  4.10) required the second precursor B, the synthesis of 
which had been hampered (see later). 
4.2.3 Initial ModtIcation of the Synthetic Strategy. 
In the absence of B, the synthetic strategy required modification. Phenol had 
been reported to open the epoxide function of styrene oxide under basic conditions in 
a clean, high yielding reaction. 61  Attack was favoured at the more hindered position, 
giving a mixture of both the primary and secondary alcohols in a 4:1 ratio, see fig. 
4.15. 
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Figure 4.15: Opening of styrene oxide with phenol. 
This manipulation could be applied to the synthesis of the target structure by using 
the phenolic side chain of intermediate 3 to open 4-styrene oxide benzoic acid, with 
substitution of the resulting alcohol group with imidazole at a later step in the 
synthesis, see fig.  4.16 
To achieve the proposed target structure, the epoxide was required to open at 
the least hindered position, giving the secondary alcohol, the disfavoured isomer. It 
was considered, however, to be an acceptable deviation from the originally intended 
structure, and of equal potential interest to use the major isomer of this reaction. 
The target molecule was also modified by the removal of the benzoic acid 
group, see fig 4.10. This functionality was originally included as a site for 
attachment to a conventional solid support, however, it was deemed unnecessary, as 
this could be achieved through the 13-keto ester side chain, marked in fig.  4.16, used 
in the synthesis of Ciprofloxacin. 52 Elimination of this group meant that styrene 
oxide could be substituted for 4-styrene oxide benzoic acid, synthesised from the 
highly expensive 4-vinyl benzoic acid (see section 4.2.4). These modifications 
resulted in the modified target structure 17. 
103 
Novel ias P- I ase lflflIDltO 
o a 





















650C, 16h j 
0 
(  1 	
OH 







H0 r( 	 Decarboxyl ate 
L NO0H 
CH3 	71 








Figure 4.16: Revised synthetic strategy to the target isomer. 
Optimum conditions for the epoxide opening were established using the 
phenol/styrene oxide model, before applying these to 3. The ring opened exclusively 
at the more hindered position, giving the product 15 in sufficient quantity for 
identification purposes; however, there was insufficient material for further steps to 
be attempted towards the target isomer and supply of 3 was limited. 
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4.2.4 Synthesis of Precursor B. 
o 	 /-- N 
H 	
HON 
CH 30H, H2SO4 	MCPBA  
EEt
(or aach to resin) 	 ME
COOH 	 COOCH3 	 COaCH3 	 HE 	COOCH3 
18 	 19 	 r I B 
Figure 4.17: Proposed route to precursor B. 
For the synthesis of B, a possible strategy was to start from the commercially 
available 4-vinyl benzoic acid. Initially the benzoic group was protected as the 
methyl ester, for the duration of the target synthesis (if the reaction had been 
performed on solid phase, the resin would have been attached at that point); the 
epoxide was then formed using MCPBA (overall 70.5% yield). 
The epoxide was required to open from the more hindered side, using 
imidazole as a nucleophile, to produce B. An epoxide would normally be expected to 
open under nucleophilic attack in neutral or basic conditions via a SN2 mechanism at 
the least sterically hindered position. Under acidic conditions, it exists as the 
protonated species and may open by either an SN 1 or SN2 mechanism, however, for 
both, substitution usually occurs at the most hindered carbon. When a phenyl group 
is attached to the epoxide, the effect of the aromatic ring makes that position more 
electrophilic, and hence this would be the anticipated site of nucleophilic attack, even 
in basic conditions. This is illustrated by the previously described reaction between 
styrene oxide and phenol in aqueous NaOH. 
Imidazole is a weaker nucleophile than the phenolate ion, and requires 
activation to give epoxide opening at the most hindered site. Unfortunately, although 
exposed to a variety of reagents, see fig. 4.17, suitable conditions for the epoxide 
opening from either end were not established. 
The previous concession made that an isomer of the originally proposed 
target was an acceptable deviation (see Jig. 4.16), allowed the methodology put 
forward by Sala et alto be utilized. 62 The method enabled the synthesis of 20 in good 
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yield (74%), by the reaction of imidazole with styrene oxide in DMF, shown in fig. 
4.18 
0 	 OH 
+ 	H 	
N 	DMF 	
(Alternative isomer to B) 
20 
Figure 4.18: Opening of styrene oxide with imidazole. 
This would then enable the Mitsunobu reaction in the initial synthetic strategy 
(fig. 4.10) to be performed between 3 and 20, with subsequent completion of 17. 
Unfortunately, supply of the CCL starting material from commercial manufacturers 
was delayed, hence an alternative method for the synthesis of the p-hydroxybenzoic 
acid precursor of A was required before the Mitsunobu reaction could be attempted. 
4.2.5 Alternative Route to 2-Fluoro-4-hydroxybenzoic Acid. 
Toluene is readily oxidized to benzoic acid under a variety of conditions; this 
presented the possibility of using such a strategy to oxidise 3-fluoro-4-methyl phenol 
to the required benzoic acid 10. This substituted aromatic starting material was not 
commercially available, however its isomer 4-fluoro-3-methyl phenol was, giving the 
consequent modified target shown infig. 4.19. 
0 
KYII1 	N L j 
CH 
21 
Figure 4.19: Consequent target structure resulting from the starting material 
4-fluoro-3 -methyl phenol. 
Three possible methods were investigated: KMn0 4 , 63 KMnO4/NaOH64 and 
Pb02. 65  Although all successfully oxidised toluene to benzoic acid, the first offered 
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the cleanest, most high yielding route. This method was therefore applied to the 4-
fluoro-3-methyl phenol, but without success. 
The method could only be used to achieve the benzoic acid of this system if 
the phenolic side chain was first protected as the acetate, then the methyl transformed 
into the benzyl bromide using NBS (/1g. 4.20).66 







Figure 4.20: Transformation of 4-fluoro-3-methylphenol to 2-fluoro-5- 
hydroxybenzo ic acid. 
This method was low yielding and indirect, offering no advantage over the three step 
strategy used by Grey etal., see fig.  4.11. 
4.2.6 Alternative Synthetic Strategy 
The difficulty in synthesising A made any route requiring this precursor 
impractical. Fortunately, an extensive investigation of the literature presented an 
alternative, much shorter route to the target 17, through the initial synthesis of 7-
hydroxy-2,3-dihydroquinolin-4-one via a three step process. The two pendant groups 
were attached, as in the initial route, at positions 2 and 6 after formation of the 
heterocyclic skeleton. 
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Figure 4.21: Solution phase synthesis of the target isomer 17. 
It was Clemo and Perkin in 1924 who first observed that certain 3-
anilinopropionic acids underwent ring closure, as their N-p-toluenesulfonyl (tosyl) 
derivatives, to give the dihydro-4-quinolone species. 67  In 1946, Elderfield and 
Johnston simultaneously investigated this transformation, and reported the synthesis 
of a series of f3-anilinopropionic acids and their subsequent cyclisations. 68 Later, Koo 
published the cyclisation of the 3-ani1inopropionic acids to the corresponding 4-
hydroxyquinolone species via a simple one step treatment with polyphosphoric acid 
(PPA) 69 
Synthesis of the 7-hydroxy-2,3-dihydro-]H-quinolin-4-one analogue of 28 
(containing the free secondary amine species) had been reported by Kavrakova in 
1990.70 The communication reported a PPA induced cyclisation, as given by Koo, 
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although no experimental details were given. Hence, PPA cyclisation of 3-(3-
hydroxy-phenylamino)-propionic acid, synthesised from commercially available 3-
aminophenol and acrylic acid, was initially performed prior to N-methyl protection. 
However, the 2,4-dihydroquinolone product was not isolated from the work-up after 
the cyclisation step. 
The literature suggested that protection of the amine was beneficial, therefore 
methylation of the 3-aminophenol with methyl iodide was made the first step. 7 ' This 
afforded a mixture of the mono- and dimethylated species as a colourless oil 
(combined yield 86%). Silica chromatography afforded the product separate from the 
starting material, but unfortunately only partially resolved from the dimethylated 
species. Reduced pressure distillation also failed to achieve separation, although the 
dimethylated species was identified as a solid, while the monomethylated product an 
oil. This was not considered a significant problem however, as the dimethylated 
species would not participate in the subsequent steps, and could be eliminated later in 
the synthesis. 
Reaction of 25 with acrylic acid afforded intermediate 27 as a red oil. TLC 
showed all the monomethylated species to have been consumed, and the crude 
product to consist of three well separated components. Unfortunately, the product 
proved to be unstable to silica chromatography, and hence PPA cyclisation was 
performed on the crude material. 
Thus, 27 was combined with a ten fold excess of PPA, and the viscous 
mixture stirred manually at 100 °C until the colourless paste had turned a dark red. On 
work-up a canary yellow solid was obtained, which was purified to single spot by 
silica chromatography, and identified as the cyclised product 28. The overall yield for 
the three steps was -10%. 
Elderfield attributed the characteristic canary yellow colour of the 4-
hydroxyquinolinones to the existence of these substances as a series of tautomers, see 
fig. 4.2268 The quinoid chromophore exists in one of the latter two tautomers 
which are zwitterion in nature. 
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HOX ( J 	H'0 	- HOO1J 	HO  Q) 
6H3 	 6H 3 	 C' H 3 	
CH, 
Figure 4.22: Tautomers of 7-hydroxy- 1 -methyl-2, 3-dihydro-1H-quinolin-4-One 28. 
Optimum conditions for the Mitsunobu reaction were then established, using 
20 and phenol as a model system (fg. 4.23) .72 
N 	
+ HO 	
DEAD, PP h3 	
N 
THE, , 2 days 	
+ POPh3 cN OH 
20 	 30 
Figure 4.23: Mitsunobu reaction between 2-imidazol-yl-1-phenyl ethanol 20 
and phenol. 
Unfortunately, the product 30 was inseparable from the triphenyiphosphine oxide 
(P0 Ph3) by-product by either chromatography or washing; the use of 
tributyiphosphine did not circumvent this problem. This was also true for the product 
29 
The small quantity of 29 obtained was insufficient to attempt other means of 
separation, however contamination would not interfere with the biological testing of 
the compound. Hence 29 and 30, both contaminated with POPh 3 , together with 28, 
were submitted for testing by Parke Davis, Michigan (see later). 
The final step to complete the target synthesis (Aldol reaction with 2-
thiophenecarboxaldehyde) was not performed, as later results from the ongoing 
FTase inhibitor study of the tetralone analogues at Parke Davis indicated that the 
presence of the thiophene group was unnecessary, and in some cases actually resulted 
in an increase in the IC50 value. 46 
The ultimate aim of the project was to use combinatorial chemistry to 
investigate the SAR. To achieve this, it was necessary to adapt the solution phase 
synthesis to solid phase. This was also prompted by the failure to separate the 
Mitsunobu product from the POPh 3  by-product. The oxide remained entirely soluble 
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under the reaction conditions, making it simple to remove under solid phase 
conditions. 
4.2. 7 Solid Phase Synthesis of the Target Structure 29. 
The solution phase strategy was highly amenable to solid phase chemistry. In 
addition, the 2,4-dihydroquinolinone structure offered a number of potential sites at 
which diversity could be easily introduced onto the basic skeleton for combinatorial 
exploration. 
Initially, REM resin, was proposed as the solid support since the linker group, 
which would be cleaved with the final product, was equivalent to acrylic acid. 
Solution phase investigation of the 3-aminophenol/benzyl acrylate model 
demonstrated that the N-methylation could be performed after the Michael addition 
of the aniline, hence coupling of the 3-hydroxyaniline to the REM resin was 
performed first. Glacial acetic acid was required to promote the reaction in the 
absence of the free carboxylic acid function of the acrylic acid 
.68(a)  This meant that 
the N-alkylation step would be performed on the solid support, enabling diversity to 
be introduced at the N, prior to cleavage and cyclisation to give the target structure, 
see fig. 4.24. 
H2 N 0 
AcOH, THF 	 31 FTIR vmax/cm 1 1726.1 
REM resin 
CH3I 
0 	 C 0 MITSUNOBU ç REM FO 	NJOH 
CH3 




Figure 4.24: Proposed solid phase synthesis on REM resin. 
111 
Novel Ras FTase Inhibitor 
It was realised that Wang resin could mimic the REM resin by attachment of 
acrylic acid directly onto the linker, using the standard peptide coupling system of 
DIC/DMAP. The expense of REM resin made Wang the preferred solid support. 
Having loaded the acrylic acid, the subsequent procedures could be carried out as in 
the solution phase strategy, see fig.  4.25. 
0 
OH 
OH DIC, DMAP 
WAN–O 
32 FuR vm /cni 1 1654.8,1721.8 
AcOH, THF H 2N0H 
0 	 CHI 	
0 
____ 	 OH K2CO3 , DM F —At- 
	N 	OH 
34 6H3 	 33 	FTIRvmax/cm 1 1731.9 









P-0 	 I 
C OJ ?O I 
I 	 I 
CH3 29 
Figure 4.25: Solid phase synthesis on Wang resin. 
On-resin analysis of each intermediate proved challenging. Although 
estimation of the extent of loading could not be made, JR spectroscopy of 32 and 33 
showed firstly the appearance of the C=O (1721.8cm
1 ) and C=C (1654.8cm) 
stretches, after loading the acrylic acid onto the resin, followed by increase of the 
former (1731 .9cm') and disappearance of the latter as the conjugated system was lost 
on addition of 3-hydroxyaniline. 
Elemental analysis of 33 was also used to confirm the presence of N. The 
result suggested over 100% loading, however the value was subject to a relatively 
large error margin. 13C gel phase nmr was also performed on each of the 
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intermediates, but the resulting spectra did not provide useful information. 
Intermediate 34 differed from 33 by a single methyl group, and on-resin analysis 
techniques (including IR spectroscopy) could not detect this small change, hence a 
sample of 34 was cleaved from the resin to confirm the completion of this step. 
Ideally, it was hoped to achieve cleavage and cyclisation in one step; 
however, PPA failed to liberate the product from the solid support, possibly as it was 
too viscous to penetrate the resin matrix. Hence, 30% TFA in DCM was used to 
cleave the product, then the solvent was then removed in vacuo and the residue 
treated with PPA as before. Under this procedure, 34 was successfully cleaved from 
the resin and cyclised to give 28. 
This study demonstrated the successful adaptation of the target synthesis to 
solid phase. The basic 2,3dihydroquinOlinOfle skeleton was achieved in reasonable 
yield, with construction of the precursors on resin. Although the two step cleavage 
and cyclisation protocol was not ideal, particularly for combinatorial library 
production, it was simple and highly effective. Alternatively, another resin could be 
employed which cleaved the ester linkage giving an activated carboxylic acid, which 
could then spontaneously cyclise without the use of PPA. Diversity could be easily 
introduced, both at the N-alkylation step and in the Mitsunobu reaction. 
1 
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4.3 Biological Testing and Conclusions. 
The efficient solution phase synthesis of the novel target structure 29 was 
achieved and the reaction conditions shown to be viable to solid phase synthesis, 
although combinatorial exploration was not pursued. Three compounds were 
submitted for biological testing of their FTase inhibitor activity, the results of which 
are displayed in Table 4.2. 
Compound 	 1 IC50 (AM) 




7-(2-Imidazole- l-yI-1 -phenyt-ethoxy)- 1 -methyl-2,3-dihydro-JH- 	2.6 
quinolin-4-one 29 
Table 4.2: IC50 values of the compounds screenedfor their FTase inhibitor potential. 
Although target molecule 29 did not possess exceptional FTase inhibitor 
activity, it was comparable to PD 405123 (structure first identified from mass 
screening). The basic dihydroquinolin-4-one skeleton did not show significant 
activity; interestingly, however, 30 showed inhibitor activity comparable to that of 
the target. This simpler structure would be worthy of further investigation, and offers 
an ideal candidate for combinatorial exploration. 
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Part 1: Solid Phase Peptide Synthesis. 
5.1 General notes. 
All Fmoc protected amino acids and functionalised polystyrene resins were purchased 
either from Novabiochem or Bachem and, unless otherwise stated, the amino acids were 
of the L-configuration. All other required reagents were purchased from either Acros or 
Aldrich and were checked and purified, when necessary, before use. All solvents were 
purchased from Acros, unless otherwise stated; and the following were dried by 
refluxing over the reagents given in parenthesis when required: dichioromethane 
(calcium hydride), tetrahydrofuran (sodium wire/benzophenone) and acetonitrile 
(calcium hydride). The dimethylformamide and 1 ,4-dioxane used were peptide synthesis 
grade, supplied by Rathburn Chemicals. Melting points were determined in open 
capillaries using a Buchi 510 melting point apparatus. Ultra violet-visible (UV-vis) 
spectra were recorded on a Perkin Elmer UV/Vis Lambda 11 spectrometer in the solvent 
indicated. Mass spectra were recorded on a Perspective Biosystems Voyager 
Workstation Matrix assisted laser desorption ionisation, time of flight (MALDI ToF) 
mass spectrometer (337nm UV laser, 1.2m flight tube) using either 3,5-dimethyloxy-4-
hydroxy cinnamic acid or a-cyano-4-hydroxy cinnamic acid as the ionisation promoter. 
Electrospray ionisation mass spectroscopy was performed on a Micromass Platform II 
instrument with Mass Lynx 2.3 Build 5 software. 
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5.2 Notes on Solid Phase Peptide Synthesis (SPPS) 
All peptides described were synthesised on an Applied Biosystems 430A automated 
peptide synthesiser, equipped with an Applied Biosystems 757 absorbance detector 
linked to a Hewlett Packard HP3396A integrator for online monitoring of the 
deprotection solution. 
The Fmoc orthogonal protecting strategy was employed in the synthesis of all peptides 
and peptide libraries. Unless otherwise stated, standard acid-labile side chain protection 
groups were used for all amino acids containing reactive side chain functionalities, see 
chapter 1. p-Benzyloxybenzyl alcohol (Wang) resin was employed as the solid support 
for all peptides unless the C-terminal amino acid was His, Cys or Pro, when 2-
chlorotrityl resin was used. Both resins required the manual loading of the C-terminal 
amino acid onto the resin, see sections 5.6 and 5.8. 
Unless otherwise stated, each synthesis was performed on a 0.25mmol scale and was run 
continuously until the completed sequence was attained by the sequential, stepwise 
addition of each protected amino acid from the C- to N-terminus. The protocol was 
modified for the synthesis of the peptide libraries, see note 5.10. 
Single coupling was used throughout (except in exceptional cases). The amino acid was 
activated as the HOCt active ester using DIC in 1:1 DMF/1 ,4-dioxane as the activating 
agent for all single peptides, and the HOBt active ester in the synthesis of peptide 
libraries. 4 equivalents, immol, of amino acid was used per coupling, loaded into the 
cartridge corresponding to that residue. If the residue was His, 8 equivalents (2mmol) of 
HOBt was included in the cartridge to prevent racemisation. Following the coupling 
step, any unreacted Al' amino groups were capped using acetic anhydride to prevent their 
further participation in the synthesis. 
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The standard run cycle for the addition of one amino acid residue is detailed below: 
Capping of any free JyU  amino groups: 0.5M acetic anhydride in 1:1 DMF/1 ,4-dioxane 
with 0.125M DIEA and 0.2% HOBt. 
Washing: 5 times with 1:1 DMF/ 1,4-dioxane. 
Deprotection of the lVa  Fmoc protection by treating twice (4 min and 1.5 mm) with 
20% piperidine in 1:1 DMF/1 ,4-dioxane. Resin drained and washed 4 times with 
DMF/1 ,4-dioxane between deprotections. 
Washing: 8 times with 1:1 DMF/1,4-dioxane. 
Activation of the protected amino acid as the active ester, prior to addition to the 
resin, using 1:1 0.25M DIC in 1,4-dioxane/0.25M HOBT or HOCt in DMF. 
Transfer of the activated species to the reaction vessel, coupling allowed to proceed in 
1:1 DMF/1,4-dioxane for 30 mins. 
Washing: 6 times with 1:1 DMF/1,4-dioxane. 
After each ]yQ  deprotection the relative coupling efficiency was monitored by UV at 
302nm by the transfer of a 2m1 aliquot of the effluent, containing the chromophoric 
piperidine-fulvene adduct, in a continuous flow mode from the synthesiser to the UV 
detector. 
5.3 Notes on Reverse Phase High Pressure Liquid Chromatography (RP HPLC) 
All RP HPLC was performed on either an ABI 151 or Gilson instrument (305 pump and 
programmer, 306 pump, 805 solvent delivery system, 811C mixer and a 118 UV-vis 
detector). Unless otherwise stated, all analytical HPLC was performed on a reverse phase 
Aquapore (4.6x100mm, 20gm) or Vydac (4.6x250mm, 20tm) C18 column employing a 
flow rate of 1 ml/min, monitoring at wavelength 214 nm. When Tbfmoc was 
122 
Experimental 
incorporated into the peptide, dual wavelength monitoring was used at wavelengths 214 
and 364 nm. Semi-preparative HPLC was accomplished on an aquapore C18 reverse 
phase column (lOx25Omm, 20jim) using a flow rate of 5 ml/min with monitoring at 214 
rn-n. The programmed solvent polarity gradient system was tailored to each individual 
peptide's requirements, however the standard protocol, used in the majority of both 
analytical and preparative cases, is detailed below. The peptides were dissolved in a 
suitable solvent system, to a maximum concentration of 5mg/ml, for injection onto the 
column. 
TIME (mins) %B 
0 	10 	 where solvent A = H 20, 0.1% TFA 
2 10 
32 	90 	 solvent B = CH3 CN, 0.1% TFA 
34 10 
5.4 Notes on Amino Acid Analysis 
Peptide (1mg) was accurately weighed into a carius tube and 6M hydrochloric acid 
(containing 5mg/mi Na2SO3) added (4cm depth). The tube was connected to a vacuum 
trolley pump via a manifold. It was cooled in liquid nitrogen until solidified, then 
evacuated for 5 minutes. The vacuum was closed, the tube gently heated to melt any 
remaining solid, allowed to stand for 10 minutes, then the process repeated a further 2 
times. Having de-gassed the solution it was re-frozen, the vacuum opened and the tube 
sealed using a glass blowing torch. It was placed in an oven at 110 °C for the required 
time (standard for small peptides 20 hours), after which it was allowed to cool, opened 
and the contents quantitatively transferred to a round bottomed flask. The solvent was 
lyophilised to remove the HC1. The residue was washed twice with a small volume of 
water, again removing the solvent, then diluted with pH 2.2 sodium citrate loading 
buffer. This was quantitatively transferred to a 2ml standard flask and made up to the 
mark with additional buffer. The sample was filtered through a 0.45 micron filter 
membrane before submission for amino acid analysis. Analysis was performed on a 
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Pharmacia Biotech Biochrom 20 amino acid analyser using ninhydrin based post column 
derivatisation. 
5.5 Synthesis of ethyl-1-hydroxyl -1,2,3-triazole-4-carboxylate (HOCt).' 
C2H5O 
Step 1: Preparation of ethyl diazoacetate 
Ethyl glycinate hydrochloride (210g, 1.5 mol) in water (300m1) was mixed with 
dichioromethane (500m1) under a nitrogen blanket. The mixture was cooled to -15 0C, 
and cold sodium nitrite (124.5g, 1.8 mol) in water (200m1) added in one portion with 
stirring. The temperature was lowered to, -20 °C and a 5% aqueous sulphuric acid 
solution at 0°C added dropwise, with continuous stirring, keeping the temperature below 
-15°C. After complete addition of the acid solution, the temperature was allowed to rise 
to 0°C. The reaction mixture was transferred to a cooled separating funnel and the 
organic layer allowed to run into 5% sodium carbonate solution (400m1) at 0 °C. The 
aqueous layer was extracted once with DCM (400m1) and this was combined with the 
DCMlsodium carbonate mixture, which was stirred until no further gas evolved. The 
layers were separated, and the aqueous extracted once with DCM (400m1). The 
combined organic layers were dried (magnesium sulphate) filtered and the solvent 
evaporated giving a yellow liquid which was used directly in step 3. 
Step 2: Preparation of the Vilsmeier reagent. 
Freshly distilled thionyl chloride (53m1, 0.72mo1) was added dropwise, with stirring, to 
DMF (56m1, 0.72mo1) under nitrogen, at room temperature. After complete addition, the 
mixture was warmed to 40°C and stirred for 2 hours until a thick oil was obtained. The 
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oil was then evaporated in vacuo until an off white solid was obtained (2 hours). The 
product was used immediately in step 3. 
Step 3: Preparation of the iminium chloride. 
The Vilsmeier reagent was dissolved in dry chloroform (400m1) and cooled in an ice/salt 
bath under nitrogen. Ethyl diazoacetate was then added dropwise, keeping the 
temperature below 5°C. Addition complete, the reaction was stirred at room temperature 
for 30 minutes, then evaporated to give an oily residue. Addition of ether to the residue 
caused the product to precipitate out as a yellow solid, which was filtered off under 
nitrogen with suction and washed with ether. The sticky pale yellow solid was stored 
overnight in a desiccator and then used in step 4. 
Step 4: Preparation of diazo-oxime. 
NH20H.HCI (44g, 0.63mo1) was dissolved in a minimum amount of water and cooled in 
an ice/salt bath. Sodium carbonate (33.6g, 0.32mo1) was added slowly with stirring to 
achieve pH 7.5. The product from step 3 (130g, 0.63mo1) was added, with stirring, and 
the diazo-oxime product precipitated out as a yellow solid. After several minutes, the 
precipitate was collected by filtration and washed with a small volume of ice cold water. 
Step 5: Preparation of ethyl 1 -hydroxyl-1 ,2,3-triazole-4-carboxylate (HOCt). 
The product from step 4 was dissolved in chloroform (150m1) and dried over magnesium 
sulphate, before filtration and addition of concentrated acetic acid (0.5m1). The solution 
was stood at room temperature in light until cyclisation was complete (several days). The 
solvent was removed in vacuo, giving an off white solid. Ethyl acetate was added, the 
solid isolated by filtration, washed with ethyl acetate and dried in vacuo yielding the 
product as fine, white crystals. The filtrate was concentrated and stood at 4 °C, forcing 
more of the product to crystallise out. This was filtered off and the process repeated until 
no further crystals were formed. Overall yield 21.84g, 10%. 
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m.p. 98-100°C. 'Hnmr(CDCI3, 200MHz, ö/ppm) 1.34(3H, t), 4.38(2H, q), 8.06(1H, s), 
12.5(1H, s). 13C{ 1 H}nmr(CDC13, 62MHz), ö/ppm 159.2 (qC), 136.5 (qC), 121.7 (CH), 
61.7 (CH2), 13.9 (CH3). 
5.6 General protocol for diisopropylcarbodiimide coupling of the C-terminal 
amino acid onto p—benzyloxybenzyl alcohol (Wang) resin. 
The Fmoc-amino acid (5.5 mmol, 6 equivalents relative to resin loading) was activated 
as the symmetric anhydride by treatment with diisopropylcarbodiimide (DIC) (450 tl, 
2.9 mmol, 3 equivalents) in DMF (5 ml). The mixture was sonicated for 10 minutes, 
before being added to Wang resin (1.2 g, 0.96 mmol), previously swollen in DMF (5 
ml). 4-Dimethylaminopyridine (DMAP) (10 mg, 0.09 mmol,) was added and the mixture 
sonicated for 2 hours. The resin was then filtered and washed consecutively with DMF 
and 1 ,4-dioxane. 
Determination of resin loading efficiency 
A sample of the resin was dried in vacuo, after washing with diethyl ether. The dry resin 
(3-4 mg) was accurately weighed into a 10 ml volumetric flask and made up to the mark 
with 20% (v:v) piperidine in DMF, sonicated for 10 minutes and the UV absorbance of 
the supernatant measured at 302 mm The loading of the resin was calculated using the 
relationship: 
Resin Loading (mmol/g) = 10 x Absorbance 
9 x weight of resin (mg) 
This method was used to determine both the initial manual Fmoc-amino acid loading to 
the resin and the final Fmoc-amino acid coupling to the growing peptide sequence which 
gave the overall loading of peptide on to the resin. 
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5.7 General protocol for acidolytic cleavage from Wang resin 
The JV Fmoc protecting group was removed by sonication of the resin in 20% piperidine 
in DMF for 20 mm, filtering and washing consecutively with DMF, 1 ,4-dioxane, DCM 
and diethyl ether. 
The dry resin-bound peptide was placed in a round bottomed flask. A cocktail of 
scavengers (up to 1 ml volume) was added to the resin and the mixture stirred for 30 mm. 
The choice of scavengers is dictated by the amino acids (hence protecting groups) in the 
sequence; the standard mixture, employed in the cleavage of all the peptides detailed 
here, contained ethanedithiol (EDT) (0.35m1), water (0.4m1), triisopropylsilane (TIS) 
(0.1ml), thioanisole (0.15m1) and phenol (0.2g). To this was added trifluoroacetic acid 
(TFA) (1 Omi), and the mixture stirred under nitrogen for 2 hours at room temperature. 
The cleaved resin was then filtered and washed with TFA (1x2 ml), then cold diethyl 
ether (20m1) poured into the crude peptide/TFA filtrate, causing the peptide to 
precipitate out. This suspension was stood in ice for 15 mins, before centrifugation and 
removal of the supernatant liquid. The peptide was washed a further 3 times with fresh 
cold ether, the supernatant being removed after centrifugation. 
5.8 General protocol for the coupling of the C-terminal amino acid onto 2-
chlorotritylchloride resin. 2 
The amino acid (dried overnight over NaOH) (1.17 mmol) was dissolved in dry DCM 
(10 ml). Dry DMF (catalytic amount) was added until the amino acid had completely 
dissolved, before adding the solution to 2-chlorotritylchloride resin, (dried overnight 
over NaOH) (1 g at 1.17 mmol/g). One third of the total DIEA to be used (0.98 mmol) 
was added, and the reaction stirred for 5 mins, before addition of the remaining two 
thirds DIEA in a 1:1 mixture with dry DCM. The reaction was stirred under nitrogen for 
1 hour at room temperature. Excess HPLC grade methanol (0.8 ml) was added, and the 
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reaction stirred for 10 mins, before filtering off the resin and washing consecutively 
with: DCM (3xlOml), DMF (2xlOml), isopropanol (2xlOml), DMF (2xlOml), 
isopropanol (2xlOml), methanol (2xlOml) and diethyl ether (2xlOml). The resin was 
then dried (NaOH). 
The loading level of the amino acid on the resin was determined as described above for 
Wang resin. 
5.9 Acidolytic cleavage of resin bound-peptide from 2-chlorotrityl resin. 
The dry resin-bound peptide was stirred at room temperature in a solution of 2:2:6 acetic 
acidltrifluoroethanol/DCM (20ml/g of resin) for 2 hours. The resin was filtered and 
washed with the cleavage mixture (3x5ml), hexane was added (5x vol. of solvent) and 
the solvents removed in vacuo. The residue was washed a further 3 times with hexane, 
each time evaporating to dryness. 
5.10 Notes on the synthesis of the peptide libraries. 
All peptide libraries were synthesised on a 0.25mmol scale (except Library 5, 0.2 mmol 
scale) on an Applied Biosystems 430A automated peptide synthesiser, using the Fmoc 
orthogonal protecting strategy. Non-optimum conditions were applied, using HOBt/DIC 
single coupling for the synthesis of Libraries 1-4, to give peptide libraries containing a 
significant proportion of impurities and truncates. 
The synthesis of Library 5 was found to fail under these conditions, hence HOCt active 
ester coupling was employed, with double coupling at all residues (except Gly, where an 
extended coupling time was applied). At the three sites of diversity the resin was 
removed from the synthesiser and coupled in the sonic bath, allowing extended coupling 
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time, in addition to being double coupled. Under these conditions Library 5 was 
successfully constructed with an overall 23% final coupling efficiency. 
Diversity was introduced into the libraries in one of two ways: 
Using simple multiple peptide synthesis, where, at the sites of diversity, the cartridge 
corresponding to that residue was loaded with 1 mmol equivalent of different amino 
acids. All the libraries in this work used 3 amino acids at each site of diversity, hence 
the corresponding cartridges were loaded with 1/3mmol each of the 3 selected amino 
acids. This technique was used in the synthesis of Libraries 1, 2, 3 and 5. 
Library 4 was produced using a split/pool strategy; whereby, at the sites of diversity 
the resin was removed from the automated peptide synthesiser (after deprotection of 
the JV Fmoc group), divided into 3 equal portions and the 3 selected amino acids 
coupled separately for 30 mm. in a sonic bath. After coupling, the 3 portions of resin 
were re-combined, filtered and washed, then returned to the automated synthesiser 
which continued the synthesis either to the next site of diversity, where the process 
was repeated, or to the end of the peptide sequence. 
After completion of the synthesis the N-terminal Fmoc was removed from the libraries, 
Tbfmoc was loaded (see below) and the libraries cleaved from the resin using standard 
methods. Libraries 2-5 were then subjected to an affinity purification protocol using 
carbon, see section 5.12. 
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5.11 General protocol for the loading of tetrabenzo[a,c,g,i]fluorenyl-17-methoxy 
carbonyl (Tbfmoc) onto the 1V of the resin-bound peptide. 
The IV-Fmoc was removed by sonicating the resin bound peptide in 10% piperidine in 
1 ,4-dioxane for 20 minutes. After washing thoroughly with 1 ,4-dioxane and DCM, the 
resin (1 g) was swollen in DCM (lOmi), and TbfmocCl (3 equivalents) dissolved in 
DCM (lOml) added, together with DIEA (3 equivalents). The mixture was sonicated, in 
the absence of light, for 3 hours at room temperature. The resin was then filtered and 
washed with copious DCM and diethyl ether, and dried in vacuo. 
Determination of resin loading efficiency 
A known weight of dry resin (3-6mg) was weighed into a lOml volumetric flask and 
made up to the mark with 10% piperidine in 1,4-dioxane. After sonicating for 10 
minutes, the UV absorption of the solution was measured at 364 nm. The loading of the 
Tbfmoc onto the peptide was calculated using the relationship: 
Tbfmoc loading (mmol/g) = Absorbance x 0.613 
Weight of resin (mg) 
5.12 Carbon purification of Tbfmoc-peptides and peptide libraries. 
Using porous graphitised carbon (PGC) 
Method 1: Used for the purification of Libraries 2 and 3. 
The crude peptide material with Jya  Tbfmoc (200mg), obtained from acidolytic cleavage, 
was dissolved in 1:1 6M guanidine hydrochloride/isopropanol (10 ml). PGC (150mg) 
was added, and the suspension vortexed (10 mins), until all material with a 
corresponding 364 nm absorbance had been adsorbed, as assessed by HPLC after 
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centrifugation. The supernatant was then discarded, and the PGC washed repeatedly with 
1:1 6M GuHC1/iPrOH (4x20 ml) using the vortex/centrifuge technique. On obtaining a 
flat baseline on RP HPLC, the peptide was cleaved from the Tbfmoc (which remained 
adsorbed onto the PGC) by vortexing for 15 minutes in 10% piperidine in 1:1 
GuHC1/iPrOH (lOmi). This was repeated, then the carbon rinsed twice with neutral 
solvent, the supernatants combined and neutralised with glacial acetic acid to pH 5.5. 
The isopropanol was removed, then the mixture desalted by preparative RP HPLC. The 
HPLC conditions were as detailed previously, except the gradient was held at 10% 
acetonitrile until all the guanidine and salt had been eluted. The relevant peptide peaks 
were collected and lyophilised. 
Using activated charcoal 
The activated decolourising charcoal was prepared by washing repeatedly using a 
vortex/centrifuge technique with 10% piperidine in a suitable polar solvent system, until 
the supernatant ran clear (6x25ml). The charcoal was then rinsed with that same solvent 
system without piperidine (4x25ml), followed by TFA (lOml) for immediate use. 
The solvent system was selected by cleaving a small portion of resin, carrying the 
peptide(s) without Tbfmoc, and establishing a suitable solvent to solubilize the crude 
material. 1:1 Acetonitrile/water was found to solubilize Library 4, while 3:2 




Method 2a: Optimised procedure used for the purification of Library 4. 
Using the vortex/centrifuge technique, the library (200mg of peptide) was adsorbed onto 
the pre-washed charcoal (100mg) straight from the TFA cleavage solution, without 
isolating the crude material. The charcoal was washed with 1:1 acetonitrile/water 
(4x25m1) until a flat baseline was obtained on RP HPLC. The library was then cleaved 
using 10% piperidine in 1:1 acetonitrile/water (2xlOml). The carbon was washed twice 
further with 1:1 acetonitrile/water (2xlOml) to remove any remaining peptidic material, 
the supernatants combined and neutralised with glacial acetic acid. The acetonitrile was 
removed by rotary evaporation and the residual peptide solution de-salted by preparative 
RP HPLC, holding the gradient at 2% acetonitrile until the salt had been eluted. The 
relevant peaks were collected and lyophilised. 
Method 2b: Optimised procedure used in the purification of Library 5. 
Pre-washed charcoal was loaded into a small sintered glass column containing a layer of 
celite. The column was then operated by a dry flash column chromatography technique. 
The IVUTbfmocLibrary  5 was adsorbed onto the charcoal straight from the TFA 
cleavage by passing the TFA solution through the column 3 times. After checking the 
supernatant by HPLC (all 364nm material adsorbed from solution), the charcoal was 
washed with 3:2 acetonitrile/water (lOOmI) (flat baseline on RP HPLC), then the 
peptides cleaved with 10% piperidine in acetonitrile/water (2x20m1). The piperidine was 
allowed to remain in contact with the charcoal for several minutes by removing the 
vacuum and passing the solution repeatedly through the column. The charcoal was 
further washed with 3:2 acetonitrile/water (2x2Oml), the washings combined with the 
piperidine cleavages, neutralised with glacial acetic acid and the acetonitrile removed. 
The peptide solution was then de-salted by preparative RP HPLC, holding the gradient at 
2% acetonitrile until the salt had eluted, the relevant peaks collected and lyophilised. 
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5.13 In vitro testing of truncated big ET-1 analogues. (Performed by Parke Davis) 3 
A mixture containing bigET- 1 (0.1 tM), Hepes-KOH (pH 7.0) (100mM), NaCl (50mM), 
pepstatin A (501.iM), leupeptin (100tM), phenylmethylsuiphonyl fluoride (200p.M), an 
indicated concentration of BigET-1 analogue (as the inhibitor, DMSO for control), and 
the membrane fraction of CHO/human ECE-1 cells. The final concentration of DMSO 
was 1.5%. After incubation for 1 hr at 37'C, the reaction was stopped by adding EDTA 
to give a final concentration of 10mM. This final mixture was then directly analysed for 
mature ET-1 by enzyme-linked immunosorbant assay. 
The analogues were judged to be substrates if the hydrolysis could be completely 
inhibited by a specific ECE-1 inhibitor, as determined by RP HPLC analysis (Ref An et 
al. BBRC 1998, 243, 184). 
5.14 Kinetic Testing of the big ET-1(16-38) analogues. (Performed by Parke Davis) 3 
The assays were performed as described in section 5.13. They were carried out for 1 hour 
and then analysed by RP HPLC (C18 column) using a linear gradient from 0-50% 
acetonitrile. Rates were determined by appearance of the [22-38] product. A standard 
plot was used to relate moles of [22-38] to peak area of the peptide. Initial rate data was 
analysed by Kaleidagraph (Synergy Software, Reading , PA), which fitted to the 
Michaelis-Menten equation hyperbola (see chapter 2). 
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Part 2: Heterocyclic Investigations into a Potential Ras FTase Inhbitor. 
5.15 Techniques and instrumentation 
Thin layer chromatography (TLC) was run on aluminium sheets pre-coated with silica 
gel (Kieselgel 60 F252) from Merck. The compounds were visualised by ultra-violet 
absorption at 254nm and potassium permanganate or 0.2% bromocresol in ethanol, in 
the case of acid functionalities. Wet flash chromatography was performed using silica 
gel 60 (230-400 mesh) (from BDH). Fourier Transform Infra Red (FTIR) Spectroscopy 
was performed on a Bio-Rad FTS-7 spectrometer, either in the solvent indicated or 
prepared as a KBr disc. Proton NMR spectra were recorded on either a Gemini Varian 
200, Brucker WP 200 (200 MHz) or Brucker AC 250 (250 MHz) instrument, in the 
deuterated solvent indicated, using tetramethylsilane (TMS) as an external standard. 
Carbon and fluorine NMR were recorded on either of the latter instruments. High and 
low resolution mass spectra were measured either by fast atom bombardment (FAB) on a 
Kratos MS50TC machine, or by electron impact (El) on a Kratos 902MS. CHN 
elemental analysis was carried out on a Carlo Erba 1106 or Perkin Elmer 2400 
instrument. All further techniques and instrumentation employed in the analysis of the 
work has been detailed previously. All reactions were performed under anhydrous 
conditions. 
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5.16 Preparation of 2-fluoro, 4-hydroxyl benzoic acid (10). 	/ 
HO 
COOH 
3-Fluorophenol (0.094mo1, 1 equiv.), sodium hydroxide (0.846mo1, 9 equiv.), water 
(33.84m1) and copper powder (2.2mmol, 0.023 equiv.) were combined in a round bottom 
flask and stirred mechanically. The slurry was heated to 80 °C, and carbon tetrachloride 
(0.097mo1, 1.03 equiv.) added gradually over 5 hours at such a rate as to keep the 
reaction at gentle reflux. Additional copper powder (0.088g) was added after 2 and 4 
hours. The reaction was allowed to stir at 80 °C overnight. The resulting slurry was 
diluted with water and filtered, before being cooled on an ice bath and acidified (conc. 
hydrochloric acid), causing the product to precipitate out as a pale orange solid. After re-
crystallising from water three times, with decolourising charcoal, (10) was obtained as a 
white crystalline solid (3.52g, 0.02mol, 24%). 
RI 0.80 (diethyl ether). m.p. 203-204°C (Lit. 204205.5 0C). FTIR vmax/cm'(nujol) 
1520, 1593 (Ar); 1686 (C0); 3469 (OH). &ma xlnm (methanol, c/dm 3 MOO cm') 
246(13884). 'Hnmr(DMSO, 200MHz, ö/ppm) 10.73(1H, s, OH); 7.88-7.82(1H, m, 
AM); 6.84-6.72(2H, m, ArH). 13C{'H)nmr (DMSO, 62MHz), s/ppm 171.44 (COOH); 
166.41 (d, J=251.lHz, ArCF); 163.33 (d, J13.9Hz, q ArC o to F); 132.94 (d, J1 1.21-1z, 
ArH p to F); 110.15 (d, J=2.7Hz, q ArCOH); 107.18 (d, J=22.3Hz, ArCH m to F); 
103.95 (d, J=24.2Hz, ArCH o to F). 19Fnmr (DMSO), s/ppm -104.26 (ArF). HRMS 
(El, M+/z) C7H5F03 (M) requires 156.0223, found 156.0222. 
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Under an N2 atmosphere, 2-fluoro, 4-hydroxy benzoic acid (6.41mmol, 1 equiv.) was 
dissolved in dry THF (12.8m1). Freshly distilled triethylamine (19.23mmol, 3 equiv.) 
was added, followed by t-butyldimethylsilyl chloride (12.82mmol, 2 equiv.) solution in 
THF (3m1), and the reaction was stirred at room temperature for two hours. The solvent 
was then removed, and the residue taken up in diethyl ether and washed with water, sat. 
NaHCO3 solution, water and brine. The organic layer was dried (Na 2SO4) and the 
solvent removed to give the product as an oil. Purification was achieved via Kugelrohr 
distillation under trolley pump vacuum, giving a colourless oil (1.297g, 3.4mmol, 5 3%). 
Rf 0.92 (diethyl ether). FTIR vmax/cm 1 (DCM) 1571, 1614; 1696 (C0); 2886, 2931 
(CH). Xmax/flm (methanol, */dm 3mor'cm) 238(12375). 1 Hnmr(CDCI3, 200MHz, 
6/ppm) 7.66-7.57 (1H, m, ArH); 6.44-6.30 (21-1, m, ArH); 0.77 (914, s, tBu); 0.74 (9H, s, 
tBu); 0.13 (61-1, s, 2xCH3); 0.00 (614, s, 2xCH3). 13C{'H}nmr (CDC13, 62MHz), 6/ppm 
169.32 (qCO), 169.24 (qArC), 164.41 (d, J262.4Hz, ArC-F), 162.61 (qArC), 162.54 
(2xqC), 134.3 (d, J1.7Hz, ArCHp toP), 116.42 (d, J2.6Hz, ArCH m toF), 109.04 (d, 
J=23.4Hz, ArCH o to F), 26.00 (4xCH3), 25.91 (6x CH3). HRMS (FAB, M+/z) 
C 19H33FO3Si2 (MH) requires 385.1953, found 385.1968. 
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2-Fluoro, 4-hydroxy benzoic acid (0.10g, 6.41mmol, 1 equiv.) was dissolved in DMF 
(12m1), under N2. To this was added potassium carbonate (1.97g, 12.82mmol, 2 equiv.), 
followed by benzyl bromide (1.65g, 9.62 mmol, 1.5 equiv.), and the reaction was stirred 
at 60°C overnight. The resulting suspension was filtered, the solvent removed by 
evaporation and the residue re-dissolved in ethyl acetate. After washing with 1M HC1 
(3xlOml) and brine (2xlOml), the organic layer was dried (MgSO 4) and the solvent 
removed to give the product. Re-crystallisation from hexane gave (11) as a white 
crystalline solid (1.lOg, 3.27mmol, 5 1%). 
Rf 0.83 (1:1 diethyl ether/hexane). FTIR vmax/cm'(DCM) 1276.9 (C-O); 1616.9 (CH); 
1715.7 (C=O); 3063.2 (ArCH). X maxffllfl (methanol, E/dm 3mol'cm) 252 (13230). 
'Hnmr(CDCI3, 200MHz, Wppm) 7.97-7.88 (1H, m, ArH); 7.48-7.32 (1 OH, m, ArH); 
6.82-6.68 (214, m, ArH); 5.35 (21-1, s, C112); 5.10 (211, s, CH2). 13C{'H}nmr (CDC13, 
62MHz), s/ppm 163.8 (qArCOOBn), 163.7 (qArCOBn), 163.6 (d, J=1 1.714z, qArC o to 
F), 163.4 (d, J=260.7Hz, qArC-F), 135.9 (qArC), 135.5 (qArC), 133.4 (d, J=1.8Hz, 
ArCHp to F), 128.6 (2xArCH), 128.4 (2xArCH), 128.3 (ArCH), 128.0 (ArCH), 127.9 
(2xArCH), 127.4 (2xArCH), 110.8 (d, J=2.6Hz, ArCH m to F), 103.1 (d, J=26.OHz, 
ArCH o to F), 70.4 (CH 2), 66.4 (CH2). HRMS (FAB, M+/z) C211117F03 (MH) requires 
337.1162, found 337.1150. 
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(11) (0.94mmol, 1 equiv.) was suspended in 2:1 2M sodium hydroxide/1,4-dioxane 
(3m!). After stirring overnight at room temperature, the solvent was removed and the 
residue diluted in water. After extracting twice with diethyl ether, the aqueous layer was 
cooled in an ice bath and acidified with conc. hydrochloric acid, causing (A) to 
precipitate out as a white solid (0.1 5g, 0.63mmo!, 67%). 
Rf 0.82 (diethyl ether). FTIR vmax/cm'(DCM) 1619.2; 1704.8 (C0); 3414.4 (OH). 
Xmax/flm (methanol, Eldm 3mor'cm) 241 (4182). 'Hnmr(CDC13 , 200MHz, s/ppm) 
8.01-7.93 (11-1, m, ArH); 7.43-7.38 (514, m, ArH); 6.85-6.70 (21-1, m, ArH); 5.11 (2H, s, 
CH2). 13C{'H}nmr (CDCI3 , 62MHz), ö/ppm 164.8 (qC=O), 164.8 (qArCOBn), 163.3 
(d, J11.61-1z, qArC), 162.9 (d, J=257.3, ArC-F), 136.2 (qArC), 133.5 (d, J=2.4Hz, 
ArCH p to F), 128.7 (2xArCH), 128.4 (ArCH), 128.1 (2xArCH), 111.5 (d, J=2.6Hz, 
ArCH m to F), 103.4 (d, J26.OHz, ArCH o to F), 70.2 (CI-12). HRMS (FAB, M+/z) 
C14H11F03 (MH) requires 247.0692; found 247.0771. 
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5.20 Preparation of ethyl 3-keto-3-(4-benzyloxy-2-fluorobenzene) propanoate via 
the Acid Chloride (2). 
DO 
OBn 
Under N2 atmosphere, 4-benzyloxy-2-fluorobenzoic acid (0.78mmol) was heated in 
thionyl chloride (5m1) for 1.5 hours. The excess thionyl chloride was then removed by 
distillation. (FTIR v ma /cm 1 (liquid film) 1769 (C=O)) 
Under N2 atmosphere, potassium ethyl malonate (1 .6mmol, 2.06 equiv.) in dry MeCN 
(1.5m1) was cooled to 10-15 °C, and to this was added Et3N (1.56mmol, 2 equiv.), 
followed by M902 (1 .95rnmol, 2.5 equiv.). Stirring was then continued at room 
temperature for 2.5 hours. The resulting slurry was re-cooled to 0 °C, and the acid 
chloride in dry MeCN (1 .5m1) added dropwise over 20 mins, followed by additional 
Et3N (0.17mmol, 0.22 equiv.). The mixture was allowed to stir overnight at room 
temperature, after which it was concentrated and taken up in toluene (lOmi) twice. 
Further toluene was added (lOml), and the mixture stirred and cooled to 10-15 °C. 
Aqueous HC1 (13%, 3m1) was added cautiously, keeping the temperature below 25 °C. 
The aqueous layer was separated and the organic layer washed with 13% aq HC1 
(2x5m1), followed by H 20 (2x5m1), then concentrated under vacuum to give (2) as a 
white solid (145.4mg, 0.46mmol, 59%). 
Rf 0.80 (diethyl ether). FTIR V max/C1fl'(DCM) 1616.3 (C=C), 1691.5 (C0), 1728.8 
(ester C0), 2996.4 (CH), 3063.9 (ArCH). maxIflm (methanol, c/dm 3mof'cm') 246 
(26062). 'Hnmr(CDCI3, 200MHz, s/ppm) 7.99-7.92 (1H, m, ArH); 7.42-7.34 (51-1, m, 
ArH); 6.83-6.69 (2H, m, ArH); 5.10 (21-1, s, CH 2Ph); 4.24 (214, dd, J=0.06, 0.03Hz, 
CH2Me); 3.44 (2H, s, -OC-CH2-CO-); 1.30 (31-1, t, 3J0.03Hz, CH3). 13C{'H}nmr 
(CDCI3, 62MHz), 8/ppm 171.06 (q ArC-013n); 168.96 (d, J=3.7Hz, q CO); 167.04 (q 
139 
Experimental 
C0); 164.42 (d, J11.8Hz, q ArC o to F); 164.05 (d, J262.1Hz, q ArC-F); 135.32 (q 
ArC); 134.02 (d, J2.2Hz, ArCH p to F); 128.67 (2xArCH); 128.37 (ArCH); 127.41 
(ArCH); 110.98 (d, J=2.9, ArCH m to F); 103.20 (d, J25.7, ArCH o to F); 70.49 (CH2); 
61.93 (CH 2); 40.55 (CH2); 13.90 (CH,). 19Fnmr (CDCI3), ö/ppm -104.84 (ArF). HRMS 
(FAB, M4 /z) C 18H 17F04 (MH) requires 317.1111, found 317.1125. 
5.21 Preparation of ethyl 3-keto-3-(2-fluoro-4-hydroxybenzene) propanoate (3). 
EtO'jL H 
Ethyl 3 -keto-3 -(4-benzyloxy-2-fluorobenzene) propanoate (2) (128.8mg, 0 .4O8mmol) 
was dissolved in methanol (5m1) and a catalytic amount of 10% palladium on charcoal 
added. The vessel was charged with H2 three times, then the suspension allowed to stir 
under a hydrogen atmosphere for 2.5 hours. The suspension was then filtered and the 
solvent removed in vacuo to yield (3) (58mg, 0.26mmol, 63.4%). 
RI 0.7 (diethyl ether). FTIR vmax/cm'(DCM) 1687.4 (CO), 1735.1 (ester C+O), 
2984.1 (CH), 3041.9 (ArCH). 2 max/nm (methanol, c/dm 3mol'cm') 244 (9176). 
'Hnmr(CDC13, 200MHz, 6/ppm) 7.99-7.92 (1H, m, ArH); 6.83-6.69 (2H, m, ArH); 
4.24 (214, dd, J0.06, 0.03Hz, CH 2Me); 3.44 (2H, s, -OC-CH 2-CO-); 1.30 (31-1, t, 










C  0!?, OH 14 
I 
Phenol (2g, 21.3mmol) was dissolved in aqueous sodium hydroxide (0.85g, 21.3mmol in 
2m1 H20). The solution was heated to 70 °C and styrene oxide (2.43m1, 21 .3mmol) added 
dropwise over 3 mm. The reaction was stirred for 4.5 hours, then poured onto ice 
causing a precipitate to form. After ensuring the solution was basic, the insoluble 
material was extracted with diethyl ether (2x20m1). The organic layers were combined, 
dried (sodium sulphate) and the solvent removed giving the product as a mixture of two 
isomers (13) and (14) (-4:1) (2.4g, 1 1.2mmol, 53%). Partial separation was achieved by 
flash column chromatography (1:1 diethyl ether/hexane). 
Rf 0.51 (1:1 diethyl ether/hexane). FTIR vmax/cm'(DCM) 1491.2, 1594.9 (Ph); 
2359.4, 2335.2; 3061.9 (ArCH); 3590.6 (OH). X maxlnm (methanol, E/dm3mol'cm') 
265 (1818), 271 (1817), 278 (1413). 'Hnmr(CDC13, 200MHz, ö/ppm) 7.41-7.17 (71-1, 
m, ArH), 6.95-6.87 (31-1, m, ArH), 5.29 (11-1, dd, J8.04, 3.7Hz, CH), 3.88 (2H, 
dddddddd, CH2), 2.54 (1H, dd, J=9.25, 4.11Hz, OH). 13C{ 1 H}nmr (CDC13, 62MHz), 
Ippm 157.58 (qArC), 137.64 (qArC), 129.25 (2xArCH), 128.57 (2xArCH), 127.98 
(ArCH), 126.11 (2xArCH), 121.04 (ArCH), 115.73 (2xArCH), 80.90 (CH), 67.37 (CH2). 
HR1\'IS (FAB, M+/Z) C 14H 1402 (MH) requires 215.0994, found 215.1002. Elemental 
Analysis C14H1402 requires 78.48% C, 6.59% H; found 77.94% C, 6.54% H. 
Rf 0.48 (1:1 diethyl ether/hexane). FTIR vmax/cm'(DCM) 1276.9 (C-U); 1490.8, 
1594.1; 2921.0 (CH); 3051.4, 3073.5 (ArH); 3590.5 (OH). ? max /nm (methanol, 
/dm3moI'cm') 264 (1664), 271 (1902), 278 (1427). 'Hnmr(CDC13, 200MHz, s/ppm) 
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7.34-6.92 (1 OH, m, ArH), 4.07 (1H, dt, J=8.8, 3J=2.9, CH), 4.0 (2H, m, CH2), 3.0 (1H, d, 
J=3.lHz OH). HRMS (El, M+/z) C 14H 1402 (M) requires 214.0994 , found 214.0990. 
Elemental Analysis C 14H 1 402 requires 78.48% C, 6.59% H; found 78.12% C, 6.38% H. 
00 
EtO5 OH Q  
(3) (0.03g, 0.13mmol) was used to open styrene oxide under the conditions detailed 
above. The product was shown to consist solely the isomer (15) (crude yield -P25%). 
Rf 0.74 (1:1 hexane/ethyl acetate). FTIR vmax/cm'(DCM) 1690.4 (C=O); 1745.2 (C=O 
ester); 2990.3 (CH); 3064.8, 3081.7 (ArH). 'Hnmr(CDC13, 200MHz, ö/ppm) 7.99-7.91 
(1H, m, ArH), 7.47-7.11 (5H, m, ArH), 6.91-6.59 (211, m, ArH), 6.32 (1H, dd, J=7.91, 
2.9Hz, CH), 4.21 (2H, dd, J0.05, 0.03Hz, CH2), 4.01 (2H, m, CH 20H), 3.46 (2H, s, 
C112), 2.26 (111, dd, J= 9.15, 4.02Hz, OH), 1.26 (3H, t, 3J0.03Hz, CH3). HRMS (FAB, 
M'/z) C 1 9H1905F (MH) requires 346.1216; found 346.1222. 
5.23 Preparation of methyl 4-vinyl benzoate (18). 
C00CH 3 
4-Vinylbenzoic acid (2g, 13. 5mmol), methanol (1 5m1) and concentrated sulphuric acid 
(catalytic amount) were combined, and the mixture heated at reflux for 4 hours. The 
excess methanol was then removed, the residue dissolved in DCM (1 5m1) and extracted 
with water(20m1). The aqueous layer was then extracted twice with DCM (2x 1 Oml), the 
organic layers combined and washed with saturated sodium bicarbonate until no further 
gas was evolved, then washed once with water. The organic extract was dried (MgSO4) 




Rf 0.62 (1:1 diethyl ether/hexane). FTIR vmax/cm'(DCM) 1289.5 (C-O), 1607.9 (C=C), 
1720.6 (CO), 3063.4 (ArH). X maxtnm (DCM, /dm3moF'cm) 241 (11448). 
'Hnmr(CDC13, 200MHz, ö/ppm) 7.94-7.90 (2H, m, ArH); 7.41-7.37 (2H, m, ArH); 
6.68 (1H, dd, J=17.6, 11.0Hz, vinyl H); 5.79 (1H, d, J=17.6Hz, vinyl H); 5.31 (1H, d 
J11.OHz, vinyl H); 3.84 (31-1, s, CH 3 ). 13C{'H}nmr (CDC13, 62MHz), s/ppm 166.51 
(C0), 130.05 (qArC), 129.98 (qArC), 129.82 (2xArCH), 129.42 (2xArCH), 126.69 
(vinyl CH), 52.33 (vinyl CH2), 52.03 (CH3). HRMS (El, M+/z) C 10H 1002 (M) requires 
162.0681; found 162.0681. 




Methyl 4-vinylbenzoate (0.56g, 3.5mmol) was added to a solution of 
metachloroperbenzoic acid (MCPBA) (0.59g, 3.5mmol) in chloroform (lOmi). The 
reaction was stirred at 0 °C for 24 hours, then shaken with 10% NaOH and washed with 
water. The chloroform solution was dried (MgSO4), and the solvent removed giving (19) 
as a white solid (0.50g, 2.84mmol, 81%). 
Rf 0.64 (1:1 diethyl ether/hexane). FTIR vmax/cm'(DCM) 1722 (C0); 2304; 2953, 
2987 (CH); 3053 (ArCH). ? max/nm (DCM, *Idm 3mol'cm) 240 (14351). 
1 Hnmr(CDCI3, 200MHz, s/ppm) 7.96-7.90 (211, m, ArH); 7.41-7.19 (2H, m, ArH); 
3.84 (4H, s, CH3 + epoxide H); 3.10 (1H, dd, J5.5, 4.21-1z, epoxide H); 2.71 (1H, dd, 
J=5.5, 2.6Hz, epoxide H). 13C{'H}nmr(DMSO, 62MHz), ö/ppm 166.65 (C0), 129.93 
(qArC), 129.83 (qArC), 129.67 (2xArCH), 125.27 (2xArCH), 52.02 (CH3), 51.80 
(epoxide CH), 51.32 (epoxide CH2). HRI\'IS (El, M+/z) C 1 0H1003 (M) requires 
178.0630, found 178.0629. 
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5.25 Preparation of 2-imidazol-1-yl-1-phenyl-ethanol (20).' ° 
OH 
I 
Imidazole (2g, 0.029mo1) and freshly distilled styrene oxide (3.4m1, 0.029mo1) in DMF 
(20m1), were heated at 90°C with stirring under nitrogen for 50 hours. After cooling to 
room temperature, the mixture was diluted with water (300m1) and extracted with diethyl 
ether (2x200m1). The organic layers were combined, dried (Na 2SO4) and the solvent 
evaporated, affording the crude product, which was recrystallised from diethyl ether to 
give a beige crystalline solid. Yield 75%. 
Rf 0.69 (1:1 DCM/methanol). m.p. 146°C (lit. °C). FTIR vmax/cm4 (bromoform) 877.6 
(C=C); 1389.4 (OH bending); 1444.9;1709.2 (C0);3386.9 (N-H). ? ma xInm (methanol, 
/dm3moF'cm) 252 (193), 257 (217), 263 (169). 1 Hnmr(DMSO, 200MHz, ölppm) 
7.57(1H, s, ImCH); 7.43-7.35(5H, m, ArH); 7.15(1H, t, 3J=1.23Hz, ImCH); 6.98(1H, t, 
3J1.06Hz, ImCH); 5.00(1H, m, CH); 4.26(2H, m, CH 2). 13C{1H}nmr(DMSO, 
62MHz), ö/ppm 141.07(qArC); 137.10(CH); 127.54(2xCH); 127.00(CH); 126.45(CH); 
125.1 8(2xCH); 1 99.59(CH); 72.30(CH); 53.38(CH2). HRMS(FAB, M+/z) C 1 1 H 1 2N20 
(MH) requires 189.0950, found 189.0958. Elemental Analysis C 11 H 1 2N20 requires 
70.19% C, 6.43% H, 14.88% N; found 70.11% C, 6.26% H, 14.85% N. 
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Method 1 " 
Water (9.2m1), toluene (2.5g, 0.0275mo1) and KMn04 (4.59g, 0.029mo1, 1.06 equiv.) 
were heated at gentle reflux until the colour had disappeared (lh.). A second portion of 
KMn04 (4.59g, 0.029mo1, 1.06 equiv.) was added with water (2m1), and the heating 
continued until the purple colour was destroyed (2.5h.). The reaction was allowed to cool 
slightly, and the brown manganese dioxide precipitate filtered off and washed with hot 
water. The filtrate was concentrated under reduced pressure and acidified to pH3 with 
conc. HC1, causing the benzoic acid product to crash out as a white solid. It was 
recrystallised from ethanol, with hot filtration to remove the salts (yield 86%). 
m.p. 121-122°C (lit. 122.6-123.1 0C). MS(FAB, M+/z) C71-1602 (MH) requires 122, 
found 122. 
Method 212 
Toluene (2.5g, 0.088mol) and KMn04 (13.33g, 0.264mo1, 3.07 equiv.) were added to a 
solution of NaOH (22g, 1 .76mo1, 20 equiv.) in water (330ml). The mixture was heated 
under reflux at 100 °C with stirring for 15mins, then the slurry allowed to cool and 
ethanol (5m1) added, to react with the excess K1V1n04. The manganese dioxide was 
filtered off with suction through a plug of celite, giving a colourless solution. The filtrate 
was allowed to cool in an ice bath and carefully acidified with conc. HCl causing the 
benzoic acid to precipitate out. It was recrystallised from ethanol, with hot filtration to 
remove the salts (yield 23%). 





A RB flask, fitted with a mechanical stirrer, was charged with KOH pellets (25.1g, 
0.46mo1) and water (5.2m1). When the slurry had cooled, toluene (2.5g, 0.0275mo1) was 
added and stirring commenced. Lead dioxide (25.12g, 0.105mol) was added and the 
mixture heated via a graphite bath on a hot plate. The temperature was maintained at 
240°C, and after several minutes the lumpy brown mass rapidly formed a bright orange 
melt. After a further 15 minutes at this temperature, the melt was briefly heated to 250 °C 
before being allowed to cool slightly. After a few minutes the liquid was poured into a 
large beaker, forming a thin film on the walls of the beaker. When the material had 
cooled to room temperature, water (1 OOml) was poured into the beaker and the contents 
stirred for lh. The suspension was filtered under suction and the solids washed with 
water, the filtrate partially neutralized with conc. HCl (1 5m1) and sufficient sodium 
suphide added to precipitate out the lead. The suspension was heated to coagulate the 
lead sulphide, then allowed to cool slightly and filtered under suction. The filtrate was 
placed in an ice bath and acidified with conc. HC1 (1 5m1). The product precipitated out 
as a cream solid which was filtered off (crude yield 81%). The quality of the product 
achieved was poor and would require considerable purification, hence the KMn04 
oxidation method 1 was preferred. 




5.27 Preparation of acetic acid 3-fluoro-4-methyl-phenyl ester (22).' 
OyCH 3 
F >  a 0 
To 3-methyl-4-fluorophenOl (5.0g, 39.6 mmol) in dry THF (150m1) at room temperature 
was added triethylamine (6.18m1, 44.6mmol, 1.126 equiv), forming a yellow solution. 
Acetic anhydride (8.56m1, 90.58mmol, 2.29 equiv.) and DMAP (lOmol%) were stirred 
in dry THF (15m1) for 15 minutes, before slow addition to the phenolate via a cannula. 
Stirring was continued for 90 minutes, then the solution quenched with 1M HC1 and the 
organic products extracted with ether (2x20m1). The combined organic layers were 
washed with sodium bicarbonate solution and dried (Na 2 SO4). The solvent was then 
evaporated, giving the product as a yellow liquid (6.01 g, 90.4%). 
Rf 0.80 (1:1 diethyl ether/hexane). FTIR vmax/cm'(DCM) 1195.5, 1370.3, 1494.9, 
1756.3 (C0). max1flm (methanol, */dm 3mo1'cm) 266 (1581), 272 (1482). 
1 Hnmr(CDC13, 200MHz, ö/ppm) 7.04-6.82 (3H, m, ArH), 2.27 (311, s, CH3), 2.26 (3H, 
s, CH3). 13C{'H}nmr(CDCI3, 62MHz), ö/ppm 169.28 (qCO), 158.51 (d, J=243.0, 
ArC-F), 145.91 (d, J=2.74Hz, qArCp to F), 188.62 (d, J19.4Hz, qArC o to F), 123.98 
(d, J=5.5Hz, ArCH m to F), 119.82 (d, J8.8Hz, ArCH m to F), 115.21 (d, J=24.911z, 
ArCH o to F), 20.59 (CH3), 14.23 (d, J3.lHz, ArCH3), 19Fnmr (CDCI3), s/ppm - 
121.53 (ArF). HRMS(FAB, M+/z) C9H902F (MH) requires 169.0587; found 169.0601. 
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5.28 Preparation of acetic acid 4bromomethyl-3-flUOrO-PhCnYI ester (23).' 
BrH 2C( < OyCH3 
Acetic acid 3-fluoro-4-methyl-phenyl ester (2.0g, 11 .9mmol), N-bromosuccinimide 
(2.12g, 11 .9mmol) and a catalytic amount of azobisisobutyronitrile were combined in 
DCM (20m1) and heated at reflux for 1 hour under irradiation with a 500W bulb. The 
solution was then filtered, and the filtrate washed with aqueous sodium carbonate, dried 
(Na2SO4) and the solvent evaporated giving the crude product as a yellow oil (2.18g, 
75.0%). 
Rf 0.72 (1:1 diethyl ether/hexane). FTIR vmax/cm'(DCM) 1196.5 (C-O), 1370.4, 
1497.9, 1761.5 (C0), 2985.0 (CH). X max/nm (methanol, c/dm 3moF'cm') 272 (1647). 
1 Hnmr(CDCI3, 200MHz, E,/ppm) 7.16-7.01 (3H, m, ArH), 4.47 (21-1, s, CH2), 2.28 (3H, 
s, CH3). ' 3C{'H}nmr(CDC13, 62MHz), ö/ppm 169.41 (qCO), 157.75 (d, J=248.3Hz, 
ArC-F), 146.24 (d, J3.OHz, ArCp to F), 125.86 (d, J16.5Hz, qArC o to F), 123.87 (d, 
J=3.3Hz, ArCH m to F), 123.28 (d, J=8.5Hz, ArCH m to F), 116.29 (d, J=15.2Hz, ArCH 
o to F), 24.75 (d, J=4.2Hz, CH2), 20.76 (CH3). 19Fnmr (CDC13), s/ppm -120.85 (ArF). 
HRMS(FAB, M4 /z) C9H802BrF (MH) requires 246.9692; found 246.9770. 
5.29 Preparation of 4acetoxy-2-fluorO-benZOiC acid (24)." 
HOOC - OyCH3 
F 	
0 
Acetic acid 4bromomethY1-3-flUorOPheflYl ester (1.13g, 4.05mmol), potassium 
permanganate (0.68g, 4.28mmol, 1.06 equiv.) and water (20m1) were stirred at reflux 
until the purple colour had disappeared (1 hour). A second portion of potassium 
permanganate (1.06 equiv.) was added with water (4m1), and heating continued until the 
colour was again destroyed (2.5 hours). The reaction mixture was allowed to cool 
slightly, then the precipitate filtered off and washed thoroughly with hot water. The 
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filtrate was concentrated, then acidified to pH3 with conc. HC1. The solution was 
evaporated to dryness, and the solid residue re-dissolved in methanol. The remaining 
solid (KCI) was filtered off, and the filtrate evaporated to dryness, giving the product 
(crude yield 0.1g, 13%). 
RI 0.2 (1:1 DCM/methanol). FTIR v max/cm'(bromoform) 1455.8, 1622.2, 1704.4 
(C0). ? n,ax/nm (methanol, g/dm 3moi'cm') 290 (2860). 'Hnmr(CD30D, 200MHz, 
Ippm) 7.25-7.08 (314, m, ArH), 2.29 (3H, s, CH3). HRMS(FAB, M+/z) C911704F 
(MH) requires 199.0328; found 199-0313. 
5.30 Preparation of 3-methylaminophenol (25).16 
HO NHCH3 HO N(CH3)2 
(25) 	 (26 
3-Aminophenol (8.05g, 74mmol) and methyl iodide (10.2g, 73mmol) were heated in 
DMF (40m1) with potassium carbonate (lOg, 0.74mmol) for 2 hours at 100°C under 
nitrogen. The reaction mixture was then evaporated, the residue diluted with water 
(20m1) and extracted with diethyl ether (2x20m1). The organic extracts were combined, 
washed with sat. sodium bicarbonate solution and water, dried (Na 2SO4) and the solvent 
evaporated. Partial purification was achieved by Kugelrohr distillation (b.pt. 144°C at 
0.09 mbar). Unfortunately, the monomethylated product was contaminated with the 
dimethylated species, hampering analysis of the product (combined yield 86%). 
Rf 0.79 (dimethylated (26)), 0.70 (monomethylated (25)) (diethyl ether). FTIR v.,,,/cm 
'(DCM) 1152.4, 1334.3, 1514.3, 1620.9, 2971.9 (CH), 3053.7 (ArH), 3584.4 (OH). 
	
? max
/nm (methanol) 250, 293 (unable to calculate 	due to unknown weight). 
'Hnmr(CDCI3, 200MHz, 6/ppm) 7.10-7.00(m, ArH); 6.40-6.08(m, ArH); 5.31(s, 
ArNH); 2.87(s, CH3); 2.74(s,CH3). HRMS(EI, M+/Z) (25) C 7H9NO (M) requires 





The same reaction conditions were employed for the methylation of (34) on Wang resin, 
using 4 equivalents of methyl iodide and base. After 3 hours reaction the resin was 
filtered off and washed consecutively with water, DMF, DCM and diethyl ether. 
Confirmation of the reaction was made by cleavage and cyclisation of the product, see 
section 5.37. 
5.31 Preparation of 3I(3hydroxypheny1)methYlammfb1Pr0Pb0mc acid (27)! 
HO 	N 	OH 
CH3 
A solution of crude 3-methylaminophenOl (25) (12.5g, 0.lmol) and acrylic acid (7.2g, 
0. imol) in dry THF (50m1) was stirred with heating at reflux for 16 hours. The THF was 
then removed in vacuo, yielding a red oil (crude yield 89%), which was used directly in 
the next step. Again, analysis was hampered by difficulty in purification. 
Rf 0.57 (diethyl ether). FTIR vmax/cm'(bromofOrm) 1168.3, 1238.4, 1613.9, 1714.4 
(C0). Xmax/nm (methanol) 257, 296 (unable to calculate E due to unknown weight). 
'Hnmr(CJJ30D, 200MHz, ö/ppm) 7.03-6.95(m, ArH); 6.39-6.12(m, ArH); 3.60(t, 
3J7.25Hz, C142); 2.87(s, CH3); 2.85(s, CH3); 2.50(t, 3 J7.25Hz, CI-12). HRMS(EI, 
M+/Z) C 10H 1 303N requires 195.0895, found 195.0897. 
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acid (27) (2.02g, 0.01 imol) and 
polyphosphoric acid (44.3g, 0.11mol, 10 equiv.) were combined with manual stirring. 
The viscous mixture was gradually heated, then the temperature maintained at 100°C 
until a deep red colour appeared (10 minutes). The reaction was then allowed to cool 
slightly before being poured into a beaker of ice/water and stirred for an hour. The 
product was extracted into diethyl ether (3x 50ml), the organic extracts combined and 
dried (Na2SO4). Removal of the solvents under reduced pressure afforded a viscous dark 
yellow oil. Purification was achieved by silica chromatography (ethyl acetate/hexane, 
3:2) giving the product as a yellow solid (overall yield for 3 steps 25-28 10.4%). 
Rf 0.49 (diethyl ether). FTIR vmax/cm'(DCM) 1587.3, 1624.5, 1665.5, 1730.5 (C=O), 
2068.1, 2222.1, 2234.3, 2674.8. ? max/flm (methanol, E/dm3mol'cm ) 236 (17307), 253 
(21043), 284 (10227), 379 (4917). 'Hnmr(CD30D, 200MHz, ö/ppm) 7.68(1H, d, 
J8.79Hz, ArH); 6.19(1H, dd, J=8.79, 2.20Hz, ArH); 6.11(1H, d, J2.2OHz, ArH); 
3.41(2H, t, 3J7.33Hz, CH2); 2.93(3H, s, CH3); 2.60(2H, t, 3J7.32Hz, CH2). 
13C{'H}nmr(CDCI3, 62MHz), ö/ppm 194.09 (qCO), 165.20 (qArC), 156.03 (qArC), 
137.17 (qArC), 130.37 (ArCH), 106.65 (ArCH), 98.28 (ArCH), 51.32 (CH2), 38.40 
(CH3), 37.70 (CH2). HRMS(EI, M+/z) C 10H 11NO2 (MH) requires 177.0790, found 
177.0792. Elemental Analysis C 10H 11NO2 requires 67.78% C, 6.26% H, 7.90% N; 
found 67.57% C, 6.04% H, 7.62% N. 
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5.33 Preparation of 
quinolin-4-one (29).' 
CH, 
The alcohol (20) (0.076g, 0.41mmol) and triphenyiphosphine (0.161g, 0.615 mmol) 
were combined in THF (2ml), under an N2 atmosphere, and cooled in an ice bath. A 
solution of the 2,4-dihydroquiflolofle (28) (0.072g, 0.41mmol) and DEAD (97[t1, 
0.615mmol) in THF, was added dropwise over 1 hour. The resulting solution was 
allowed to stir at room temperature for 2 days. The THF was then removed in vacuo, and 
the residue dissolved in ethyl acetate. This was washed with water, sat. sodium 
bicarbonate solution and brine, dried (MgSO4) and the solvent evaporated. Partial 
separation of the product was achieved by silica chromatography (5% methanol in 
DCM), unfortunately the product was co-eluted with triphenylphosphine oxide 
((0)PPh3). This made determination of yield and analysis of the product difficult. 
Rf 0.20 (2% methanol in DCM). FTIR vmax/cm'(DCM) 1120.4; 1610.0, 1665.2 
(conjugated C=C); 2069.3; 2541.9; 2676.7. X max lflm (methanol) 273, 279, 370 (unable 
to calculate E due to unknown weight). 'Hnmr(CD30D, 200MHz, s/ppm) 7.70-6.92(9-
1OH, m, Im+ArH); 6.26(1H, dd, J8.72, 2.3011z, ArH); 6.11(1H, d, J=2.28Hz, ArH); 
3.38(m, CH2); 2.78(3H, s, CH3); -.2.52(2H, m, CH2). 13C{ 1 H}nmr(CD30D, 62MHz), 
s/ppm 194.05 (qCO), 164.16 (qArC), 155.28 (qArC), 138.26 (qArC), 137.94 (qArC), 
52.84 (CH2), 51.17 (CH2), 38.31 (CH3), 37.61 (CH2). Contamination with Ph 3PO made 
complete assignment difficult, several possibilities existed for the remaining CH groups. 




tçi 	 (30) 
Conditions for the Mitsunobu reaction described above were optimised by the reaction of 
styrene oxide with (20), to give (30). Again, the product co-eluted with POPh3, making 
analysis difficult. 
Rf 0.54 (DCM). FTIR v max/cm'(DCM) 
1511.9, 1657.3, 26.65.7, 3105.6, 3372.9. 
'Hnmr(CD30D, 200MHz, ö/ppm) 7.57-6.89 (13H, m, ArH), 5.14 (11-1, m, CH), 4.46 
(2H, m, CH2). HR1VIS(FAB, M+/z) C 17
H16N20 (MH) requires 265.1263; found 
265.1265. 
5.34 Preparation of benzyl 3-(3-hydroxy-phenylamino)-propanoate- 
20 
HO 	N OBn 
3-Aminophenol (log , 0.09mol), benzyl acrylate (14.6g, 0.09mol) and glacial acetic acid 
(5m1) were combined in THF (20m1) under nitrogen. The solution was heated at reflux 
for 2 days until a deep red colour was observed. The THF was removed and the residue 
dissolved in diethyl ether. This was washed consecutively with water, 5% sodium 
bicarbonate solution and water, dried (Mg2SO4) and the solvent removed giving a solid 
residue. This was recrystalised twice from toluene, giving the product as a white 
crystalline solid (52%). 
Rf 0.82 (diethyl ether). FTIR v max/cm'(DCM) 1258.1, 1513.6, 1621.5, 1732.2 (C=O), 
3421.8 (OH). 2 max/nm (methanol, E/dmmo1 1 cm') 
208 (33423), 248 (8431), 290 
(2409). 'Hnmr(CD30D, 200MHz, Wppm) 7.43-7.38(5H, 
m, ArH); 7.04-6.97(1H, m, 
ArH); 6.25-6.20(3H, m, ArH); 5.20(2H, s, C112); 3.45(2H, t, 3 J6.77Hz, C112) ; 2.71(2H, 
t, 3J6.77Hz, CH2). 13C{'H}nmr (CD3
0D, 62MHz), ö/ppm 171.90(ArC-OH); 
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1 57.38(qArC-N); 149.06(qCO); 1 35.63(qArC); 128.98(ArCH); 127.61(2xArCH); 
127.25(3xArCH); 104.41 (ArCH); 103.72(ArCH); 99.1 6(ArCH); 65.41 (CH2); 
38.72(CH2); 33.10(CH2). HRMS(FAB, M+/Z) C 1 61-1 17NO3 (MH) requires 272.1208, 
found 272.1219. Elemental Analysis C 161-1 17NO3 requires 70.83% C, 6.32% H, 5.16% 
N; found 70.58% C, 6.06% H, 5.13% N. 
0 NjaOH 
These same conditions were used to load 3-aminophenol onto both REM (31) and Wang 
resin (33),using a 10 fold excess of reagent. The minimum volume of THF was used to 
swell the resin, in a 1:1 solution with acetic acid. The resin was then filtered off, and 
washed with DCM and diethyl ether. 
FTIR vmax/cm 1 (DCM) (31) 1726.1(C0), (33) 173 1.9(C0). Elemental Analysis (33) 
%N 0.35±0.3. 
5.35 Attachment of acrylic Acid to Wang Resin (32). 
Qo 
Wang resin (1.Og at 0.56mmol/g, 0.56mmol) was swollen in DMF (5m!) and a catalytic 
amount of DMAP added. DIC (0.106g, 1 .68mmol) was added to acrylic acid (0.242g, 
3.36mmol) in DMF (5m!), and the solution sonicated for 1 Smins. This mixture was then 
poured into the Wang resin suspension and sonicated for 3 hours. The resin was then 
filtered off, and washed consecutively with DMF, DCM and diethyl ether. 
FTIR v max/cm'(DCM) 1 654.8(CC), 1721 .8(C0). 
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5.36 Cleavage and cyclisation of 7hydroxy-1-methyl-2,3-dihydro-1H-qUif101in4 
one (28) from Wang resin. 18 
HO 0 
CH3 
The dry resin (ig, presuming 0.56mmol/g) was stirred in 30% TFA in DCM (lOmi) for 
40 minutes at room temperature. The resin was then removed, and the solvent 
evaporated in vacuo. The residue was treated with PPA (I g), and the mixture heated with 
stirring until the temperature reached 100 °C. The temperature was maintained at 100°C 
until a deep red colour appeared (10 minutes), then the reaction allowed to cool slightly 
before being added to ice/water and stirred for 1 hour. The product was extracted with 
diethyl ether (3x 20m1), the organic extracts combined and dried (Na2SO4), and the 
solvent removed under reduced pressure, affording a yellow oil (crude yield 0.04g, 
40%). 
The analysis was concordant with that of the solution phase synthesis product. 
Rf 0.50 (diethyl ether). FTIR vmax/cm4 (DCM) 1589.4, 1669.5, 1732.8 (C=O), 2070.4, 
2676.1. XmaxIIlm (methanol, E/dm3mor'cm) 233 (17707), 261 (19887), 280 (10107), 
382 (4942). 1 Hnmr(CD30D, 200MHz, ö/ppm) 7.68(1H, d, J=8.79Hz, ArH); 6.19(1H, 
dd, J=8.79, 2.2011z, ArH); 6.11(1H, d, J2.2OHz, ArH); 3.41(2H, t, 3J=7.33Hz, CH2); 
2.93(3H, s, CH3); 2.60(2H, t, 3J=7.32Hz, CH2). HRMS(EI, M+/z) C 10H 11NO2 (MH) 
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Appendix I: MALDI ToE mass spectroscopy results for truncated big ET-] 
analogues. 
PEPTIDE PREDICTED VALUE MASS DETERMINED 
BigET-1[16-34] 2158.11 2160.73 
Big ET-1[17-34] 2022.07 2023.57 
Big ET-1[18-34] 1910.18 1908.86 
BigET-1[16-32] 1988.01 1989.98 
Big ET-1[16-27] 1473.75 1475.50 
Big ET-1 [16-38, Cys 22 ] 2590.29 2591.55 
Big ET-1[16-32, Cys 22 ] 1992.94 1993.25 
Big ET-1[16-32, Cys 21 ] 1905.93 1907.21 
Big ET-1[16-32, Cys 21 ' 22] 1906.86 1908.46 
Big ET-1[16-27, Cys 22] 1477.69 1476.81 
Big ET-1 [16-38, D-Va1 22 ] 2586.35 2586.48 
MALDI ToF mass spectroscopy results from SAR investigation of ECE-]. 
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PEPTIDE 	 PREDICTED VALUE 
	
MASS DETERMINED 
Big ET-1 [16-38, Phe 21 ] 2547.32 2546.53 
Big ET-1[16-38, Leu21 ] 2523.33 2521.56 
Big ET-l[16-38, Ala21 ] 2471.30 2470.38 
Big ET-1[16-38, Pro 21 1 2497.30 2495.35 
Big ET-l[16-38, G1u 21 ] 2529.29 2541.04 
Big ET-1[16-38, Arg21 ] 2556.35 2554.68 
Big ET-1[16-38, Phe22 ] 2634.33 2637.33 
Big ET-1[16-38, Leu22] 2600.34 2602.18 
Big ET-1[16-38, Ala 22] 2555.31 2551.85 
Big ET-1 [16-38, Pr022] 2584.31 2588.4 
Big ET-1[16-38, G1u22 1 2616.30 2618.36 
Big ET-1[16-38, Arg22 1 2643.36 2645.27 
MALDI ToE mass spectroscopy results from subsite specificity study of ECE-] 
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Appendix 11: Amino acid analysis results for truncated big ET-1 analogues. 
AMINO ACID RATIO 
PREDICTED/RATIO OBTAINED 
PEPTIDE His Leu Asp lie Val Thr Pro Glu Tyr Gly 	Ser 	Arg Cys 
Big ET- l[16-34] 2/2.0 211.8 2/1.9 211.8 3/2.5 1/0.8 2/1.8 1/0.9 1/1.0 2/2.0 - - - 
Big ET- I[l7-34] 1/1.1 2/1.9 2/1.8 211.7 3/2.6 1/0.9 2/1.6 1/0.8 1/1.1 2/2.0 	- 	- - 
Big ET- I[18-34] 1/0.9 1/1.0 2/1.9 2/1.7 3/2.5 1/0.9 2/1.6 1/1.1 1/1.0 2/2.0 	- 	- - 
Big ET- I[16-32] 2/1.9 1/1.0 2/2.1 2/1.8 3/2.8 1/0.7 2/2.4 1/0.8 1/0.9 1/1.0 	- 	- - 
Big ET-1[16-27J 2/1.8 1/0.8 2/1.9 2/1.9 1/0.8 1/1.0 1/0.9 1/0.9 - - 	 - 	 - - 
B1gET-1[16-38,Cys 22 ] 2/2.0 2/2.2 2/2.1 2/1.8 2/1.9 1/0.8 3/2.6 1/0.9 1/0.9 2/2.0 	2/1.7 	1/1.1 1/0.8 
BigET-1[16-32,Cys 22 ] 2/2.2 1/0.9 2/2.2 2/1.7 2/1.8 1/0.9 2/2.2 1/0.8 1/1.1 1/1.0 	- 	- 1/0.7 
BigET-1[16-32,Cys 21 ] 2/2.0 1/1.0 2/2.2 2/1.8 3/2.7 110.9 2/1.8 1/0.8 1/1.1 1/1.0 	- 	- 1/1.8 
BigET-I[16-32,Cys 2122 ] 2/2.2 1/0.8 2/2.4 2/1.6 2/1.8 1/1.0 2/1.7 1/0.9 1/0.8 1/1.0 	- 	- 2/1.6 
BigET-1[16-27,Cys 22 ] 2/2.1 1/1.0 2/1.7 2/1.7 - 1/0.8 1/0.7 1/0.6 - - 	 - 	 - 1/0.8 
BigET-1[16-38,D-Va1 22 J 2/1.9 2/2.1 2/1.9 2/1.8 3/2.6 1/0.9 3/2.8 1/1.0 1/0.9 2/2.0 	2/1.8 	1/1.1 - 
Amino acid analysis results from SAR investigation of ECE-1. 
AMINO ACID RATIO 
PREDICTED/RATIO OBTAINED 
PEPTIDE His Lett Asp lie Val Thr Pro Giu Tyr Gly Ser Arg 	Phe 	Ala 
BigET-1[16-38,P11e 21 ] 2/2.1 2/2.0 2/2.1 2/1.6 3/2.7 1/0.8 3/3.2 1/0.8 1/0.8 2/2.0 2/1.8 1/1.0 1/1.0 	- 
BigET-I[16-38,Leu 21 ] 2/2.0 3/3.1 2/2.0 2/1.8 3/2.9 1/0.7 3/2.7 1/1.0 1/0.7 2/2.0 2/1.7 1/1.1 	- 	- 
BIgET-1[16-38,AIa 21 ] 2/2.2 2/1.8 2/2.1 2/1.5 3/2.6 1/0.9 3/3.1 1/1.1 1/0.9 2/2.0 2/1.7 1/1.0 	- 	1/1.0 
BIgET-1[16-38,Pro 21 ] 2/2.0 2/1.7 2/2.3 2/1.6 3/2.8 1/0.8 4/4.I 1/0.8 1/0.9 2/2.0 2/1.8 1/0.7 	- 	- 
BigET-1[16-38,G1u 21 ] 2/2.1 2/1.9 2/1.8 2/1.7 3/2.80 110.7 3/3.2 2/1.8 1/0.7 2/2.0 2/1.8 1/I.2 	- 	- 
B1gET-1[16-38,Arg 2t ] 2/2.0 2/2.2 2/2.1 2/I.7 3/2.7 1/0.9 3/2.8 1/0.7 1/0.8 2/2.0 2/1.8 2/2.0 	- 	- 
B1gET-1[16-38,Phe 22 ] 2/2.2 2/I.7 2/2.0 2/1.8 2/1.6 1/0.6 3/3.2 1/0.8 1/0.8 2/2.0 2/1.6 1/1.1 	1/0.9 	- 
B1gET-I[l6-38,Leu 22 ] 2/2.0 3/2.9 2/2.0 2/1.5 2/1.9 1/0.7 3/3.3 1/0.9 1/0.9 2/2.0 2/1.7 1/0.9 	- 	 - 
B1gET-I[16-38,A1a 22 ] 2/2.0 2/1.8 2/2.1 2/1.6 2/1.8 1/0.8 3/3.0 1/1.0 1/0.8 2/2.0 2/1.6 1/1.1 	- 	1/1.0 
BIgET-1[l6-38,Pro 22 ] 2/2.1 2/1.9 2/2.3 2/1.8 2/1.9 1/0.7 4/4.1 I/I.! 1/0.9 2/2.0 2/1.7 1/1.0 	- 	 - 
BigET-1[16-38,G1u22 } 2/2.0 2/1.0 2/2.0 2/1.9 2/1.6 1/0.8 3/2.6 2/2.0 1/0.9 2/2.0 2/1.6 1/0.7 	- 	 - 
BIgET-l[16-38,Arg22 } 2/2.1 2/1.7 2/2.2 2/1.8 2/1.8 1/0.9 3/2.7 1/1.0 1/0.9 2/2.0 2/1.7 2/1.8- 	- 
Amino acid analysis resultsftom subs ite specificity study of ECE-1. 
Appendix III: Mass spectroscopy and amino acid analysis results for Library 1. 
PREDICTED MASS DISTRIBUTION DETERMINED MASS DISTRIBUTION 
	
1306.61 	 1308.27 
1290.62 1291.42 
1329.63 	 1331.04 
MALDI ToF mass spectroscopy results for Library 1. 
AMINO ACID PREDICTED RATIO 
ACTUAL RATIO 
FIRST 	SECOND 
Asp 3 3.1 3.1 
Val 3 1.7 	2.8 
Ile 6 5.3 4.9 
Leu 3 3.4 	3.1 
Tyr 4 1.9 1.8 
Phe 1 1.0 	0.9 
His 3 2.9 2.9 
Amino acid analysis results for Library 1. 
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Appendix IV: Mass spectroscopy and amino acid analysis results for Library 2. 
PREDICTED MASS DISTRIBUTION DETERMINED MASS DISTRIBUTION 
	
1732.79 	 1733.12 
1748.78 1749.37 
1771.80 	 1772.14 
MALDI ToE mass spectroscopy results for Library 2. 
AMINO ACID PREDICTED RATIO ACTUAL RATIO 
Asp 6 7.2 
Glu 3 3.2 
Val 3 3.4 
Ile 6 4.6 
Leu 3 2.6 
Tyr 1 1.1 
Phe 4 4.2 
His 3 2.5 
Lys 3 2.9 
Amino acid analysis results for Library 2. 
162 
Appendix V: Mass spectroscopy and amino acid analysis results for Library 3. 


















MALDI ToE mass spectroscopy results for Library 3. 
AMINO ACID PREDICTED RATIO 
RATIO DETERMINED 
FIRST 	SECOND 
Asp 11 12.2 11.6 
Thr 1 1.4 	0.9 
Ser 1 1.0 0.9 
Glu 2 1.8 	1.7 
Pro 1 0.0 0.8 
Gly 3 2.9 	3.0 
Ala 6 5.9 7.5 
Leu 3 2.6 	2.7 
Tyr 4 3.8 3.7 
Phe 4 4.3 	4.2 
Amino acid analysis results for Library 3. 
163 
Appendix VI: Mass spectroscopy and amino acid analysis results for Library 4. 
PREDICTED MASS DISTRIBUTION DETERMINED MASS DISTRIBUTION 
	
1270.52 	 1269.99 
1284.54 1285.68 
1298.56 	 1299.69 
1312.94 1312.98 
MJ4LDJ ToF mass spectroscopy results for Library 4. 
AMINO ACID PREDICTED RATIO DETERMINED 
Asp 9 8.5 
Ser 3 2.9 
Glu 3 3.0 
Gly 4 3.5 
Ala 4 3.7 
Abu 1 0.7 
Val 1 1.0 
Ile 1 0.9 
Leu 1 0.8 
Tyr 3 2.4 
Phe 3 2.7 
Pro 3 1.5 
Amino acid analysis results for Library 4. 
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Appendix VII: Mass spec
troscopy and amino acid analysis results for Library 5. 




















Electrospray mass spectroscopy results for Library 5. 
AMINO ACID PREDICTED RATIO 
DETERMINED RATIO 
36 33.6 Asp 
30 26.7 Ala 
36 37.8 Glu 
27 24.7 Phe 
15 13.7 Arg 
21 22.8 His 
21 19.7 Ser 
54 50.8 Gly 
9 8.6 Tyr 
57 51.9 Val 
9 8.7 Lys 
18 19.9 Leu 
18 16.4 Ile 
9 8.7 Met 
Amino acid analysis results for Library 5. 
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